

WO 2004/003157 A2

5

GENE REGULATION IN TRANSGENIC ANIMALS USING A TRANSPOSON-BASED VECTOR

10 The U.S. Government has certain rights in this invention. The development of
this invention was partially funded by the United States Government under a HATCH
grant from the United States Department of Agriculture, partially funded by the
United States Government with Formula 1433 funds from the United States
Department of Agriculture and partially funded by the United States Government
15 under contract DAAD 19-02016 awarded by the Army.

FIELD OF THE INVENTION

 The present invention relates generally to cell-specific gene regulation in
transgenic animals. Animals may be made transgenic through administration of a
20 transposon-based vector through any method of administration including pronuclear
injection, or intraembryonic, intratesticular, intraoviductal or intravenous
administration. These transgenic animals contain the gene of interest in all cells,
including germ cells. Animals may also be made transgenic by targeting specific cells
for uptake and gene incorporation of the transposon-based vectors. Stable
25 incorporation of a gene of interest into cells of the transgenic animals is demonstrated
by expression of the gene of interest in a cell, wherein expression is regulated by a
promoter sequence. The promoter sequence may be provided as a transgene along
with the gene of interest or may be endogenous to the cell. The promoter sequence
may be constitutive or inducible, wherein inducible promoters include tissue-specific
30 promoters, developmentally regulated promoters and chemically inducible promoters.

BACKGROUND OF THE INVENTION

 Transgenic animals are desirable for a variety of reasons, including their
potential as biological factories to produce desired molecules for pharmaceutical,
35 diagnostic and industrial uses. This potential is attractive to the industry due to the
inadequate capacity in facilities used for recombinant production of desired molecules
and the increasing demand by the pharmaceutical industry for use of these facilities.
Numerous attempts to produce transgenic animals have met several problems,

including low rates of gene incorporation and unstable gene incorporation. Accordingly, improved gene technologies are needed for the development of transgenic animals for the production of desired molecules.

Improved gene delivery technologies are also needed for the treatment of disease in animals and humans. Many diseases and conditions can be treated with gene-delivery technologies, which provide a gene of interest to a patient suffering from the disease or the condition. An example of such disease is Type 1 diabetes. Type 1 diabetes is an autoimmune disease that ultimately results in destruction of the insulin producing β -cells in the pancreas. Although patients with Type 1 diabetes may be treated adequately with insulin injections or insulin pumps, these therapies are only partially effective. Insulin replacement, such as via insulin injection or pump administration, cannot fully reverse the defect in the vascular endothelium found in the hyperglycemic state (Pieper et al., 1996. Diabetes Res. Clin. Pract. Suppl. S157-S162). In addition, hyper- and hypoglycemia occurs frequently despite intensive home blood glucose monitoring. Finally, careful dietary constraints are needed to maintain an adequate ratio of consumed calories consumed. This often causes major psychosocial stress for many diabetic patients. Development of gene therapies providing delivery of the insulin gene into the pancreas of diabetic patients could overcome many of these problems and result in improved life expectancy and quality of life.

Several of the prior art gene delivery technologies employed viruses that are associated with potentially undesirable side effects and safety concerns. The majority of current gene-delivery technologies useful for gene therapy rely on virus-based delivery vectors, such as adeno and adeno-associated viruses, retroviruses, and other viruses, which have been attenuated to no longer replicate. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40).

There are multiple problems associated with the use of viral vectors. First, they are not tissue-specific. In fact, a gene therapy trial using adenovirus was recently halted because the vector was present in the patient's sperm (Gene trial to proceed despite fears that therapy could change child's genetic makeup. The New York Times, December 23, 2001). Second, viral vectors are likely to be transiently incorporated, which necessitates re-treating a patient at specified time intervals. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40). Third, there is a concern that a viral-based vector could revert to its virulent form and cause disease. Fourth, viral-based vectors require a dividing cell for stable integration. Fifth, viral-based vectors indiscriminately integrate into various cells and tissues, which can result in undesirable germline integration. Sixth, the required high titers needed to achieve the desired effect have resulted in the death of one patient and they are believed to be

responsible for induction of cancer in a separate study. (Science, News of the Week, October 4, 2002).

Accordingly, what is needed is a new vector to produce transgenic animals and humans with stably incorporated genes, which vector does not cause disease or other unwanted side effects. There is also a need for DNA constructs that would be stably incorporated into the tissues and cells of animals and humans, including cells in the resting state, which are not replicating. There is a further recognized need in the art for DNA constructs capable of delivering genes to specific tissues and cells of animals and humans.

When incorporating a gene of interest into an animal for the production of a desired protein or when incorporating a gene of interest in an animal or human for the treatment of a disease, it is often desirable to selectively activate incorporated genes using inducible promoters. These inducible promoters are regulated by substances either produced or recognized by the transcription control elements within the cell in which the gene is incorporated. In many instances, control of gene expression is desired in transgenic animals or humans so that incorporated genes are selectively activated at desired times and/or under the influence of specific substances. Accordingly, what is needed is a means to selectively activate genes introduced into the genome of cells of a transgenic animal or human. This can be taken a step further to cause incorporation to be tissue-specific, which prevents widespread gene incorporation throughout a patient's body (animal or human). This decreases the amount of DNA needed for a treatment, decreases the chance of incorporation in gametes, and targets gene delivery, incorporation, and expression to the desired tissue where the gene is needed to function.

SUMMARY OF THE INVENTION

The present invention addresses the problems described above by providing new, effective and efficient compositions for producing transgenic animals and for treating disease in animals or humans. Transgenic animals include all egg-laying animals and milk-producing animals. Transgenic animals further include but are not limited to avians, fish, amphibians, reptiles, insects, mammals and humans. In a preferred embodiment, the animal is an avian animal. In another preferred embodiment, the animal is a milk-producing animal, including but not limited to bovine, porcine, ovine and equine animals. Animals are made transgenic through administration of a composition comprising a transposon-based vector designed for stable incorporation of a gene of interest for production of a desired protein, together

with an acceptable carrier. A transfection reagent is optionally added to the composition before administration.

The transposon-based vectors of the present invention include a transposase, operably-linked to a first promoter, and a coding sequence for a protein or peptide of interest operably-linked to a second promoter, wherein the coding sequence for the protein or peptide of interest and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes the following characteristics: a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:13) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first several N-terminal amino acids of the transposase, wherein the nucleotide at the third base position of each codon was changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene.

Use of the compositions of the present invention results in highly efficient and stable incorporation of a gene of interest into the genome of transfected animals. For example, transgenic avians have been mated and produce transgenic progeny in the G1 generation. The transgenic progeny have been mated and produce transgenic progeny in the G2 generation.

The present invention also provides for tissue-specific incorporation and/or expression of a gene of interest. Tissue-specific incorporation of a gene of interest may be achieved by placing the transposase gene under the control of a tissue-specific promoter, whereas tissue-specific expression of a gene of interest may be achieved by placing the gene of interest under the control of a tissue-specific promoter. In some embodiments, the gene of interest is transcribed under the influence of an ovalbumin, or other oviduct specific, promoter. Linking the gene of interest to an oviduct specific promoter in an egg-laying animal results in synthesis of a desired molecule and deposition of the desired molecule in a developing egg. The present invention further provides for stable incorporation and expression of genes in the epithelial cells of the mammary gland in milk-producing animals. Transcription of the gene of interest in the epithelial cells of the mammary gland results in synthesis of a desired molecule

and deposition of the desired molecule in the milk. A preferred molecule is a protein. In some embodiments, the desired molecule deposited in the milk is an antiviral protein, an antibody, or a serum protein.

5 In other embodiments, specific incorporation of the proinsulin gene into liver cells of a diabetic animal results in the improvement of the animal's condition. Such improvement is achieved by placing a transposase gene under the control of a liver-specific promoter, which drives integration of the gene of interest in liver cells of the diabetic animal.

10 The present invention advantageously produces a high number of transgenic animals having a gene of interest stably incorporated. These transgenic animals successfully pass the desired gene to their progeny. The transgenic animals of the present invention also produce large amounts of a desired molecule encoded by the transgene. Transgenic egg-laying animals, particularly avians, produce large amounts of a desired protein that is deposited in the egg for rapid harvest and purification.
15 Transgenic milk-producing animals produce large amounts of a desired protein that is deposited in the milk for rapid harvest and purification.

Any desired gene may be incorporated into the novel transposon-based vectors of the present invention in order to synthesize a desired molecule in the transgenic animals. Proteins, peptides and nucleic acids are preferred desired molecules to be
20 produced by the transgenic animals of the present invention. Particularly preferred proteins are antibody proteins.

This invention provides a composition useful for the production of transgenic hens capable of producing substantially high amounts of a desired protein or peptide. Entire flocks of transgenic birds may be developed very quickly in order to produce
25 industrial amounts of desired molecules. The present invention solves the problems inherent in the inadequate capacity of fermentation facilities used for bacterial production of molecules and provides a more efficient and economical way to produce desired molecules. Accordingly, the present invention provides a means to produce large amounts of therapeutic, diagnostic and reagent molecules.

30 Transgenic chickens are excellent in terms of convenience and efficiency of manufacturing molecules such as proteins and peptides. Starting with a single transgenic rooster, thousands of transgenic offspring can be produced within a year. (In principle, up to forty million offspring could be produced in just three

generations). Each transgenic female is expected to lay at least 250 eggs/year, each potentially containing hundreds of milligrams of the selected protein. Flocks of chickens numbering in the hundreds of thousands are readily handled through established commercial systems. The technologies for obtaining eggs and
5 fractionating them are also well known and widely accepted. Thus, for each therapeutic, diagnostic, or other protein of interest, large amounts of a substantially pure material can be produced at relatively low incremental cost.

A wide range of recombinant peptides and proteins can be produced in transgenic egg-laying animals and milk-producing animals. Enzymes, hormones,
10 antibodies, growth factors, serum proteins, commodity proteins, biological response modifiers, peptides and designed proteins may all be made through practice of the present invention. For example, rough estimates suggest that it is possible to produce in bulk growth hormone, insulin, or Factor VIII, and deposit them in transgenic egg whites, for an incremental cost in the order of one dollar per gram. At such prices it
15 is feasible to consider administering such medical agents by inhalation or even orally, instead of through injection. Even if bioavailability rates through these avenues were low, the cost of a much higher effective-dose would not be prohibitive.

In one embodiment, the egg-laying transgenic animal is an avian. The method of the present invention may be used in avians including Ratites, Psittaciformes,
20 Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. Preferably, the egg-laying transgenic animal is a poultry bird. More preferably, the bird is a chicken, turkey, duck, goose or quail. Another preferred bird is a ratite, such as, an emu, an ostrich, a rhea, or a cassowary. Other preferred birds are partridge,
25 pheasant, kiwi, parrot, parakeet, macaw, falcon, eagle, hawk, pigeon, cockatoo, song birds, jay bird, blackbird, finch, warbler, canary, toucan, mynah, or sparrow.

In another embodiment, the transgenic animal is a milk-producing animal, including but not limited to bovine, ovine, porcine, equine, and primate animals. Milk-producing animals include but are not limited to cows, goats, horses, pigs,
30 buffalo, rabbits, non-human primates, and humans.

Accordingly, it is an object of the present invention to provide novel transposon-based vectors.

It is another object of the present invention to provide novel transposon-based vectors that encode for the production of desired proteins or peptides in cells.

It is an object of the present invention to produce transgenic animals through administration of a transposon-based vector.

5 Another object of the present invention is to produce transgenic animals through administration of a transposon-based vector, wherein the transgenic animals produce desired proteins or peptides.

Yet another object of the present invention is to produce transgenic animals through administration of a transposon-based vector, wherein the transgenic animals
10 produce desired proteins or peptides and deposit the proteins or peptides in eggs or milk.

It is a further object of the present invention to produce transgenic animals through intraembryonic, intratesticular or intraoviductal administration of a transposon-based vector.

15 It is further an object of the present invention to provide a method to produce transgenic animals through administration of a transposon-based vector that are capable of producing transgenic progeny.

Yet another object of the present invention is to provide a method to produce transgenic animals through administration of a transposon-based vector that are
20 capable of producing a desired molecule, such as a protein, peptide or nucleic acid.

Another object of the present invention is to provide a method to produce transgenic animals through administration of a transposon-based vector, wherein such administration results in modulation of endogenous gene expression.

It is another object of the present invention to provide transposon-vectors
25 useful for cell- or tissue-specific expression of a gene of interest in an animal or human with the purpose of gene therapy.

It is yet another object of the present invention to provide a method to produce transgenic avians through administration of a transposon-based vector that are capable of producing proteins, peptides or nucleic acids.

30 It is another object of the present invention to produce transgenic animals through administration of a transposon-based vector encoding an antibody or a fragment thereof.

Still another object of the present invention is to provide a method to produce transgenic avians through administration of a transposon-based vector that are capable of producing proteins or peptides and depositing these proteins or peptides in the egg.

Another object of the present invention is to provide transgenic avians that
5 contain a stably incorporated transgene.

Still another object of the present invention is to provide eggs containing desired proteins or peptides encoded by a transgene incorporated into the transgenic avian that produces the egg.

It is further an object of the present invention to provide a method to produce
10 transgenic milk-producing animals through administration of a transposon-based vector that are capable of producing proteins, peptides or nucleic acids.

Still another object of the present invention is to provide a method to produce transgenic milk-producing animals through administration of a transposon-based vector that are capable of producing proteins or peptides and depositing these proteins
15 or peptides in their milk.

Another object of the present invention is to provide transgenic milk-producing animals that contain a stably incorporated transgene.

Another object of the present invention is to provide transgenic milk-producing animals that are capable of producing proteins or peptides and depositing
20 these proteins or peptides in their milk.

Yet another object of the present invention is to provide milk containing desired molecules encoded by a transgene incorporated into the transgenic milk-producing animals that produce the milk.

Still another object of the present invention is to provide milk containing
25 desired proteins or peptides encoded by a transgene incorporated into the transgenic milk-producing animals that produce the milk.

A further object of the present invention to provide a method to produce transgenic sperm through administration of a transposon-based vector to an animal.

A further object of the present invention to provide transgenic sperm that
30 contain a stably incorporated transgene.

An advantage of the present invention is that transgenic animals are produced with higher efficiencies than observed in the prior art.

Another advantage of the present invention is that these transgenic animals possess high copy numbers of the transgene.

Another advantage of the present invention is that the transgenic animals produce large amounts of desired molecules encoded by the transgene.

5 Still another advantage of the present invention is that desired molecules are produced by the transgenic animals much more efficiently and economically than prior art methods, thereby providing a means for large scale production of desired molecules, particularly proteins and peptides.

10 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and claims.

BRIEF DESCRIPTION OF THE FIGURES

15 Figure 1 depicts schematically a transposon-based vector containing a transposase operably linked to a first promoter and a gene of interest operably-linked to a second promoter, wherein the gene of interest and its operably-linked promoter are flanked by insertion sequences (IS) recognized by the transposase. "Pro" designates a promoter. In this and subsequent figures, the size of the actual nucleotide sequence is not necessarily proportionate to the box representing that sequence.

20

Figure 2 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg white wherein Ov pro is the ovalbumin promoter, Ov protein is the ovalbumin protein and PolyA is a polyadenylation sequence. The TAG sequence includes a spacer, the gp41 hairpin loop from HIV I and a protein cleavage site.

25

Figure 3 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg white wherein Ovo pro is the ovomucoid promoter and Ovo SS is the ovomucoid signal sequence. The TAG sequence includes a spacer, the gp41 hairpin loop from HIV I and a protein cleavage site.

30

Figure 4 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg yolk wherein Vit pro is the vitellogenin promoter and Vit targ is the vitellogenin targeting sequence.

5 Figure 5 depicts schematically a transposon-based vector for expression of antibody heavy and light chains. Prepro indicates a prepro sequence from cecropin and pro indicates a pro sequence from cecropin.

10 Figure 6 depicts schematically a transposon-based vector for expression of antibody heavy and light chains. Ent indicates an enterokinase cleavage sequence.

15 Figure 7 depicts schematically egg white targeted expression of antibody heavy and light chains from one vector in either tail-to-tail (Figure 7A) or tail-to-head (Figure 7B) configuration. In the tail-to-tail configuration, the ovalbumin signal sequence adjacent to the gene for the light chain contains on its 3' end an enterokinase cleavage site (not shown) to allow cleavage of the signal sequence from the light chain, and the ovalbumin signal sequence adjacent to the gene for the heavy chain contains on its 5' end an enterokinase cleavage site (not shown) to allow cleavage of the signal sequence from the heavy chain. In the tail-to-head configuration, the
20 ovalbumin signal sequence adjacent to the gene for the heavy chain and the light chain contains on its 3' end an enterokinase cleavage site (not shown) to allow cleavage of the signal sequence from the heavy or light chain.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention provides a new, effective and efficient method of producing transgenic animals, particularly egg-laying animals and milk-producing animals, through administration of a composition comprising a transposon-based vector designed for stable incorporation of a gene of interest for production of a desired molecule.

30 Definitions

It is to be understood that as used in the specification and in the claims, "a" or "an" can mean one or more, depending upon the context in which it is used. Thus, for example, reference to "a cell" can mean that at least one cell can be utilized.

The term "antibody" is used interchangeably with the term "immunoglobulin" and is defined herein as a protein synthesized by an animal or a cell of the immune system in response to the presence of a foreign substance commonly referred to as an "antigen" or an "immunogen". The term antibody includes fragments of antibodies.

- 5 Antibodies are characterized by specific affinity to a site on the antigen, wherein the site is referred to an "antigenic determinant" or an "epitope". Antigens can be naturally occurring or artificially engineered. Artificially engineered antigens include but are not limited to small molecules, such as small peptides, attached to haptens such as macromolecules, for example proteins, nucleic acids, or polysaccharides.
- 10 Artificially designed or engineered variants of naturally occurring antibodies and artificially designed or engineered antibodies not occurring in nature are all included in the current definition. Such variants include conservatively substituted amino acids and other forms of substitution as described in the section concerning proteins and polypeptides.
- 15 As used herein, the term "egg-laying animal" includes all amniotes such as birds, turtles, lizards and monotremes. Monotremes are egg-laying mammals and include the platypus and echidna. The term "bird" or "fowl," as used herein, is defined as a member of the Aves class of animals which are characterized as warm-blooded, egg-laying vertebrates primarily adapted for flying. Avians include, without
- 20 limitation, Ratites, Psittaciformes, Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. The term "Ratite," as used herein, is defined as a group of flightless, mostly large, running birds comprising several orders and including the emus, ostriches, kiwis, and cassowaries. The term "Psittaciformes",
- 25 as used herein, includes parrots and refers to a monofamilial order of birds that exhibit zygodactylism and have a strong hooked bill. A "parrot" is defined as any member of the avian family Psittacidae (the single family of the Psittaciformes), distinguished by the short, stout, strongly hooked beak. The term "chicken" as used herein denotes chickens used for table egg production, such as egg-type chickens, chickens reared for
- 30 public meat consumption, or broilers, and chickens reared for both egg and meat production ("dual-purpose" chickens). The term "chicken" also denotes chickens produced by primary breeder companies, or chickens that are the parents,

grandparents, great-grandparents, etc. of those chickens reared for public table egg, meat, or table egg and meat consumption.

The term "egg" is defined herein as a large female sex cell enclosed in a porous, calcarous or leathery shell, produced by birds and reptiles. The term "ovum" is defined as a female gamete, and is also known as an egg. Therefore, egg production in all animals other than birds and reptiles, as used herein, is defined as the production and discharge of an ovum from an ovary, or "ovulation". Accordingly, it is to be understood that the term "egg" as used herein is defined as a large female sex cell enclosed in a porous, calcarous or leathery shell, when a bird or reptile produces it, or it is an ovum when it is produced by all other animals.

The term "milk-producing animal" refers herein to mammals including, but not limited to, bovine, ovine, porcine, equine, and primate animals. Milk-producing animals include but are not limited to cows, llamas, camels, goats, reindeer, zebu, water buffalo, yak, horses, pigs, rabbits, non-human primates, and humans.

The term "gene" is defined herein to include a coding region for a protein, peptide or polypeptide.

The term "vector" is used interchangeably with the terms "construct", "DNA construct" and "genetic construct" to denote synthetic nucleotide sequences used for manipulation of genetic material, including but not limited to cloning, subcloning, sequencing, or introduction of exogenous genetic material into cells, tissues or organisms, such as birds. It is understood by one skilled in the art that vectors may contain synthetic DNA sequences, naturally occurring DNA sequences, or both. The vectors of the present invention are transposon-based vectors as described herein.

When referring to two nucleotide sequences, one being a regulatory sequence, the term "operably-linked" is defined herein to mean that the two sequences are associated in a manner that allows the regulatory sequence to affect expression of the other nucleotide sequence. It is not required that the operably-linked sequences be directly adjacent to one another with no intervening sequence(s).

The term "regulatory sequence" is defined herein as including promoters, enhancers and other expression control elements such as polyadenylation sequences, matrix attachment sites, insulator regions for expression of multiple genes on a single construct, ribosome entry/attachment sites, introns that are able to enhance expression, and silencers.

Transposon-Based Vectors

While not wanting to be bound by the following statement, it is believed that the nature of the DNA construct is an important factor in successfully producing transgenic animals. The "standard" types of plasmid and viral vectors that have previously been almost universally used for transgenic work in all species, especially avians, have low efficiencies and may constitute a major reason for the low rates of transformation previously observed. The DNA (or RNA) constructs previously used often do not integrate into the host DNA, or integrate only at low frequencies. Other factors may have also played a part, such as poor entry of the vector into target cells. The present invention provides transposon-based vectors that can be administered to an animal that overcome the prior art problems relating to low transgene integration frequencies. Two preferred transposon-based vectors of the present invention in which a transposase, gene of interest and other polynucleotide sequences may be introduced are termed pTnMCS (SEQ ID NO:36) and pTnMod (SEQ ID NO:1).

The transposon-based vectors of the present invention produce integration frequencies an order of magnitude greater than has been achieved with previous vectors. More specifically, intratesticular injections performed with a prior art transposon-based vector (described in U.S. Patent No. 5,719,055) resulted in 41% sperm positive roosters whereas intratesticular injections performed with the novel transposon-based vectors of the present invention resulted in 77% sperm positive roosters. Actual frequencies of integration were estimated by either or both comparative strength of the PCR signal from the sperm and histological evaluation of the testes and sperm by quantitative PCR.

The transposon-based vectors of the present invention include a transposase gene operably-linked to a first promoter, and a coding sequence for a desired protein or peptide operably-linked to a second promoter, wherein the coding sequence for the desired protein or peptide and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes one or more of the following characteristics: a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:13) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first several N-terminal amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c)

addition of one or more stop codons to enhance the termination of transposase synthesis; and, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene. Figure 1 shows a schematic representation of several components of the transposon-based vector. The present invention further includes vectors containing more than one gene of interest, wherein a second or subsequent gene of interest is operably-linked to the second promoter or to a different promoter. It is also to be understood that the transposon-based vectors shown in the Figures are representational of the present invention and that the order of the vector elements may be different than that shown in the Figures, that the elements may be present in various orientations, and that the vectors may contain additional elements not shown in the Figures.

Transposases and Insertion Sequences

In a further embodiment of the present invention, the transposase found in the transposase-based vector is an altered target site (ATS) transposase and the insertion sequences are those recognized by the ATS transposase. However, the transposase located in the transposase-based vectors is not limited to a modified ATS transposase and can be derived from any transposase. Transposases known in the prior art include those found in AC7, Tn5SEQ1, Tn916, Tn951, Tn1721, Tn 2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn903, Tn501, Tn1000 ($\gamma\delta$), Tn1681, Tn2901, AC transposons, Mp transposons, Spm transposons, En transposons, Dotted transposons, Mu transposons, Ds transposons, dSpm transposons and I transposons. According to the present invention, these transposases and their regulatory sequences are modified for improved functioning as follows: a) the addition one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:13) at the 3' end of the promoter operably-linked to the transposase; b) a change of the codons for the first several amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) the addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) the addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene.

Although not wanting to be bound by the following statement, it is believed that the modifications of the first several N-terminal codons of the transposase gene increase transcription of the transposase gene, in part, by increasing strand

dissociation. It is preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the transposase are modified such that the third base of each codon is changed to an A or a T without changing the encoded amino acid. In one embodiment, the first ten N-terminal codons of the transposase gene are modified in this manner. It is also preferred that the transposase contain mutations that make it less specific for preferred insertion sites and thus increases the rate of transgene insertion as discussed in U.S. Patent No. 5,719,055.

In some embodiments, the transposon-based vectors are optimized for expression in a particular host by changing the methylation patterns of the vector DNA. For example, prokaryotic methylation may be reduced by using a methylation deficient organism for production of the transposon-based vector. The transposon-based vectors may also be methylated to resemble eukaryotic DNA for expression in a eukaryotic host.

Transposases and insertion sequences from other analogous eukaryotic transposon-based vectors that can also be modified and used are, for example, the *Drosophila* P element derived vectors disclosed in U.S. Patent No. 6,291,243; the *Drosophila* mariner element described in Sherman et al. (1998); or the sleeping beauty transposon. See also Hackett et al. (1999); D. Lampe et al., 1999. Proc. Natl. Acad. Sci. USA, 96:11428-11433; S. Fischer et al., 2001. Proc. Natl. Acad. Sci. USA, 98:6759-6764; L. Zagoraiou et al., 2001. Proc. Natl. Acad. Sci. USA, 98:11474-11478; and D. Berg et al. (Eds.), Mobile DNA, Amer. Soc. Microbiol. (Washington, D.C., 1989). However, it should be noted that bacterial transposon-based elements are preferred, as there is less likelihood that a eukaryotic transposase in the recipient species will recognize prokaryotic insertion sequences bracketing the transgene.

Many transposases recognize different insertion sequences, and therefore, it is to be understood that a transposase-based vector will contain insertion sequences recognized by the particular transposase also found in the transposase-based vector. In a preferred embodiment of the invention, the insertion sequences have been shortened to about 70 base pairs in length as compared to those found in wild-type transposons that typically contain insertion sequences of well over 100 base pairs.

While the examples provided below incorporate a "cut and insert" Tn10 based vector that is destroyed following the insertion event, the present invention also

encompasses the use of a "rolling replication" type transposon-based vector. Use of a rolling replication type transposon allows multiple copies of the transposon/transgene to be made from a single transgene construct and the copies inserted. This type of transposon-based system thereby provides for insertion of multiple copies of a transgene into a single genome. A rolling replication type transposon-based vector may be preferred when the promoter operably-linked to gene of interest is endogenous to the host cell and present in a high copy number or highly expressed. However, use of a rolling replication system may require tight control to limit the insertion events to non-lethal levels. Tn1, Tn2, Tn3, Tn4, Tn5, Tn9, Tn21, Tn501, Tn551, Tn951, Tn1721, Tn2410 and Tn2603 are examples of a rolling replication type transposon, although Tn5 could be both a rolling replication and a cut and insert type transposon.

Stop Codons and PolyA Sequences

In one embodiment, the transposon-based vector contains two stop codons operably-linked to the transposase and/or to the gene of interest. In an alternate embodiment, one stop codon of UAA or UGA is operably linked to the transposase and/or to the gene of interest. As used herein an "effective polyA sequence" refers to either a synthetic or non-synthetic sequence that contains multiple and sequential nucleotides containing an adenine base (an A polynucleotide string) and that increases expression of the gene to which it is operably-linked. A polyA sequence may be operably-linked to any gene in the transposon-based vector including, but not limited to, a transposase gene and a gene of interest. In one embodiment, a polyA sequence comprises the polynucleotide sequence provided in SEQ ID NO:28. A preferred polyA sequence is optimized for use in the host animal or human. In one embodiment, the polyA sequence is optimized for use in a bird, and more specifically, a chicken. The chicken optimized polyA sequence generally contains a minimum of 60 base pairs, and more preferably between approximately 60 and several hundred base pairs, that precede the A polynucleotide string and thereby separate the stop codon from the A polynucleotide string. A chicken optimized polyA sequence may also have a reduced amount of CT repeats as compared to a synthetic polyA sequence. In one embodiment of the present invention, the polyA sequence comprises a conalbumin polyA sequence as provided in SEQ ID NO:33 and as taken from GenBank accession # Y00407, base pairs 10651-11058.

Promoters and Enhancers

The first promoter operably-linked to the transposase gene and the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter. Constitutive promoters include, but are not limited to, immediate early cytomegalovirus (CMV) promoter, herpes simplex virus 1 (HSV1) immediate early promoter, SV40 promoter, lysozyme promoter, early and late CMV promoters, early and late HSV promoters, β -actin promoter, tubulin promoter, Rous-Sarcoma virus (RSV) promoter, and heat-shock protein (HSP) promoter. Inducible promoters include tissue-specific promoters, developmentally-regulated promoters and chemically inducible promoters. Examples of tissue-specific promoters include the glucose 6 phosphate (G6P) promoter, vitellogenin promoter, ovalbumin promoter, ovomucoid promoter, conalbumin promoter, ovotransferrin promoter, prolactin promoter, kidney uromodulin promoter, and placental lactogen promoter. In one embodiment, the vitellogenin promoter includes a polynucleotide sequence of SEQ ID NO:17. The G6P promoter sequence may be deduced from a rat G6P gene untranslated upstream region provided in GenBank accession number U57552.1. Examples of developmentally-regulated promoters include the homeobox promoters and several hormone induced promoters. Examples of chemically inducible promoters include reproductive hormone induced promoters and antibiotic inducible promoters such as the tetracycline inducible promoter and the zinc-inducible metallothioneine promoter.

Other inducible promoter systems include the Lac operator repressor system inducible by IPTG (isopropyl beta-D-thiogalactoside) (Cronin, A. et al. 2001. *Genes and Development*, v. 15), ecdysone-based inducible systems (Hoppe, U. C. et al. 2000. *Mol. Ther.* 1:159-164); estrogen-based inducible systems (Brasemann, S. et al. 1993. *Proc. Natl. Acad. Sci.* 90:1657-1661); progesterone-based inducible systems using a chimeric regulator, GLVP, which is a hybrid protein consisting of the GAL4 binding domain and the herpes simplex virus transcriptional activation domain, VP16, and a truncated form of the human progesterone receptor that retains the ability to bind ligand and can be turned on by RU486 (Wang, et al. 1994. *Proc. Natl. Acad. Sci.* 91:8180-8184); CID-based inducible systems using chemical inducers of dimerization (CIDs) to regulate gene expression, such as a system wherein rapamycin induces dimerization of the cellular proteins FKBP12 and FRAP (Belshaw, P. J. et al. 1996. *J.*

Chem. Biol. 3:731-738; Fan, L. et al. 1999. Hum. Gene Ther. 10:2273-2285; Shariat, S.F. et al. 2001. Cancer Res. 61:2562-2571; Spencer, D.M. 1996. Curr. Biol. 6:839-847). Chemical substances that activate the chemically inducible promoters can be administered to the animal containing the transgene of interest via any method known to those of skill in the art.

Other examples of cell or tissue-specific and constitutive promoters include but are not limited to smooth-muscle SM22 promoter, including chimeric SM22alpha/telokin promoters (Hoggatt A.M. et al., 2002. Circ Res. 91(12):1151-9); ubiquitin C promoter (Biochim Biophys Acta, 2003. Jan. 3;1625(1):52-63); Hsf2 promoter; murine COMP (cartilage oligomeric matrix protein) promoter; early B cell-specific mb-1 promoter (Sigvardsson M., et al., 2002. Mol. Cell Biol. 22(24):8539-51); prostate specific antigen (PSA) promoter (Yoshimura I. et al., 2002, J. Urol. 168(6):2659-64); exorh promoter and pineal expression-promoting element (Asaoka Y., et al., 2002. Proc. Natl. Acad. Sci. 99(24):15456-61); neural and liver ceramidase gene promoters (Okino N. et al., 2002. Biochem. Biophys. Res. Commun. 299(1):160-6); PSP94 gene promoter/enhancer (Gabril M.Y. et al., 2002. Gene Ther. 9(23):1589-99); promoter of the human FAT/CD36 gene (Kuriki C., et al., 2002. Biol. Pharm. Bull. 25(11):1476-8); VL30 promoter (Staplin W.R. et al., 2002. Blood October 24, 2002); IL-10 promoter (Brenner S., et al., 2002. J. Biol. Chem. December 18, 2002).

Examples of avian promoters include, but are not limited to, promoters controlling expression of egg white proteins, such as ovalbumin, ovotransferrin (conalbumin), ovomucoid, lysozyme, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, ovostatin (ovomacroglobin), cystatin, avidin, thiamine-binding protein, glutamyl aminopeptidase minor glycoprotein 1, minor glycoprotein 2; and promoters controlling expression of egg-yolk proteins, such as vitellogenin, very low-density lipoproteins, low density lipoprotein, cobalamin-binding protein, riboflavin-binding protein, biotin-binding protein (Awade, 1996. Z. Lebensm. Unters. Forsch. 202:1-14). An advantage of using the vitellogenin promoter is that it is active during the egg-laying stage of an animal's life-cycle, which allows for the production of the protein of interest to be temporally connected to the import of the protein of interest into the egg yolk when the protein of interest is equipped with an appropriate targeting sequence.

Liver-specific promoters of the present invention include, but are not limited to, the following promoters, vitellogenin promoter, G6P promoter, cholesterol-7-alpha-hydroxylase (CYP7A) promoter, phenylalanine hydroxylase (PAH) promoter, protein C gene promoter, insulin-like growth factor I (IGF-I) promoter, bilirubin
5 UDP-glucuronosyltransferase promoter, aldolase B promoter, furin promoter, metallothioneine promoter, albumin promoter, and insulin promoter.

Also included in the present invention are promoters that can be used to target expression of a protein of interest into the milk of a milk-producing animal including, but not limited to, β lactoglobulin promoter, whey acidic protein promoter, lactalbumin
10 promoter and casein promoter.

Promoters associated with cells of the immune system may also be used. Acute phase promoters such as interleukin (IL)-1 and IL-2 may be employed. Promoters for heavy and light chain Ig may also be employed. The promoters of the T cell receptor components CD4 and CD8, B cell promoters and the promoters of
15 CR2 (complement receptor type 2) may also be employed. Immune system promoters are preferably used when the desired protein is an antibody protein.

Also included in this invention are modified promoters/enhancers wherein elements of a single promoter are duplicated, modified, or otherwise changed. In one embodiment, steroid hormone-binding domains of the ovalbumin promoter are moved
20 from about -6.5 kb to within approximately the first 1000 base pairs of the gene of interest. Modifying an existing promoter with promoter/enhancer elements not found naturally in the promoter, as well as building an entirely synthetic promoter, or drawing promoter/enhancer elements from various genes together on a non-natural backbone, are all encompassed by the current invention.

Accordingly, it is to be understood that the promoters contained within the transposon-based vectors of the present invention may be entire promoter sequences or fragments of promoter sequences. For example, in one embodiment, the promoter operably linked to a gene of interest is an approximately 900 base pair fragment of a chicken ovalbumin promoter (SEQ ID NO:40). The constitutive and inducible
25 promoters contained within the transposon-based vectors may also be modified by the
30 addition of one or more modified Kozak sequences of ACCATG (SEQ ID NO:13).

As indicated above, the present invention includes transposon-based vectors containing one or more enhancers. These enhancers may or may not be operably-

linked to their native promoter and may be located at any distance from their operably-linked promoter. A promoter operably-linked to an enhancer is referred to herein as an "enhanced promoter." The enhancers contained within the transposon-based vectors are preferably enhancers found in birds, and more preferably, an ovalbumin enhancer, but are not limited to these types of enhancers. In one embodiment, an approximately 675 base pair enhancer element of an ovalbumin promoter is cloned upstream of an ovalbumin promoter with 300 base pairs of spacer DNA separating the enhancer and promoter. In one embodiment, the enhancer used as a part of the present invention comprises base pairs 1-675 of a Chicken Ovalbumin enhancer from GenBank accession #S82527.1. The polynucleotide sequence of this enhancer is provided in SEQ ID NO:37.

Also included in some of the transposon-based vectors of the present invention are cap sites and fragments of cap sites. In one embodiment, approximately 50 base pairs of a 5' untranslated region wherein the capsite resides are added on the 3' end of an enhanced promoter or promoter. An exemplary 5' untranslated region is provided in SEQ ID NO:38. A putative cap-site residing in this 5' untranslated region preferably comprises the polynucleotide sequence provided in SEQ ID NO:39.

In one embodiment of the present invention, the first promoter operably-linked to the transposase gene is a constitutive promoter and the second promoter operably-linked to the gene of interest is a tissue-specific promoter. In this embodiment, use of the first constitutive promoter allows for constitutive activation of the transposase gene and incorporation of the gene of interest into virtually all cell types, including the germline of the recipient animal. Although the gene of interest is incorporated into the germline generally, the gene of interest is only expressed in a tissue-specific manner. It should be noted that cell- or tissue-specific expression as described herein does not require a complete absence of expression in cells or tissues other than the preferred cell or tissue. Instead, "cell-specific" or "tissue-specific" expression refers to a majority of the expression of a particular gene of interest in the preferred cell or tissue, respectively.

When incorporation of the gene of interest into the germline is not preferred, the first promoter operably-linked to the transposase gene can be a tissue-specific promoter. For example, transfection of a transposon-based vector containing a transposase gene operably-linked to a liver-specific promoter such as the G6P

promoter or vitellogenin promoter provides for activation of the transposase gene and incorporation of the gene of interest in the cells of the liver but not into the germline and other cells generally. In this second embodiment, the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter.

- 5 In a preferred embodiment, both the first promoter and the second promoter are a G6P promoter. In embodiments wherein tissue-specific expression or incorporation is desired, it is preferred that the transposon-based vector is administered directly to the tissue of interest or to an artery leading to the tissue of interest.

- Accordingly, cell specific promoters may be used to enhance transcription in
10 selected tissues. In birds, for example, promoters that are found in cells of the fallopian tube, such as ovalbumin, conalbumin, ovomucoid and/or lysozyme, are used in the vectors to ensure transcription of the gene of interest in the epithelial cells and tubular gland cells of the fallopian tube, leading to synthesis of the desired protein encoded by the gene and deposition into the egg white. In mammals, promoters
15 specific for the epithelial cells of the alveoli of the mammary gland, such as prolactin, insulin, beta lactoglobulin, whey acidic protein, lactalbumin, casein, and/or placental lactogen, are used in the design of vectors used for transfection of these cells for the production of desired proteins for deposition into the milk. In liver cells, the G6P promoter may be employed to drive transcription of the gene of interest for protein
20 production. Proteins made in the liver of birds may be delivered to the egg yolk.

- In order to achieve higher or more efficient expression of the transposase gene, the promoter and other regulatory sequences operably-linked to the transposase gene may be those derived from the host. These host specific regulatory sequences can be tissue specific as described above or can be of a constitutive nature. For
25 example, an avian actin promoter and its associated polyA sequence can be operably-linked to a transposase in a transposase-based vector for transfection into an avian. Examples of other host specific promoters that could be operably-linked to the transposase include the myosin and DNA or RNA polymerase promoters.

Directing Sequences

- 30 In some embodiments of the present invention, the gene of interest is operably-linked to a directing sequence or a sequence that provides proper conformation to the desired protein encoded by the gene of interest. As used herein, the term "directing sequence" refers to both signal sequences and targeting sequences.

An egg directing sequence includes, but is not limited to, an ovomucoid signal sequence, an ovalbumin signal sequence and a vitellogenin targeting sequence. The term "signal sequence" refers to an amino acid sequence, or the polynucleotide sequence that encodes the amino acid sequence, that directs the protein to which it is
5 linked to the endoplasmic reticulum in a eukaryote, and more preferably the translocational pores in the endoplasmic reticulum, or the plasma membrane in a prokaryote, or mitochondria, such as for the purpose of gene therapy of mitochondrial diseases. Signal and targeting sequences can be used to direct a desired protein into, for example, the milk, when the transposon-based vectors are administered to a milk-
10 producing animal.

Signal sequences can also be used to direct a desired protein into, for example, a secretory pathway for incorporation into the egg yolk or the egg white, when the transposon-based vectors are administered to a bird or other egg-laying animal. One example of such a transposon-based vector is provided in Figure 3 wherein the gene
15 of interest is operably linked to the ovomucoid signal sequence. The present invention also includes a gene of interest operably-linked to a second gene containing a signal sequence. An example of such an embodiment is shown in Figure 2 wherein the gene of interest is operably-linked to the ovalbumin gene that contains an ovalbumin signal sequence. Other signal sequences that can be included in the
20 transposon-based vectors include, but are not limited to the ovotransferrin and lysozyme signal sequences.

As also used herein, the term "targeting sequence" refers to an amino acid sequence, or the polynucleotide sequence encoding the amino acid sequence, which amino acid sequence is recognized by a receptor located on the exterior of a cell.
25 Binding of the receptor to the targeting sequence results in uptake of the protein or peptide operably-linked to the targeting sequence by the cell. One example of a targeting sequence is a vitellogenin targeting sequence that is recognized by a vitellogenin receptor (or the low density lipoprotein receptor) on the exterior of an oocyte. In one embodiment, the vitellogenin targeting sequence includes the
30 polynucleotide sequence of SEQ ID NO:18. In another embodiment, the vitellogenin targeting sequence includes all or part of the vitellogenin gene. Other targeting sequences include VLDL and Apo E, which are also capable of binding the vitellogenin receptor. Since the ApoE protein is not endogenously expressed in birds,

its presence may be used advantageously to identify birds carrying the transposon-based vectors of the present invention.

Genes of Interest Encoding Desired Proteins

A gene of interest selected for stable incorporation is designed to encode any
5 desired protein or peptide or to regulate any cellular response. In some embodiments, the desired proteins or peptides are deposited in an egg or in milk. It is to be understood that the present invention encompasses transposon-based vectors containing multiple genes of interest. The multiple genes of interest may each be operably-linked to a separate promoter and other regulatory sequence(s) or may all be
10 operably-linked to the same promoter and other regulatory sequences(s). In one embodiment, multiple gene of interest are linked to a single promoter and other regulatory sequence(s) and each gene of interest is separated by a cleavage site or a pro portion of a signal sequence.

Protein and peptide hormones are a preferred class of proteins in the present
15 invention. Such protein and peptide hormones are synthesized throughout the endocrine system and include, but are not limited to, hypothalamic hormones and hypophysiotropic hormones, anterior, intermediate and posterior pituitary hormones, pancreatic islet hormones, hormones made in the gastrointestinal system, renal hormones, thymic hormones, parathyroid hormones, adrenal cortical and medullary
20 hormones. Specifically, hormones that can be produced using the present invention include, but are not limited to, chorionic gonadotropin, corticotropin, erythropoietin, glucagons, IGF-1, oxytocin, platelet-derived growth factor, calcitonin, follicle-stimulating hormone, leutinizing hormone, thyroid-stimulating hormone, insulin, gonadotropin-releasing hormone and its analogs, vasopressin, octreotide,
25 somatostatin, prolactin, adrenocorticotrophic hormone, antidiuretic hormone, thyrotropin-releasing hormone (TRH), growth hormone-releasing hormone (GHRH), dopamine, melatonin, thyroxin (T₄), parathyroid hormone (PTH), glucocorticoids such as cortisol, mineralocorticoids such as aldosterone, androgens such as testosterone, adrenaline (epinephrine), noradrenaline (norepinephrine), estrogens such
30 as estradiol, progesterone, glucagons, calcitrol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin (CCK), neuropeptide Y, ghrelin, PYY₃₋₃₆, angiotensinogen, thrombopoietin, and leptin. By using appropriate polynucleotide sequences, species-specific hormones may be made by transgenic animals.

In one embodiment of the present invention, the gene of interest is a proinsulin gene and the desired molecule is insulin. Proinsulin consists of three parts: a C-peptide and two long strands of amino acids (called the alpha and beta chains) that later become linked together to form the insulin molecule. Figures 2 and 3 are schematics of transposon-based vector constructs containing a proinsulin gene operably-linked to an ovalbumin promoter and ovalbumin protein or an ovomucoid promoter and ovomucoid signal sequence, respectively. In these embodiments, proinsulin is expressed in the oviduct tubular gland cells and then deposited in the egg white. One example of a proinsulin polynucleotide sequence is shown in SEQ ID NO:21, wherein the C-peptide cleavage site spans from Arg at position 31 to Arg at position 65.

Serum proteins including lipoproteins such as high density lipoprotein (HDL), HDL-Milano and low density lipoprotein, albumin, clotting cascade factors, factor VIII, factor IX, fibrinogen, and globulins are also included in the group of desired proteins of the present invention. Immunoglobulins are one class of desired globulin molecules and include but are not limited to IgG, IgM, IgA, IgD, IgE, IgY, lambda chains, kappa chains and fragments thereof; Fc fragments, and Fab fragments. Desired antibodies include, but are not limited to, naturally occurring antibodies, human antibodies, humanized antibodies, and hybrid antibodies. Genes encoding modified versions of naturally occurring antibodies or fragments thereof and genes encoding artificially designed antibodies or fragments thereof may be incorporated into the transposon-based vectors of the present invention. Desired antibodies also include antibodies with the ability to bind specific ligands, for example, antibodies against proteins associated with cancer-related molecules, such as anti-her 2, or anti-CA125. Accordingly, the present invention encompasses a transposon-based vector containing one or more genes encoding a heavy immunoglobulin (Ig) chain and a light Ig chain. Further, more than one gene encoding for more than one antibody may be administered in one or more transposon-based vectors of the present invention. In this manner, an egg may contain more than one type of antibody in the egg white, the egg yolk or both.

In one embodiment, a transposon-based vector contains a heavy Ig chain and a light Ig chain, both operably linked to a promoter. Figures 5 and 6 schematically depict exemplary constructs of this embodiment. More specifically, Figure 5 shows a

construct containing a cecropin pre-pro sequence and a cecropin pro sequence, wherein the pre sequence functions to direct the resultant protein into the endoplasmic reticulum and the pro sequences and the pro sequences are cleaved upon secretion of the protein from a cell into which the construct has been transfected. Figure 6 shows
5 a construct containing an enterokinase cleavage site. In this embodiment, it may be required to further remove several additional amino acids from the light chain following cleavage by enterokinase. In another embodiment, the transposon-based vector comprises a heavy Ig chain operably-linked to one promoter and a light Ig chain operably-linked to another promoter. Figure 7 schematically depicts an
10 exemplary construct of this embodiment. The present invention also encompasses a transposon-based vector containing genes encoding portions of a heavy Ig chain and/or portions of a light Ig chain. The present invention further includes a transposon-based vector containing a gene that encodes a fusion protein comprising a heavy and/or light Ig chain, or portions thereof.

15 Antibodies used as therapeutic reagents include but are not limited to antibodies for use in cancer immunotherapy against specific antigens, or for providing passive immunity to an animal or a human against an infectious disease or a toxic agent. Antibodies used as diagnostic reagents include, but are not limited to
20 antibodies that may be labeled and detected with a detector, for example antibodies with a fluorescent label attached that may be detected following exposure to specific wavelengths. Such labeled antibodies may be primary antibodies directed to a specific antigen, for example, rhodamine-labeled rabbit anti-growth hormone, or may be labeled secondary antibodies, such as fluorescein-labeled goat-anti chicken IgG. Such labeled antibodies are known to one of ordinary skill in the art. Labels useful
25 for attachment to antibodies are also known to one of ordinary skill in the art. Some of these labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety.

30 Antibodies produced with using the present invention may be used as laboratory reagents for numerous applications including radioimmunoassay, western blots, dot blots, ELISA, immunoaffinity columns and other procedures requiring antibodies as known to one of ordinary skill in the art. Such antibodies include

primary antibodies, secondary antibodies and tertiary antibodies, which may be labeled or unlabeled.

Antibodies that may be made with the practice of the present invention include, but are not limited to primary antibodies, secondary antibodies, designer antibodies, anti-protein antibodies, anti-peptide antibodies, anti-DNA antibodies, anti-RNA antibodies, anti-hormone antibodies, anti-hypophysiotropic peptides, antibodies against non-natural antigens, anti-anterior pituitary hormone antibodies, anti-posterior pituitary hormone antibodies, anti-venom antibodies, anti-tumor marker antibodies, antibodies directed against epitopes associated with infectious disease, including, anti-viral, anti-bacterial, anti-protozoal, anti-fungal, anti-parasitic, anti-receptor, anti-lipid, anti-phospholipid, anti-growth factor, anti-cytokine, anti-monokine, anti-idiotypic, and anti-accessory (presentation) protein antibodies. Antibodies made with the present invention, as well as light chains or heavy chains, may also be used to inhibit enzyme activity.

Antibodies that may be produced using the present invention include, but are not limited to, antibodies made against the following proteins: Bovine γ -Globulin, Serum; Bovine IgG, Plasma; Chicken γ -Globulin, Serum; Human γ -Globulin, Serum; Human IgA, Plasma; Human IgA₁, Myeloma; Human IgA₂, Myeloma; Human IgA₂, Plasma; Human IgD, Plasma; Human IgE, Myeloma; Human IgG, Plasma; Human IgG, Fab Fragment, Plasma; Human IgG, F(ab')₂ Fragment, Plasma; Human IgG, Fc Fragment, Plasma; Human IgG₁, Myeloma; Human IgG₂, Myeloma; Human IgG₃, Myeloma; Human IgG₄, Myeloma; Human IgM, Myeloma; Human IgM, Plasma; Human Immunoglobulin, Light Chain κ , Urine; Human Immunoglobulin, Light Chains κ and λ , Plasma; Mouse γ -Globulin, Serum; Mouse IgG, Serum; Mouse IgM, Myeloma; Rabbit γ -Globulin, Serum; Rabbit IgG, Plasma; and Rat γ -Globulin, Serum. In one embodiment, the transposon-based vector comprises the coding sequence of light and heavy chains of a murine monoclonal antibody that shows specificity for human seminoprotein (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

A further non-limiting list of antibodies that recognize other antibodies is as follows: Anti-Chicken IgG, heavy (H) & light (L) Chain Specific (Sheep); Anti-Goat γ -Globulin (Donkey); Anti-Goat IgG, Fc Fragment Specific (Rabbit); Anti-Guinea Pig γ -Globulin (Goat); Anti-Human Ig, Light Chain, Type κ Specific; Anti-Human Ig,

Light Chain, Type λ Specific; Anti-Human IgA, α -Chain Specific (Goat); Anti-Human IgA, Fab Fragment Specific; Anti-Human IgA, Fc Fragment Specific; Anti-Human IgA, Secretory; Anti-Human IgE, ϵ -Chain Specific (Goat); Anti-Human IgE, Fc Fragment Specific; Anti-Human IgG, Fc Fragment Specific (Goat); Anti-Human
 5 IgG, γ -Chain Specific (Goat); Anti-Human IgG, Fc Fragment Specific; Anti-Human IgG, Fd Fragment Specific; Anti-Human IgG, H & L Chain Specific (Goat); Anti-Human IgG₁, Fc Fragment Specific; Anti-Human IgG₂, Fc Fragment Specific; Anti-Human IgG₂, Fd Fragment Specific; Anti-Human IgG₃, Hinge Specific; Anti-Human IgG₄, Fc Fragment Specific; Anti-Human IgM, Fc Fragment Specific; Anti-Human
 10 IgM, μ -Chain Specific; Anti-Mouse IgE, ϵ -Chain Specific; Anti-Mouse γ -Globulin (Goat); Anti-Mouse IgG, γ -Chain Specific (Goat); Anti-Mouse IgG, γ -Chain Specific (Goat) F(ab')₂ Fragment; Anti-Mouse IgG, H & L Chain Specific (Goat); Anti-Mouse IgM, μ -Chain Specific (Goat); Anti-Mouse IgM, H & L Chain Specific (Goat); Anti-Rabbit γ -Globulin (Goat); Anti-Rabbit IgG, Fc Fragment Specific (Goat); Anti-Rabbit
 15 IgG, H & L Chain Specific (Goat); Anti-Rat γ -Globulin (Goat); Anti-Rat IgG, H & L Chain Specific; Anti-Rhesus Monkey γ -Globulin (Goat); and, Anti-Sheep IgG, H & L Chain Specific.

Another non-limiting list of the antibodies that may be produced using the present invention is provided in product catalogs of companies such as Phoenix
 20 Pharmaceuticals, Inc. (www.phoenixpeptide.com; 530 Harbor Boulevard, Belmont, CA), Peninsula Labs San Carlos CA, SIGMA, St. Louis, MO www.sigma-aldrich.com, Cappel ICN, Irvine, California, www.icnbiomed.com, and Calbiochem, La Jolla, California, www.calbiochem.com, which are all incorporated herein by reference in their entirety. The polynucleotide sequences encoding these antibodies
 25 may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons that encode for each amino acid in the desired antibody. Antibodies made by the transgenic animals of the present invention include antibodies that may be used as
 30 therapeutic reagents, for example in cancer immunotherapy against specific antigens, as diagnostic reagents and as laboratory reagents for numerous applications including immunoneutralization, radioimmunoassay, western blots, dot blots, ELISA, immunoprecipitation and immunoaffinity columns. Some of these antibodies include,

The following is yet another non-limiting of antibodies that can be produced by the methods of present invention: abciximab (ReoPro), abciximab anti-platelet aggregation monoclonal antibody, anti-CD11a (hu1124), anti-CD18 antibody, anti-CD20 antibody, anti-cytomegalovirus (CMV) antibody, anti-digoxin antibody, anti-hepatitis B antibody, anti-HER-2 antibody, anti-idiotypic antibody to GD3 glycolipid, anti-IgE antibody, anti-IL-2R antibody, antimetastatic cancer antibody (mAb 17-1A), anti-rabies antibody, anti-respiratory syncytial virus (RSV) antibody, anti-Rh antibody, anti-TCR, anti-TNF antibody, anti-VEGF antibody and fab fragment thereof, rattlesnake venom antibody, black widow spider venom antibody, coral snake venom antibody, antibody against very late antigen-4 (VLA-4), C225 humanized antibody to EGF receptor, chimeric (human & mouse) antibody against TNF α .

antibody directed against GPIIb/IIIa receptor on human platelets, gamma globulin, anti-hepatitis B immunoglobulin, human anti-D immunoglobulin, human antibodies against *S aureus*, human tetanus immunoglobulin, humanized antibody against the epidermal growth receptor-2, humanized antibody against the α subunit of the interleukin-2 receptor, humanized antibody CTLA4IG, humanized antibody to the IL-2 R α -chain, humanized anti-CD40-ligand monoclonal antibody (5c8), humanized mAb against the epidermal growth receptor-2, humanized mAb to rous sarcoma virus, humanized recombinant antibody (IgG1k) against respiratory syncytial virus (RSV), lymphocyte immunoglobulin (anti-thymocyte antibody), lymphocyte immunoglobulin, mAb against factor VII, MDX-210 bi-specific antibody against HER-2, MDX-22, MDX-220 bi-specific antibody against TAG-72 on tumors, MDX-33 antibody to Fc γ R1 receptor, MDX-447 bi-specific antibody against EGF receptor, MDX-447 bispecific humanized antibody to EGF receptor, MDX-RA immunotoxin (ricin A linked) antibody, Medi-507 antibody (humanized form of BTI-322) against CD2 receptor on T-cells, monoclonal antibody LDP-02, muromonab-CD3(OKT3) antibody, OKT3 ("muromomab-CD3") antibody, PRO 542 antibody, ReoPro ("abciximab") antibody, and TNF-IgG fusion protein.

The antibodies prepared using the methods of the present invention may also be designed to possess specific labels that may be detected through means known to one of ordinary skill in the art. The antibodies may also be designed to possess specific sequences useful for purification through means known to one of ordinary skill in the art. Specialty antibodies designed for binding specific antigens may also be made in transgenic animals using the transposon-based vectors of the present invention.

Production of a monoclonal antibody using the transposon-based vectors of the present invention can be accomplished in a variety of ways. In one embodiment, two vectors may be constructed: one that encodes the light chain, and a second vector that encodes the heavy chain of the monoclonal antibody. These vectors may then be incorporated into the genome of the target animal by methods disclosed herein. In an alternative embodiment, the sequences encoding light and heavy chains of a monoclonal antibody may be included on a single DNA construct. For example, the coding sequence of light and heavy chains of a murine monoclonal antibody that show specificity for human seminoprotein can be expressed using transposon-based

constructs of the present invention (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

Further included in the present invention are proteins and peptides synthesized by the immune system including those synthesized by the thymus, lymph nodes, spleen, and the gastrointestinal associated lymph tissues (GALT) system. The immune system proteins and peptides proteins that can be made in transgenic animals using the transposon-based vectors of the present invention include, but are not limited to, alpha-interferon, beta-interferon, gamma-interferon, alpha-interferon A, alpha-interferon 1, G-CSF, GM-CSF, interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF- α , and TNF- β . Other cytokines included in the present invention include cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1 alpha), 2, 3 alpha, 3 beta, 4 and 5.

Lytic peptides such as p146 are also included in the desired molecules of the present invention. In one embodiment, the p146 peptide comprises an amino acid sequence of SEQ ID NO:19. The present invention also encompasses a transposon-based vector comprising a p146 nucleic acid comprising a polynucleotide sequence of SEQ ID NO:20.

Enzymes are another class of proteins that may be made through the use of the transposon-based vectors of the present invention. Such enzymes include but are not limited to adenosine deaminase, alpha-galactosidase, cellulase, collagenase, dnaseI, hyaluronidase, lactase, L-asparaginase, pancreatin, papain, streptokinase B, subtilisin, superoxide dismutase, thrombin, trypsin, urokinase, fibrinolysin, glucocerebrosidase and plasminogen activator. In some embodiments wherein the enzyme could have deleterious effects, additional amino acids and a protease cleavage site are added to the carboxy end of the enzyme of interest in order to prevent expression of a functional enzyme. Subsequent digestion of the enzyme with a protease results in activation of the enzyme.

Extracellular matrix proteins are one class of desired proteins that may be made through the use of the present invention. Examples include but are not limited to collagen, fibrin, elastin, laminin, and fibronectin and subtypes thereof. Intracellular

proteins and structural proteins are other classes of desired proteins in the present invention.

Growth factors are another desired class of proteins that may be made through the use of the present invention and include, but are not limited to, transforming growth factor- α ("TGF- α "), transforming growth factor- β (TGF- β), platelet-derived growth factors (PDGF), fibroblast growth factors (FGF), including FGF acidic isoforms 1 and 2, FGF basic form 2 and FGF 4, 8, 9 and 10, nerve growth factors (NGF) including NGF 2.5s, NGF 7.0s and beta NGF and neurotrophins, brain derived neurotrophic factor, cartilage derived factor, growth factors for stimulation of the production of red blood cells, growth factors for stimulation of the production of white blood cells, bone growth factors (BGF), basic fibroblast growth factor, vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), insulin like growth factor (IGF) I and II, hepatocyte growth factor, glial neurotrophic growth factor (GDNF), stem cell factor (SCF), keratinocyte growth factor (KGF), transforming growth factors (TGF), including TGFs alpha, beta, beta1, beta2, beta3, skeletal growth factor, bone matrix derived growth factors, bone derived growth factors, erythropoietin (EPO) and mixtures thereof.

Another desired class of proteins that may be made may be made through the use of the present invention include but are not limited to leptin, leukemia inhibitory factor (LIF), tumor necrosis factor alpha and beta, ENBREL, angiostatin, endostatin, thrombospondin, osteogenic protein-1, bone morphogenetic proteins 2 and 7, osteonectin, somatomedin-like peptide, and osteocalcin.

A non-limiting list of the peptides and proteins that may be made may be made through the use of the present invention is provided in product catalogs of companies such as Phoenix Pharmaceuticals, Inc. (www.phoenixpeptide.com; 530 Harbor Boulevard • Belmont, CA), Peninsula Labs San Carlos CA, SIGMA, St.Louis, MO www.sigma-aldrich.com, Cappel ICN, Irvine, California, www.icnbiomed.com, and Calbiochem, La Jolla, California, www.calbiochem.com. The polynucleotide sequences encoding these proteins and peptides of interest may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons that encode for each amino acid in the desired protein or peptide.

Some of these desired proteins or peptides that may be made through the use of the present invention include but are not limited to the following: adrenomedulin, amylin, calcitonin, amyloid, calcitonin gene-related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide, interleukin, interferon, cortistatin, 5 somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone, melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM, 10 PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiotensin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide, 15 peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:19, 20 amino acid sequence, SEQ ID NO:20, nucleotide sequence), thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, and prohormones, propeptides, splice variants, fragments and analogs thereof.

Other desired proteins that may be made by the transgenic animals of the present invention include bacitracin, polymixin b, vancomycin, cyclosporine, anti- 25 RSV antibody, alpha-1 antitrypsin (AAT), anti-cytomegalovirus antibody, anti-hepatitis antibody, anti-inhibitor coagulant complex, anti-rabies antibody, anti-Rh(D) antibody, adenosine deaminase, anti-digoxin antibody, antivenin crotalidae (rattlesnake venom antibody), antivenin latrodectus (black widow spider venom antibody), antivenin micrurus (coral snake venom antibody), aprotinin, corticotropin 30 (ACTH), diphtheria antitoxin, lymphocyte immune globulin (anti-thymocyte antibody), protamine, thyrotropin, capreomycin, α -galactosidase, gramicidin, streptokinase, tetanus toxoid, tyrothricin, IGF-1, proteins of varicella vaccine, anti-TNF antibody, anti-IL-2r antibody, anti-HER-2 antibody, OKT3 ("muromonab-

CD3") antibody, TNF-IgG fusion protein, ReoPro ("abciximab") antibody, ACTH fragment 1-24, desmopressin, gonadotropin-releasing hormone, histrelin, leuprolide, lypressin, nafarelin, peptide that binds GPIIb/GPIIIa on platelets (integrilin), goserelin, capreomycin, colistin, anti-respiratory syncytial virus, lymphocyte immune globulin (Thymoglovin, Atgam), panorex, alpha-antitrypsin, botulinin, lung surfactant protein, tumor necrosis receptor-IgG fusion protein (enbrel), gonadorelin, proteins of influenza vaccine, proteins of rotavirus vaccine, proteins of haemophilus b conjugate vaccine, proteins of poliovirus vaccine, proteins of pneumococcal conjugate vaccine, proteins of meningococcal C vaccine, proteins of influenza vaccine, megakaryocyte growth and development factor (MGDF), neuroimmunophilin ligand-A (NIL-A), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), leptin (native), leptin B, leptin C, IL-1RA (interleukin-1RA), R-568, novel erythropoiesis-stimulating protein (NESP), humanized mAb to rous sarcoma virus (MEDI-493), glutamyl-tryptophan dipeptide IM862, LFA-3TIP immunosuppressive, humanized anti-CD40-ligand monoclonal antibody (5c8), gelsolin enzyme, tissue factor pathway inhibitor (TFPI), proteins of meningitis B vaccine, antimetastatic cancer antibody (mAb 17-1A), chimeric (human & mouse) mAb against TNF α , mAb against factor VII, relaxin, capreomycin, glycopeptide (LY333328), recombinant human activated protein C (rhAPC), humanized mAb against the epidermal growth receptor-2, altepase, anti-CD20 antigen, C2B8 antibody, insulin-like growth factor-1, atrial natriuretic peptide (anaritide), tenectapase, anti-CD11a antibody (hu 1124), anti-CD18 antibody, mAb LDP-02, anti-VEGF antibody, fab fragment of anti-VEGF Ab, APO2 ligand (tumor necrosis factor-related apoptosis-inducing ligand), rTGF- β (transforming growth factor- β), alpha-antitrypsin, ananain (a pineapple enzyme), humanized mAb CTLA4IG, PRO 542 (mAb), D2E7 (mAb), calf intestine alkaline phosphatase, α -L-iduronidase, α -L-galactosidase (humanglutamic acid decarboxylase, acid sphingomyelinase, bone morphogenetic protein-2 (rhBMP-2), proteins of HIV vaccine, T cell receptor (TCR) peptide vaccine, TCR peptides, V beta 3 and V beta 13.1. (IR502), (IR501), BI 1050/1272 mAb against very late antigen-4 (VLA-4), C225 humanized mAb to EGF receptor, anti-idiotypic antibody to GD3 glycolipid, antibacterial peptide against *H. pylori*, MDX-447 bispecific humanized mAb to EGF receptor, anti-cytomegalovirus (CMV), Medi-491 B19 parvovirus vaccine, humanized recombinant mAb (IgG1k) against respiratory syncytial virus (RSV), urinary tract

infection vaccine (against "pili" on *Escherechia coli* strains), proteins of lyme disease vaccine against *B. burgdorferi* protein (DbpA), proteins of Medi-501 human papilloma virus-11 vaccine (HPV), *Streptococcus pneumoniae* vaccine, Medi-507 mAb (humanized form of BTI-322) against CD2 receptor on T-cells, MDX-33 mAb to FcγR1 receptor, MDX-RA immunotoxin (ricin A linked) mAb, MDX-210 bi-specific mAb against HER-2, MDX-447 bi-specific mAb against EGF receptor, MDX-22, MDX-220 bi-specific mAb against TAG-72 on tumors, colony-stimulating factor (CSF) (molgramostim), humanized mAb to the IL-2 R α-chain (basiliximab), mAb to IgE (IGE 025A), myelin basic protein-altered peptide (MSP771A),
5 humanized mAb against the epidermal growth receptor-2, humanized mAb against the α subunit of the interleukin-2 receptor, low molecular weight heparin, anti-hemophilic factor, and bactericidal/permeability-increasing protein (r-BPI).

The peptides and proteins made using the present invention may be labeled using labels and techniques known to one of ordinary skill in the art. Some of these
15 labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety. Some of these labels may be genetically engineered into the polynucleotide sequence for the expression of the selected protein or peptide. The peptides and proteins may also have label-incorporation "handles"
20 incorporated to allow labeling of an otherwise difficult or impossible to label protein.

It is to be understood that the various classes of desired peptides and proteins, as well as specific peptides and proteins described in this section may be modified as described below by inserting selected codons for desired amino acid substitutions into the gene incorporated into the transgenic animal.

25 The present invention may also be used to produce desired molecules other than proteins and peptides including, but not limited to, lipoproteins such as high density lipoprotein (HDL), HDL-Milano, and low density lipoprotein, lipids, carbohydrates, siRNA and ribozymes. In these embodiments, a gene of interest encodes a nucleic acid molecule or a protein that directs production of the desired
30 molecule.

The present invention further encompasses the use of inhibitory molecules to inhibit endogenous (i.e., non-vector) protein production. These inhibitory molecules include antisense nucleic acids, siRNA and inhibitory proteins. In one embodiment, a

transposon-based vector containing an ovalbumin DNA sequence, that upon transcription forms a double stranded RNA molecule, is transfected into an animal such as a bird and the bird's production of endogenous ovalbumin protein is reduced by the interference RNA mechanism (RNAi). Additionally, inducible knockouts or knockdowns of the endogenous protein may be created to achieve a reduction or inhibition of endogenous protein production.

Modified Desired Proteins and Peptides

"Proteins", "peptides," "polypeptides" and "oligopeptides" are chains of amino acids (typically L-amino acids) whose alpha carbons are linked through peptide bonds formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain (i.e., the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain (i.e., the carboxy terminal) has a free carboxyl group. As such, the term "amino terminus" (abbreviated N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (i.e., amino acid mimetics). Moreover, an amide bond mimetic includes peptide backbone modifications well known to those skilled in the art.

Furthermore, one of skill will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a

small percentage of amino acids (typically less than about 5%, more typically less than about 1%) in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

A conservative substitution is a substitution in which the substituting amino acid (naturally occurring or modified) is structurally related to the amino acid being substituted, i.e., has about the same size and electronic properties as the amino acid being substituted. Thus, the substituting amino acid would have the same or a similar functional group in the side chain as the original amino acid. A "conservative substitution" also refers to utilizing a substituting amino acid which is identical to the amino acid being substituted except that a functional group in the side chain is protected with a suitable protecting group.

Suitable protecting groups are described in Green and Wuts, "Protecting Groups in Organic Synthesis", John Wiley and Sons, Chapters 5 and 7, 1991, the teachings of which are incorporated herein by reference. Preferred protecting groups are those which facilitate transport of the peptide through membranes, for example, by reducing the hydrophilicity and increasing the lipophilicity of the peptide, and which can be cleaved, either by hydrolysis or enzymatically (Ditter et al., 1968. J. Pharm. Sci. 57:783; Ditter et al., 1968. J. Pharm. Sci. 57:828; Ditter et al., 1969. J. Pharm. Sci. 58:557; King et al., 1987. Biochemistry 26:2294; Lindberg et al., 1989. Drug Metabolism and Disposition 17:311; Tunek et al., 1988. Biochem. Pharm. 37:3867; Anderson et al., 1985 Arch. Biochem. Biophys. 239:538; and Singhal et al., 1987. FASEB J. 1:220). Suitable hydroxyl protecting groups include ester, carbonate and carbamate protecting groups. Suitable amine protecting groups include acyl groups and alkoxy or aryloxy carbonyl groups, as described above for N-terminal protecting

groups. Suitable carboxylic acid protecting groups include aliphatic, benzyl and aryl esters, as described below for C-terminal protecting groups. In one embodiment, the carboxylic acid group in the side chain of one or more glutamic acid or aspartic acid residues in a peptide of the present invention is protected, preferably as a methyl, ethyl, benzyl or substituted benzyl ester, more preferably as a benzyl ester.

Provided below are groups of naturally occurring and modified amino acids in which each amino acid in a group has similar electronic and steric properties. Thus, a conservative substitution can be made by substituting an amino acid with another amino acid from the same group. It is to be understood that these groups are non-limiting, i.e. that there are additional modified amino acids which could be included in each group.

Group I includes leucine, isoleucine, valine, methionine and modified amino acids having the following side chains: ethyl, n-propyl n-butyl. Preferably, Group I includes leucine, isoleucine, valine and methionine.

Group II includes glycine, alanine, valine and a modified amino acid having an ethyl side chain. Preferably, Group II includes glycine and alanine.

Group III includes phenylalanine, phenylglycine, tyrosine, tryptophan, cyclohexylmethyl glycine, and modified amino residues having substituted benzyl or phenyl side chains. Preferred substituents include one or more of the following: halogen, methyl, ethyl, nitro, —NH_2 , methoxy, ethoxy and —CN . Preferably, Group III includes phenylalanine, tyrosine and tryptophan.

Group IV includes glutamic acid, aspartic acid, a substituted or unsubstituted aliphatic, aromatic or benzylic ester of glutamic or aspartic acid (e.g., methyl, ethyl, n-propyl iso-propyl, cyclohexyl, benzyl or substituted benzyl), glutamine, asparagine, —CO—NH— alkylated glutamine or asparagines (e.g., methyl, ethyl, n-propyl and iso-propyl) and modified amino acids having the side chain $\text{—(CH}_2)_3\text{—COOH}$, an ester thereof (substituted or unsubstituted aliphatic, aromatic or benzylic ester), an amide thereof and a substituted or unsubstituted N-alkylated amide thereof. Preferably, Group IV includes glutamic acid, aspartic acid, methyl aspartate, ethyl aspartate, benzyl aspartate and methyl glutamate, ethyl glutamate and benzyl glutamate, glutamine and asparagine.

Group V includes histidine, lysine, ornithine, arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic acid, homologs of lysine, homologs of arginine and homologs of ornithine. Preferably, Group V includes histidine, lysine, arginine and ornithine. A homolog of an amino acid includes from 1 to about 3 additional or subtracted methylene units in the side chain.

Group VI includes serine, threonine, cysteine and modified amino acids having C1-C5 straight or branched alkyl side chains substituted with $-\text{OH}$ or $-\text{SH}$, for example, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$ or $-\text{CH}_2\text{CH}_2\text{OHCH}_3$. Preferably, Group VI includes serine, cysteine or threonine.

In another aspect, suitable substitutions for amino acid residues include "severe" substitutions. A "severe substitution" is a substitution in which the substituting amino acid (naturally occurring or modified) has significantly different size and/or electronic properties compared with the amino acid being substituted. Thus, the side chain of the substituting amino acid can be significantly larger (or smaller) than the side chain of the amino acid being substituted and/or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of severe substitutions of this type include the substitution of phenylalanine or cyclohexylmethyl glycine for alanine, isoleucine for glycine, a D amino acid for the corresponding L amino acid, or $-\text{NH}-\text{CH}[(\text{CH}_2)_5-\text{COOH}]-\text{CO}-$ for aspartic acid. Alternatively, a functional group may be added to the side chain, deleted from the side chain or exchanged with another functional group. Examples of severe substitutions of this type include adding of valine, leucine or isoleucine, exchanging the carboxylic acid in the side chain of aspartic acid or glutamic acid with an amine, or deleting the amine group in the side chain of lysine or ornithine. In yet another alternative, the side chain of the substituting amino acid can have significantly different steric and electronic properties than the functional group of the amino acid being substituted. Examples of such modifications include tryptophan for glycine, lysine for aspartic acid and $(\text{CH}_2)_4\text{COOH}$ for the side chain of serine. These examples are not meant to be limiting.

In another embodiment, for example in the synthesis of a peptide 26 amino acids in length, the individual amino acids may be substituted according in the following manner:

- AA₁ is serine, glycine, alanine, cysteine or threonine;
- 5 AA₂ is alanine, threonine, glycine, cysteine or serine;
- AA₃ is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA₄ is proline, leucine, valine, isoleucine or methionine;
- 10 AA₅ is tryptophan, alanine, phenylalanine, tyrosine or glycine;
- AA₆ is serine, glycine, alanine, cysteine or threonine;
- AA₇ is proline, leucine, valine, isoleucine or methionine;
- AA₈ is alanine, threonine, glycine, cysteine or serine;
- AA₉ is alanine, threonine, glycine, cysteine or serine;
- 15 AA₁₀ is leucine, isoleucine, methionine or valine;
- AA₁₁ is serine, glycine, alanine, cysteine or threonine;
- AA₁₂ is leucine, isoleucine, methionine or valine;
- AA₁₃ is leucine, isoleucine, methionine or valine;
- AA₁₄ is glutamine, glutamic acid, aspartic acid, asparagine, or a substituted or
- 20 unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- AA₁₅ is arginine, N-nitroarginine, β -cycloarginine, γ -hydroxy-arginine, N-amidinocitruline or 2-amino-4-guanidino-butanoic acid
- AA₁₆ is proline, leucine, valine, isoleucine or methionine;
- AA₁₇ is serine, glycine, alanine, cysteine or threonine;
- 25 AA₁₈ is glutamic acid, aspartic acid, asparagine, glutamine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- AA₁₉ is aspartic acid, asparagine, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- 30 AA₂₀ is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA₂₁ is alanine, threonine, glycine, cysteine or serine;

AA₂₂ is alanine, threonine, glycine, cysteine or serine;

AA₂₃ is histidine, serine, threonine, cysteine, lysine or ornithine;

AA₂₄ is threonine, aspartic acid, serine, glutamic acid or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;

5 AA₂₅ is asparagine, aspartic acid,, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid; and

AA₂₆ is cysteine, histidine, serine, threonine, lysine or ornithine.

10 It is to be understood that these amino acid substitutions may be made for longer or shorter peptides than the 26 mer in the preceding example above, and for proteins.

In one embodiment of the present invention, codons for the first several N-terminal amino acids of the transposase are modified such that the third base of each codon is changed to an A or a T without changing the corresponding amino acid. It is
15 preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the gene of interest are modified such that the third base of each codon is changed to an A or a T without changing the corresponding amino acid. In one embodiment, the first ten N-terminal codons of the gene of interest are modified in this manner.

20 When several desired proteins, protein fragments or peptides are encoded in the gene of interest to be incorporated into the genome, one of skill in the art will appreciate that the proteins, protein fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join
25 the desired proteins, protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. The spacer may also be contained within a nucleotide sequence with a purification handle or be flanked by
30 proteolytic cleavage sites.

Such polypeptide spacers may have from about 5 to about 40 amino acid residues. The spacers in a polypeptide are independently chosen, but are preferably all the same. The spacers should allow for flexibility of movement in space and are

therefore typically rich in small amino acids, for example, glycine, serine, proline or alanine. Preferably, peptide spacers contain at least 60%, more preferably at least 80% glycine or alanine. In addition, peptide spacers generally have little or no biological and antigenic activity. Preferred spacers are (Gly-Pro-Gly-Gly)_x (SEQ ID NO:5) and (Gly₄-Ser)_y, wherein x is an integer from about 3 to about 9 and y is an integer from about 1 to about 8. Specific examples of suitable spacers include (Gly-Pro-Gly-Gly)₃

SEQ ID NO:6 Gly Pro Gly Gly Gly Pro Gly Gly Gly Pro Gly Gly
(Gly₄-Ser)₃

10 SEQ ID NO:7 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
or (Gly₄-Ser)₄

SEQ ID NO:8 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser.

15 Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may also be built into the vector. Such sequences are known in the art and include the glutathione binding domain from glutathione S-transferase, polylysine, hexa-histidine or other cationic amino acids, thioredoxin, hemagglutinin antigen and maltose binding protein.

20 Additionally, nucleotide sequences may be inserted into the gene of interest to be incorporated so that the protein or peptide can also include from one to about six amino acids that create signals for proteolytic cleavage. In this manner, if a gene is designed to make one or more peptides or proteins of interest in the transgenic animal, specific nucleotide sequences encoding for amino acids recognized by enzymes may be incorporated into the gene to facilitate cleavage of the large protein or peptide
25 sequence into desired peptides or proteins or both. For example, nucleotides encoding a proteolytic cleavage site can be introduced into the gene of interest so that a signal sequence can be cleaved from a protein or peptide encoded by the gene of interest. Nucleotide sequences encoding other amino acid sequences which display pH sensitivity or chemical sensitivity may also be added to the vector to facilitate
30 separation of the signal sequence from the peptide or protein of interest.

In one embodiment of the present invention, a TAG sequence is linked to the gene of interest. The TAG sequence serves three purposes: 1) it allows free rotation of the peptide or protein to be isolated so there is no interference from the native

protein or signal sequence, i.e. vitellogenin, 2) it provides a "purification handle" to isolate the protein using column purification, and 3) it includes a cleavage site to remove the desired protein from the signal and purification sequences. Accordingly, as used herein, a TAG sequence includes a spacer sequence, a purification handle and a cleavage site. The spacer sequences in the TAG proteins contain one or more repeats shown in SEQ ID NO:25. A preferred spacer sequence comprises the sequence provided in SEQ ID NO:26. One example of a purification handle is the gp41 hairpin loop from HIV I. Exemplary gp41 polynucleotide and polypeptide sequences are provided in SEQ ID NO:24 and SEQ ID NO:23, respectively. However, it should be understood that any antigenic region may be used as a purification handle, including any antigenic region of gp41. Preferred purification handles are those that elicit highly specific antibodies. Additionally, the cleavage site can be any protein cleavage site known to one of ordinary skill in the art and includes an enterokinase cleavage site comprising the Asp Asp Asp Asp Lys sequence (SEQ ID NO:9) and a furin cleavage site. Constructs containing a TAG sequence are shown in Figures 2 and 3. In one embodiment of the present invention, the TAG sequence comprises a polynucleotide sequence of SEQ ID NO:22.

Methods of Administering Transposon-Based Vectors

In addition to the transposon-based vectors described above, the present invention also includes methods of administering the transposon-based vectors to an animal, methods of producing a transgenic animal wherein a gene of interest is incorporated into the germline of the animal and methods of producing a transgenic animal wherein a gene of interest is incorporated into cells other than the germline cells of the animal. The transposon-based vectors of the present invention may be administered to an animal via any method known to those of skill in the art, including, but not limited to, intraembryonic, intratesticular, intraoviduct, intraperitoneal, intraarterial, intravenous, topical, oral, nasal, and pronuclear injection methods of administration, or any combination thereof. The transposon-based vectors may also be administered within the lumen of an organ, into an organ, into a body cavity, into the cerebrospinal fluid, through the urinary system or through any route to reach the desired cells.

The transposon-based vectors may be delivered through the vascular system to be distributed to the cells supplied by that vessel. For example, the compositions may

be placed in the artery supplying the ovary or supplying the fallopian tube to transfect cells in those tissues. In this manner, follicles could be transfected to create a germline transgenic animal. Alternatively, supplying the compositions through the artery leading to the oviduct would preferably transfect the tubular gland and epithelial cells. Such transfected cells could manufacture a desired protein or peptide for deposition in the egg white. Administration of the compositions through the portal vein would target uptake and transformation of hepatic cells. Administration through the urethra and into the bladder would target the transitional epithelium of the bladder. Administration through the vagina and cervix would target the lining of the uterus. Administration through the internal mammary artery would transfect secretory cells of the lactating mammary gland to perform a desired function, such as to synthesize and secrete a desired protein or peptide into the milk.

In a preferred embodiment, the animal is an egg-laying animal, and more preferably, an avian. In one embodiment, between approximately 1 and 50 μg , preferably between 1 and 20 μg , and more preferably between 5 and 10 μg of transposon-based vector DNA is administered to the oviduct of a bird. Optimal ranges depending upon the type of bird and the bird's stage of sexual maturity. Intraoviduct administration of the transposon-based vectors of the present invention result in a PCR positive signal in the oviduct tissue, whereas intravascular administration results in a PCR positive signal in the liver. In other embodiments, the transposon-based vector is administered to an artery that supplies the oviduct or the liver. These methods of administration may also be combined with any methods for facilitating transfection, including without limitation, electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

The present invention includes a method of intraembryonic administration of a transposon-based vector to an avian embryo comprising the following steps: 1) incubating an egg on its side at room temperature for two hours to allow the embryo contained therein to move to top dead center (TDC); 2) drilling a hole through the shell without penetrating the underlying shell membrane; 3) injecting the embryo with the transposon-based vector in solution; 4) sealing the hole in the egg; and 5) placing the egg in an incubator for hatching. Administration of the transposon-based vector can occur anytime between immediately after egg lay (when the embryo is at Stage X) and hatching. Preferably, the transposon-based vector is administered between 1 and

7 days after egg lay, more preferably between 1 and 2 days after egg lay. The transposon-based vectors may be introduced into the embryo in amounts ranging from about 5.0 μg to 10 μg , preferably 1.0 μg to 100 μg . Additionally, the transposon-based vector solution volume may be between approximately 1 μl to 75 μl in quail and between approximately 1 μl to 500 μl in chicken.

The present invention also includes a method of intratesticular administration of a transposon-based vector including injecting a bird with a composition comprising the transposon-based vector, an appropriate carrier and an appropriate transfection reagent. In one embodiment, the bird is injected before sexual maturity, preferably between approximately 4-14 weeks, more preferably between approximately 6-14 weeks and most preferably between 8-12 weeks old. In another embodiment, a mature bird is injected with a transposon-based vector an appropriate carrier and an appropriate transfection reagent. The mature bird may be any type of bird, but in one example the mature bird is a quail.

A bird is preferably injected prior to the development of the blood-testis barrier, which thereby facilitates entry of the transposon-based vector into the seminiferous tubules and transfection of the spermatogonia or other germline cells. At and between the ages of 4, 6, 8, 10, 12, and 14 weeks, it is believed that the testes of chickens are likely to be most receptive to transfection. In this age range, the blood/testis barrier has not yet formed, and there is a relatively high number of spermatogonia relative to the numbers of other cell types, e.g., spermatids, etc. See J. Kumaran et al., 1949. Poultry Sci., 29:511-520. See also E. Oakberg, 1956. Am. J. Anatomy, 99:507-515; and P. Kluin et al., 1984. Anat. Embryol., 169:73-78.

The transposon-based vectors may be introduced into a testis in an amount ranging from about 0.1 μg to 10 μg , preferably 1 μg to 10 μg , more preferably 3 μg to 10 μg . In a quail, about 5 μg is a preferred amount. In a chicken, about 5 μg to 10 μg per testis is preferred. These amounts of vector DNA may be injected in one dose or multiple doses and at one site or multiple sites in the testis. In a preferred embodiment, the vector DNA is administered at multiple sites in a single testis, both testes being injected in this manner. In one embodiment, injection is spread over three injection sites: one at each end of the testis, and one in the middle. Additionally, the transposon-based vector solution volume may be between approximately 1 μl to 75 μl in quail and between approximately 1 μl to 500 μl in chicken. In a preferred

embodiment, the transposon-based vector solution volume may be between approximately 20 μ l to 60 μ l in quail and between approximately 50 μ l to 250 μ l in chicken. Both the amount of vector DNA and the total volume injected into each testis may be determined based upon the age and size of the bird.

5 According to the present invention, the transposon-based vector is administered in conjunction with an acceptable carrier and/or transfection reagent. Acceptable carriers include, but are not limited to, water, saline, Hanks Balanced Salt Solution (HBSS), Tris-EDTA (TE) and lyotropic liquid crystals. Transfection reagents commonly known to one of ordinary skill in the art that may be employed
10 include, but are not limited to, the following: cationic lipid transfection reagents, cationic lipid mixtures, polyamine reagents, liposomes and combinations thereof; SUPERFECT®, Cytofectene, BioPORTER®, GenePORTER®, NeuroPORTER®, and perfectin from Gene Therapy Systems; lipofectamine, cellfectin, DMRIE-C oligofectamine, and PLUS reagent from InVitrogen; Xtreme gene, fugene, DOSPER
15 and DOTAP from Roche; Lipotaxi and Genejammer from Strategene; and Escort from SIGMA. In one embodiment, the transfection reagent is SUPERFECT®. The ratio of DNA to transfection reagent may vary based upon the method of administration. In one embodiment, the transposon-based vector is administered intratesticularly and the ratio of DNA to transfection reagent can be from 1:1.5 to
20 1:15, preferably 1:2 to 1:10, all expressed as wt/vol. Transfection may also be accomplished using other means known to one of ordinary skill in the art, including without limitation electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

 Depending upon the cell or tissue type targeted for transfection, the form of
25 the transposon-based vector may be important. Plasmids harvested from bacteria are generally closed circular supercoiled molecules, and this is the preferred state of a vector for gene delivery because of the ease of preparation. In some instances, transposase expression and insertion may be more efficient in a relaxed, closed circular configuration or in a linear configuration. In still other instances, a purified
30 transposase protein may be co-injected with a transposon-based vector containing the gene of interest for more immediate insertion. This could be accomplished by using a transfection reagent complexed with both the purified transposase protein and the transposon-based vector.

Testing for and Breeding Animals Carrying the Transgene

Following administration of a transposon-based vector to an animal, DNA is extracted from the animal to confirm integration of the gene of interest. Actual frequencies of integration are estimated both by comparative strength of the PCR signal, and by histological evaluation of the tissues by quantitative PCR. Another method for estimating the rate of transgene insertion is the so-called primed in situ hybridization technique (PRINS). This method determines not only which cells carry a transgene of interest, but also into which chromosome the gene has inserted, and even what portion of the chromosome. Briefly, labeled primers are annealed to chromosome spreads (affixed to glass slides) through one round of PCR, and the slides are then developed through normal in situ hybridization procedures. This technique combines the best features of in situ PCR and fluorescence in situ hybridization (FISH) to provide distinct chromosome location and copy number of the gene in question. The 28s rRNA gene will be used as a positive control for spermatogonia to confirm that the technique is functioning properly. Using different fluorescent labels for the transgene and the 28s gene causes cells containing a transgene to fluoresce with two different colored tags.

Breeding experiments are also conducted to determine if germline transmission of the transgene has occurred. In a general bird breeding experiment performed according to the present invention, each male bird was exposed to 2-3 different adult female birds for 3-4 days each. This procedure was continued with different females for a total period of 6-12 weeks. Eggs were collected daily for up to 14 days after the last exposure to the transgenic male, and each egg was incubated in a standard incubator. In the first series of experiments the resulting embryos were examined for transgene presence at day 3 or 4 using PCR.

Any male producing a transgenic embryo was bred to additional females. Eggs from these females were incubated, hatched, and the chicks tested for the exogenous DNA. Any embryos that died were necropsied and examined directly for the transgene or protein encoded by the transgene, either by fluorescence or PCR. The offspring that hatched and were found to be positive for the exogenous DNA were raised to maturity. These birds were bred to produce further generations of transgenic birds, to verify efficiency of the transgenic procedure and the stable

incorporation of the transgene into the germ line. The resulting embryos were examined for transgene presence at day 3 or 4 using PCR.

It is to be understood that the above procedure can be modified to suit animals other than birds and that selective breeding techniques may be performed to amplify gene copy numbers and protein output.

Production of Desired Proteins or Peptides in Egg White

In one embodiment, the transposon-based vectors of the present invention may be administered to a bird for production of desired proteins or peptides in the egg white. These transposon-based vectors preferably contain one or more of an ovalbumin promoter, an ovomucoid promoter, an ovalbumin signal sequence and an ovomucoid signal sequence. Oviduct-specific ovalbumin promoters are described in B. O'Malley et al., 1987. EMBO J., vol. 6, pp. 2305-12; A. Qiu et al., 1994. Proc. Nat. Acad. Sci. (USA), vol. 91, pp. 4451-4455; D. Monroe et al., 2000. Biochim. Biophys. Acta, 1517 (1):27-32; H. Park et al., 2000. Biochem., 39:8537-8545; and T. Muramatsu et al., 1996. Poult. Avian Biol. Rev., 6:107-123. Examples of transposon-based vectors designed for production of a desired protein in an egg white are shown in Figures 2 and 3.

Production of Desired Proteins or Peptides in Egg Yolk

The present invention is particularly advantageous for production of recombinant peptides and proteins of low solubility in the egg yolk. Such proteins include, but are not limited to, membrane-associated or membrane-bound proteins, lipophilic compounds; attachment factors, receptors, and components of second messenger transduction machinery. Low solubility peptides and proteins are particularly challenging to produce using conventional recombinant protein production techniques (cell and tissue cultures) because they aggregate in water-based, hydrophilic environments. Such aggregation necessitates denaturation and re-folding of the recombinantly-produced proteins, which may deleteriously affect their structure and function. Moreover, even highly soluble recombinant peptides and proteins may precipitate and require denaturation and renaturation when produced in sufficiently high amounts in recombinant protein production systems. The present invention provides an advantageous resolution of the problem of protein and peptide solubility during production of large amounts of recombinant proteins.

In one embodiment of the present invention, deposition of a desired protein into the egg yolk is accomplished by attaching a sequence encoding a protein capable of binding to the yolk vitellogenin receptor to a gene of interest that encodes a desired protein. This transposon-based vector can be used for the receptor-mediated uptake of the desired protein by the oocytes. In a preferred embodiment, the sequence ensuring the binding to the vitellogenin receptor is a targeting sequence of a vitellogenin protein. The invention encompasses various vitellogenin proteins and their targeting sequences. In a preferred embodiment, a chicken vitellogenin protein targeting sequence is used, however, due to the high degree of conservation among vitellogenin protein sequences and known cross-species reactivity of vitellogenin targeting sequences with their egg-yolk receptors, other vitellogenin targeting sequences can be substituted. One example of a construct for use in the transposon-based vectors of the present invention and for deposition of an insulin protein in an egg yolk is provided in SEQ ID NO:27. In this embodiment, the transposon-based vector contains a vitellogenin promoter, a vitellogenin targeting sequence, a TAG sequence, a pro-insulin sequence and a synthetic polyA sequence. The present invention includes, but is not limited to, vitellogenin targeting sequences residing in the N-terminal domain of vitellogenin, particularly in lipovitellin I. In one embodiment, the vitellogenin targeting sequence contains the polynucleotide sequence of SEQ ID NO:18.

In a preferred embodiment, the transposon-based vector contains a transposase gene operably-linked to a liver-specific promoter and a gene of interest operably-linked to a liver-specific promoter and a vitellogenin targeting sequence. Figure 4 shows an example of such a construct. In another preferred embodiment, the transposon-based vector contains a transposase gene operably-linked to a constitutive promoter and a gene of interest operably-linked to a liver-specific promoter and a vitellogenin targeting sequence.

Isolation and Purification of Desired Protein or Peptide

For large-scale production of protein, an animal breeding stock that is homozygous for the transgene is preferred. Such homozygous individuals are obtained and identified through, for example, standard animal breeding procedures or PCR protocols.

Once expressed, peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, high performance liquid chromatography, immunoprecipitation and the like.

- 5 Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

In one embodiment of the present invention, the animal in which the desired protein is produced is an egg-laying animal. In a preferred embodiment of the present invention, the animal is an avian and a desired peptide, polypeptide or protein is
10 isolated from an egg white. Egg white containing the exogenous protein or peptide is separated from the yolk and other egg constituents on an industrial scale by any of a variety of methods known in the egg industry. See, e.g., W. Stadelman et al. (Eds.), Egg Science & Technology, Haworth Press, Binghamton, NY (1995). Isolation of the exogenous peptide or protein from the other egg white constituents is accomplished
15 by any of a number of polypeptide isolation and purification methods well known to one of ordinary skill in the art. These techniques include, for example, chromatographic methods such as gel permeation, ion exchange, affinity separation, metal chelation, HPLC, and the like, either alone or in combination. Another means that may be used for isolation or purification, either in lieu of or in addition to
20 chromatographic separation methods, includes electrophoresis. Successful isolation and purification is confirmed by standard analytic techniques, including HPLC, mass spectroscopy, and spectrophotometry. These separation methods are often facilitated if the first step in the separation is the removal of the endogenous ovalbumin fraction of egg white, as doing so will reduce the total protein content to be further purified by
25 about 50%.

To facilitate or enable purification of a desired protein or peptide, transposon-based vectors may include one or more additional epitopes or domains. Such epitopes or domains include DNA sequences encoding enzymatic or chemical cleavage sites including, but not limited to, an enterokinase cleavage site; the glutathione binding
30 domain from glutathione S-transferase; polylysine; hexa-histidine or other cationic amino acids; thioredoxin; hemagglutinin antigen; maltose binding protein; a fragment of gp41 from HIV; and other purification epitopes or domains commonly known to one of skill in the art.

In one representative embodiment, purification of desired proteins from egg white utilizes the antigenicity of the ovalbumin carrier protein and particular attributes of a TAG linker sequence that spans ovalbumin and the desired protein. The TAG sequence is particularly useful in this process because it contains 1) a highly antigenic epitope, a fragment of gp41 from HIV, allowing for stringent affinity purification, and, 2) a recognition site for the protease enterokinase immediately juxtaposed to the desired protein. In a preferred embodiment, the TAG sequence comprises approximately 50 amino acids. A representative TAG sequence is provided below.

Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys
Gly Trp Ile Gly Leu Leu *Asp Asp Asp Asp Lys* (SEQ ID NO:22)

The underlined sequences were taken from the hairpin loop domain of HIV gp-41 (SEQ ID NO:23). Sequences in italics represent the cleavage site for enterokinase (SEQ ID NO:9). The spacer sequence upstream of the loop domain was made from repeats of (Pro Ala Asp Asp Ala) (SEQ ID NO:25) to provide free rotation and promote surface availability of the hairpin loop from the ovalbumin carrier protein.

Isolation and purification of a desired protein is performed as follows:

1. Enrichment of the egg white protein fraction containing ovalbumin and the transgenic ovalbumin-TAG-desired protein.
2. Size exclusion chromatography to isolate only those proteins within a narrow range of molecular weights (a further enrichment of step 1).
3. Ovalbumin affinity chromatography. Highly specific antibodies to ovalbumin will eliminate virtually all extraneous egg white proteins except ovalbumin and the transgenic ovalbumin-TAG-desired protein.
4. gp41 affinity chromatography using anti-gp41 antibodies. Stringent application of this step will result in virtually pure transgenic ovalbumin-TAG-desired protein.
5. Cleavage of the transgene product can be accomplished in at least one of two ways:
 - a. The transgenic ovalbumin-TAG-desired protein is left attached to the gp41 affinity resin (beads) from step 4 and the protease enterokinase is

5 added. This liberates the transgene target protein from the gp41 affinity resin while the ovalbumin-TAG sequence is retained. Separation by centrifugation (in a batch process) or flow through (in a column purification), leaves the desired protein together with enterokinase in solution. Enterokinase is recovered and reused.

10 b. Alternatively, enterokinase is immobilized on resin (beads) by the addition of poly-lysine moieties to a non-catalytic area of the protease. The transgenic ovalbumin-TAG-desired protein eluted from the affinity column of step 4 is then applied to the protease resin. Protease action cleaves the ovalbumin-TAG sequence from the desired protein and leaves both entities in solution. The immobilized enterokinase resin is recharged and reused.

c. The choice of these alternatives is made depending upon the size and chemical composition of the transgene target protein.

15 6. A final separation of either of these two (5a or 5b) protein mixtures is made using size exclusion, or enterokinase affinity chromatography. This step allows for desalting, buffer exchange and/or polishing, as needed.

Cleavage of the transgene product (ovalbumin-TAG-desired protein) by enterokinase, then, results in two products: ovalbumin-TAG and the desired protein.
20 More specific methods for isolation using the TAG label is provided in the Examples. Some desired proteins may require additions or modifications of the above-described approach as known to one of ordinary skill in the art. The method is scaleable from the laboratory bench to pilot and production facility largely because the techniques applied are well documented in each of these settings.

25 It is believed that a typical chicken egg produced by a transgenic animal of the present invention will contain at least 0.001 mg, from about 0.001 to 1.0 mg, or from about 0.001 to 100.0 mg of exogenous protein, peptide or polypeptide, in addition to the normal constituents of egg white (or possibly replacing a small fraction of the latter).

30 One of skill in the art will recognize that after biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides. In this case, it is often necessary to denature and

reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art.

Production of Protein or Peptide in Milk

5 In addition to methods of producing eggs containing transgenic proteins or peptides, the present invention encompasses methods for the production of milk containing transgenic proteins or peptides. These methods include the administration of a transposon-based vector described above to a mammal. In one embodiment, the transposon-based vector contains a transposase operably-linked to a constitutive
10 promoter and a gene of interest operably-linked to mammary specific promoter. Genes of interest can include, but are not limited to antiviral and antibacterial proteins and immunoglobulins.

Treatment of Disease and Animal Improvement

 In addition to production and isolation of desired molecules, the transposon-
15 based vectors of the present invention can be used for the treatment of various genetic disorders. For example, one or more transposon-based vectors can be administered to a human or animal for the treatment of a single gene disorder including, but not limited to, Huntington's disease, alpha-1-antitrypsin deficiency Alzheimer's disease, various forms of breast cancer, cystic fibrosis, galactosemia, congenital
20 hypothyroidism, maple syrup urine disease, neurofibromatosis 1, phenylketonuria, sickle cell disease, and Smith-Lemli-Opitz (SLO/RSH) Syndrome. Other diseases caused by single gene disorders that may be treated with the present invention include, autoimmune diseases, shipping fever in cattle, mastitis, bacterial or viral diseases, alteration of skin pigment in animals. In these embodiments, the
25 transposon-based vector contains a non-mutated, or non-disease causing form of the gene known to cause such disorder. Preferably, the transposase contained within the transposase-based vector is operably linked to an inducible promoter such as a tissue-specific promoter such that the non-mutated gene of interest is inserted into a specific tissue wherein the mutated gene is expressed in vivo.

30 In one embodiment of the present invention, a transposon-based vector comprising a gene encoding proinsulin is administered to diabetic animals or humans for incorporation into liver cells in order to treat or cure diabetes. The specific incorporation of the proinsulin gene into the liver is accomplished by placing the

transposase gene under the control of liver-specific promoter, such as G6P. This approach is useful for treatment of both Type I and Type II diabetes. The G6P promoter has been shown to be glucose responsive (Arguad, D., et al. 1996. Diabetes 45:1563-1571), and thus, glucose-regulated insulin production is achieved using DNA constructs of the present invention. Integrating a proinsulin gene into liver cells circumvents the problem of destruction of pancreatic islet cells in the course of Type I diabetes.

In another embodiment, shortly after diagnosis of Type I diabetes, the cells of the immune system destroying pancreatic β -cells are selectively removed using the transposon-based vectors of the present invention, thus allowing normal β -cells to repopulate the pancreas.

For treatment of Type II diabetes, a transposon-based vector containing a proinsulin gene is specifically incorporated into the pancreas by placing the transposase gene under the control of a pancreas-specific promoter, such as an insulin promoter. In this embodiment, the vector is delivered to a diabetic animal or human via injection into an artery feeding the pancreas. For delivery, the vector is complexed with a transfection agent. The artery distributes the complex throughout the pancreas, where individual cells receive the vector DNA. Following uptake into the target cell, the insulin promoter is recognized by transcriptional machinery of the cell, the transposase encoded by the vector is expressed, and stable integration of the proinsulin gene occurs. It is expected that a small percentage of the transposon-based vector is transported to other tissues, and that these tissues are transfected. However, these tissues are not stably transfected and the proinsulin gene is not incorporated into the cells' DNA due to failure of these cells to activate the insulin promoter. The vector DNA is likely lost when the cell dies or degraded over time.

In other embodiments, one or more transposon-based vectors are administered to an avian for the treatment of a viral or bacterial infection/disease including, but not limited to, Colibacillosis (Coliform infections), Mycoplasmosis (CRD, Air sac, Sinusitis), Fowl Cholera, Necrotic Enteritis, Ulcerative Enteritis (Quail disease), Pullorum Disease, Fowl Typhoid, Botulism, Infectious Coryza, Erysipelas, Avian Pox, Newcastle Disease, Infectious Bronchitis, Quail Bronchitis, Lymphoid Leukosis, Marek's Disease (Visceral Leukosis), Infectious Bursal Disease (Gumboro). In these

embodiments, the transposon-based vectors may be used in a manner similar to traditional vaccines.

In still other embodiments, one or more transposon-based vectors are administered to an animal for the production of an animal with enhanced growth characteristics and nutrient utilization.

The transposon-based vectors of the present invention can be used to transform any animal cell, including but not limited to: cells producing hormones, cytokines, growth factors, or any other biologically active substance; cells of the immune system; cells of the nervous system; muscle (striatal, cardiac, smooth) cells; vascular system cells; endothelial cells; skin cells; mammary cells; and lung cells, including bronchial and alveolar cells. Transformation of any endocrine cell by a transposon-based vector is contemplated as a part of a present invention. In one aspect of the present invention, cells of the immune system may be the target for incorporation of a desired gene or genes encoding for production of antibodies. Accordingly, the thymus, bone marrow, beta lymphocytes (or B cells), gastrointestinal associated lymphatic tissue (GALT), Peyer's patches, bursa Fabricius, lymph nodes, spleen, and tonsil, and any other lymphatic tissue, may all be targets for administration of the compositions of the present invention.

The transposon-based vectors of the present invention can be used to modulate (stimulate or inhibit) production of any substance, including but not limited to a hormone, a cytokine, or a growth factor, by an animal or a human cell. Modulation of a regulated signal within a cell or a tissue, such as production of a second messenger, is also contemplated as a part of the present invention. Use of the transposon-based vectors of the present invention is contemplated for treatment of any animal or human disease or condition that results from underproduction (such as diabetes) or overproduction (such as hyperthyroidism) of a hormone or other endogenous biologically active substance. Use of the transposon-based vectors of the present invention to integrate nucleotide sequences encoding RNA molecules, such as anti-sense RNA or short interfering RNA, is also contemplated as a part of the present invention.

Additionally, the transposon-based vectors of the present invention may be used to provide cells or tissues with "beacons", such as receptor molecules, for binding of therapeutic agents in order to provide tissue and cell specificity for the

therapeutic agents. Several promoters and exogenous genes can be combined in one vector to produce progressive, controlled treatments from a single vector delivery.

The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various embodiments, modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention.

10

EXAMPLE 1

Preparation of Transposon-Based Vector pTnMod

A vector was designed for inserting a desired coding sequence into the genome of eukaryotic cells, given below as SEQ ID NO:1. The vector of SEQ ID NO:1, termed pTnMod, was constructed and its sequence verified.

15

This vector employed a cytomegalovirus (CMV) promoter. A modified Kozak sequence (ACCATG) (SEQ ID NO:13) was added to the promoter. The nucleotide in the wobble position in nucleotide triplet codons encoding the first 10 amino acids of transposase was changed to an adenine (A) or thymine (T), which did not alter the amino acid encoded by this codon. Two stop codons were added and a synthetic polyA was used to provide a strong termination sequence. This vector uses a promoter designed to be active soon after entering the cell (without any induction) to increase the likelihood of stable integration. The additional stop codons and synthetic polyA insures proper termination without read through to potential genes downstream.

20

25

The first step in constructing this vector was to modify the transposase to have the desired changes. Modifications to the transposase were accomplished with the primers High Efficiency forward primer (Hef) Altered transposase (ATS)-Hef 5' ATCTCGAGACCATGTGTGAACTTGATATTTTACATGATTCTCTTTACC 3' (SEQ ID NO:10) and Altered transposase- High efficiency reverse primer (Her) 5' GATTGATCATTATCATAATTTCCCAAAGCGTAACC 3' (SEQ ID NO:11, a reverse complement primer). In the 5' forward primer ATS-Hef, the sequence CTCGAG (SEQ ID NO:12) is the recognition site for the restriction enzyme Xho I, which permits directional cloning of the amplified gene. The sequence ACCATG

30

(SEQ ID NO:13) contains the Kozak sequence and start codon for the transposase and the underlined bases represent changes in the wobble position to an A or T of codons for the first 10 amino acids (without changing the amino acid coded by the codon). Primer ATS-Her (SEQ ID NO:11) contains an additional stop codon TAA in addition to native stop codon TGA and adds a Bcl I restriction site, TGATCA (SEQ ID NO:14), to allow directional cloning. These primers were used in a PCR reaction with pTnLac (p defines plasmid, tn defines transposon, and lac defines the beta fragment of the lactose gene, which contains a multiple cloning site) as the template for the transposase and a FailSafe™ PCR System (which includes enzyme, buffers, dNTP's, MgCl₂ and PCR Enhancer; Epicentre Technologies, Madison, WI). Amplified PCR product was electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized on an ultraviolet transilluminator. A band corresponding to the expected size was excised from the gel and purified from the agarose using a Zymo Clean Gel Recovery Kit (Zymo Research, Orange, CA). Purified DNA was digested with restriction enzymes Xho I (5') and Bcl I (3') (New England Biolabs, Beverly, MA) according to the manufacturer's protocol. Digested DNA was purified from restriction enzymes using a Zymo DNA Clean and Concentrator kit (Zymo Research).

Plasmid gWhiz (Gene Therapy Systems, San Diego, CA) was digested with restriction enzymes Sal I and BamH I (New England Biolabs), which are compatible with Xho I and Bcl I, but destroy the restriction sites. Digested gWhiz was separated on an agarose gel, the desired band excised and purified as described above. Cutting the vector in this manner facilitated directional cloning of the modified transposase (mATS) between the CMV promoter and synthetic polyA.

To insert the mATS between the CMV promoter and synthetic polyA in gWhiz, a Stratagene T4 Ligase Kit (Stratagene, Inc. La Jolla, CA) was used and the ligation set up according to the manufacturer's protocol. Ligated product was transformed into *E. coli* Top10 competent cells (Invitrogen Life Technologies, Carlsbad, CA) using chemical transformation according to Invitrogen's protocol. Transformed bacteria were incubated in 1 ml of SOC (GIBCO BRL, CAT# 15544-042) medium for 1 hour at 37° C before being spread to LB (Luria-Bertani media (broth or agar)) plates supplemented with 100 µg/ml ampicillin (LB/amp plates). These plates were incubated overnight at 37° C and resulting colonies picked to

LB/amp broth for overnight growth at 37° C. Plasmid DNA was isolated using a modified alkaline lysis protocol (Sambrook et al., 1989), electrophoresed on a 1% agarose gel, and visualized on a U.V. transilluminator after ethidium bromide staining. Colonies producing a plasmid of the expected size (approximately 6.4 kbp) were cultured in at least 250 ml of LB/amp broth and plasmid DNA harvested using a Qiagen Maxi-Prep Kit (column purification) according to the manufacturer's protocol (Qiagen, Inc., Chatsworth, CA). Column purified DNA was used as template for sequencing to verify the changes made in the transposase were the desired changes and no further changes or mutations occurred due to PCR amplification. For sequencing, Perkin-Elmer's Big Dye Sequencing Kit was used. All samples were sent to the Gene Probes and Expression Laboratory (LSU School of Veterinary Medicine) for sequencing on a Perkin-Elmer Model 377 Automated Sequencer.

Once a clone was identified that contained the desired mATS in the correct orientation, primers CMVf-NgoM IV (5' TTGCCGGCATCAGATTGGCTAT (SEQ ID NO:15); underlined bases denote NgoM IV recognition site) and Syn-polyA-BstE II (5' AGAGGTCACCGGGTCAATTCTTCAGCACCTGGTA (SEQ ID NO:16); underlined bases denote BstE II recognition site) were used to PCR amplify the entire CMV promoter, mATS, and synthetic polyA for cloning upstream of the transposon in pTnLac. The PCR was conducted with FailSafe™ as described above, purified using the Zymo Clean and Concentrator kit, the ends digested with NgoM IV and BstE II (New England Biolabs), purified with the Zymo kit again and cloned upstream of the transposon in pTnLac as described below.

Plasmid pTnLac was digested with NgoM IV and BstE II to remove the ptac promoter and transposase and the fragments separated on an agarose gel. The band corresponding to the vector and transposon was excised, purified from the agarose, and dephosphorylated with calf intestinal alkaline phosphatase (New England Biolabs) to prevent self-annealing. The enzyme was removed from the vector using a Zymo DNA Clean and Concentrator-5. The purified vector and CMVp/mATS/polyA were ligated together using a Stratagene T4 Ligase Kit and transformed into *E. coli* as described above.

Colonies resulting from this transformation were screened (mini-preps) as describe above and clones that were the correct size were verified by DNA sequence

analysis as described above. The vector was given the name pTnMod (SEQ ID NO:1) and includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to base pairs 1-130 of pBluescriptII sk(-).

5 Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz. The CMV promoter was modified by the addition of an ACC sequence upstream of ATG.

10 Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons for stability of the transposase mRNA and for the expression of protein. More specifically, in each of the
15 codons for the first ten amino acids of the transposase, G or C was changed to A or T when such a substitution would not alter the amino acid that was encoded.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

20 Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of 10 pGWiz.

Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

25 Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

30 Base pairs 3838 - 4527 are the multiple cloning site from pBluescriptII sk(20), corresponding to bp 924-235 of pBluescriptII sk(-). This multiple cloning site may be used to insert any coding sequence of interest into the vector.

Base pairs 4528-4532 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4533 - 4602 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 4603 - 4644 are non-coding λ DNA that is residual from pNK2859.

Base pairs 4645 - 5488 are non-coding DNA that is residual from pNK2859.

5 Base pairs 5489 - 7689 are from the pBluescriptII sk(-) base vector - (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

Completing pTnMod is a pBlueScript backbone that contains a *colE1* origin of replication and an antibiotic resistance marker (ampicillin).

10 It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

All plasmid DNA was isolated by standard procedures. Briefly, *Escherichia coli* containing the plasmid was grown in 500 mL aliquots of LB broth (supplemented with an appropriate antibiotic) at 37°C overnight with shaking. Plasmid DNA was
15 recovered from the bacteria using a Qiagen Maxi-Prep kit (Qiagen, Inc., Chatsworth, CA) according to the manufacturer's protocol. Plasmid DNA was resuspended in 500 μ L of PCR-grade water and stored at -20°C until used.

EXAMPLE 2

20 *Preparation of Transposon-Based Vector pTnMod (CMV/Red)*

A vector was designed for inserting a reporter gene (DsRed) under the control of the CMV promoter into the genome of vertebrate cells given below as SEQ ID NO:2. The reporter gene chosen was the DsRed gene, driven by the immediate early cytomegalovirus promoter, to produce a plasmid called pTnCMV/DsRed. The DsRed
25 gene product is a red fluorescent protein from an IndoPacific sea anemone, *Discosoma* sp., which fluoresces bright red at 558 nm. It is to be understood that the reporter gene, i.e., the DsRed gene, is only one embodiment of the present invention and that any gene of interest may be inserted into the plasmid in place of the DsRed reporter gene in any Experiment described herein.

30 The vector of SEQ ID NO:2, named pTnMod (CMV/Red), was constructed, and its sequence verified by re-sequencing. SEQ ID NO:2, pTnMod (CMV/Red), includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to bp 1-130 of pBluescriptII sk(-).

Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5 Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems, corresponding to bp 229-1873 of pGWiz.

Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

10 Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons as discussed above.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

15 Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of pGWiz.

Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

20 Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4044 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 924-718 of pBluescriptII sk(-).

25 Base pairs 4045-4048 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4049-5693 are the CMV promoter/enhancer, taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz.

30 Base pairs 5694-5701 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 5702 - 6617 are the DsRed reporter coding sequence, including polyA sequence, from pDsRed1.1 (Clontech), corresponding to bp 77 - 992 of pDsRed1.1.

Base pairs 6618 - 7101 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 718-235 of pBluescriptII sk(-).

Base pairs 7102-7106 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5 Base pairs 7107 - 7176 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 7177 - 7218 are non-coding λ DNA that is residual from pNK2859.

Base pairs 7219 - 8062 are non-coding DNA that is residual from pNK2859.

10 Base pairs 8063 - 10263 are from the pBluescriptII sk(-) base vector (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s).

EXAMPLE 3

15 *Preparation of Transposon-Based Vector pTnMod (Oval/Red) - Chicken*

A vector was designed for inserting a reporter gene (DsRed) under the control of the ovalbumin promoter, and including the ovalbumin signal sequence, into the genome of a bird. One version of this vector is given below as SEQ ID NO:3. The vector of SEQ ID NO:3, named pTnMod (Oval/Red) - Chicken, includes chicken
20 ovalbumin promoter and signal sequences.

SEQ ID NO:3, pTnMod (Oval/Red) - Chicken, includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to bp 1-130 of pBluescriptII sk(-).

25 Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems, corresponding to bp 229-1873 of pGWiz.

30 Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons as discussed above.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of pGWiz.

5 Base pairs 3415 --3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from 10 pNK2859.

10 Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4044 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 924-718 of pBluescriptII sk(-).

15 Base pairs 4045-4049 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4050 - 4951 contain upstream elements of the (including SDRE, steroid-dependent response element). See GenBank accession number J00895 M24999, bp 431-1332. Base pairs 4952-4959 are a residue from ligation of
20 restriction enzyme sites used in constructing the vector.

Base pairs 4960 - 5112 are the chicken ovalbumin signal sequence (GenBank accession number J00895 M24999, bp 2996-3148).

Base pairs 5113-5118 are a residue from ligation of restriction enzyme sites used in constructing the vector.

25 Base pairs 5119 - 6011 are the DsRed reporter coding sequence, including polyA sequence, from pDsRed1.1 (Clontech), corresponding to bp 100 - 992 of pDsRed1.1.

Base pairs 6012-6017 are a residue from ligation of restriction enzyme sites used in constructing the vector.

30 Base pairs 6018 - 6056 are part of the multiple cloning site of the ZeroBlunt Topo cloning vector (Invitrogen), corresponding to bp 337-377 of ZeroBlunt.

Base pairs 6057-6062 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 6063 - 6495 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 667-235 of pBluescriptII sk(-).

Base pairs 6496-6500 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5 Base pairs 6501 - 6570 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 6571 - 6612 are non-coding λ DNA that is residual from pNK2859.

Base pairs 6613 - 7477 are non-coding DNA that is residual from pNK2859.

Base pairs 7478 - 9678 are from the pBluescriptII sk(-) base vector
10 (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s).

EXAMPLE 4

15 *Preparation of Transposon-Based Vector pTnMod(Oval/Red) - Quail*

A vector was designed for inserting a reporter gene (DsRed) under the control of the ovalbumin promoter, and including the ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:4. The vector of SEQ ID NO:4, named pTnMod (Oval/Red) - Quail, has been constructed, and selected portions of the
20 sequence have been verified by re-sequencing.

SEQ ID NO:4, pTnMod (Oval/Red) - Quail, includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to bp 1-130 of pBluescriptII sk(-).

25 Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 - 1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz.

Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites
30 used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons as discussed above.

Base pairs 2988-2993 are two engineered stop codons. Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of pGWiz.

5 Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence recognized by the transposon Tn10.

10 Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4044 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 924-718 of pBluescriptII sk(-).

15 Base pairs 4045-4049 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4050 - 4934 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332). Some deletions
20 were noted in the quail sequence, as compared to the chicken sequence.

Base pairs 4935-4942 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4943 - 5092 are the Japanese quail ovalbumin signal sequence. The quail signal sequence was isolated by its high degree of homology to the chicken
25 signal sequence (GenBank accession number J00895 M24999, base pairs 2996-3148). Some deletions were noted in the quail sequence, as compared to the chicken sequence.

Base pairs 5093-5098 are a residue from ligation of restriction enzyme sites used in constructing the vector.

30 Base pairs 5099 - 5991 are the DsRed reporter coding sequence, including polyA sequence, from pDsRed1.1 (Clontech), corresponding to bp 100 - 992 of pDsRed 1.1.

Base pairs 5998 - 6036 are part of the multiple cloning site of the ZeroBlunt Topo cloning vector (Invitrogen), corresponding to base pairs 337-377 of ZeroBlunt.

Base pairs 6043 - 6475 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 667-235 of pBluescriptII sk(-).

Base pairs 6481 - 6550 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 6551 - 6592 are non-coding λ DNA that is residual from pNK2859.

Base pairs 6593 - 7457 are non-coding DNA that is residual from pNK2859.

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s).

Transfection of Stage X Japanese Quail Eggs with pTnMod(Oval/Red) – Quail via embryo injection

Transgenic Japanese quail were produced by transfecting Stage X embryos and the heritability of the transgene delivered by embryo transfection was established. More specifically, fertile eggs were collected in the morning and placed at 15° C until enough were collected for injection, but were held no longer than 7 days. Stage X embryos (eggs) were assigned to one of two treatment groups. Before treatment, each egg was incubated on its side at room temperature for about 2 hours to allow the embryo to move to “top dead center” (TDC). Each egg was transfected by drilling a 1 mm hole (directly above the embryo) through the shell without penetrating the underlying shell membrane. A 0.5 ml syringe fitted with a 28 gauge needle was used to deliver DNA complexed to a transfecting reagent, i.e. SUPERFECT®, in a 50 µl volume. An adhesive disc was used to seal the hole and provide a label for treatment identification. After all eggs were transfected, they were set in an incubator with the adhesive disc pointing upward for hatching.

Each bird that hatched was bled at one week of age, DNA was extracted from blood cells, and PCR was conducted using 28s primers as a positive control and primers specific to DsRed. Any bird that was negative was terminated, while positive birds were monitored to determine maintenance of the transgene. Birds consistently positive were maintained until sexual maturity and bred. Positive male and female birds were mated. The eggs of mated hens were hatched and the resulting chicks, the G1 generation, were evaluated to determine if they were transgenic. All G1s resulting from this mating were bled and PCR conducted as described above.

Egg injection: Two treatment groups and one control group were used for this experiment. Vector pTnMod (Oval/Red) in supercoiled form (Treatment 1) and in linear form (Treatment 2) were used to transfect 15 eggs per treatment. To obtain linear DNA for this experiment, pTnMod (Oval/Red) was digested with NgoM IV, column purified, and resuspended in TE buffer.

Each egg was injected with 0.75 µg of DNA complexed with SUPERFECT® in a 1:3 ratio in a total injection volume of 50 µl Hank's Balanced Salt solution (HBSS) was used to bring the volume to 50 µl. The DNA Superfect mixture must be allowed to incubate (for complex formation) at room temperature for 10 minutes prior to injection and must be used within 40 minutes post initial mixing. Eggs were incubated as described above after injection.

Results: In the supercoiled injection group, 2 females and 1 male were identified as PCR positive using primers specific to the DsRed coding sequence. These birds were mated as described above. Blood was taken from the G1 chicks and PCR was conducted. The results showed that the transgene was incorporated into the gametes of these birds. The G1 chicks from these birds were examined on a weekly basis until it was verified that the gene was not present or enough transgenic G1s were obtained to initiate a breeding flock of fully transgenic birds. Eggs from these G1 chicks expressed DsRed protein in the albumin portion of their eggs.

EXAMPLE 6

Intratesticular Injection of Chickens with pTnMod(CMV/Red) (SEQ ID NO:2)

Immature birds of different ages (4, 6, 8, 10, 12, and 14 weeks) were placed under anesthesia and injected in the testes with the construct pTnMod(CMV/Red). A saline solution containing 1-5 µg of purified DNA vector, mixed with SUPERFECT® transfecting reagent (Qiagen, Valencia, CA) in a 1:6 (wt:vol) ratio. The volume of saline was adjusted so that the total volume injected into each testis was 150-200 µl, depending on the age and size of the bird. For the 4- and 6-week-old chickens, 1 µg DNA in 150 µl was injected in each testis, divided into three doses of 50 µl each. For

the older birds, 200 µl total volume was injected, containing either 3 µg DNA (for 8-week-old birds) or 5 µg DNA (for older birds) per testis. First, one testis was surgically exposed prior to injection. After injection, the incision was sutured, and the sequence was repeated for the alternate testis.

5 From six to nine months post-surgery, weekly sperm samples were taken from each injected bird, as well as from control birds. Each sperm sample was evaluated for uptake and expression of the injected gene. Samples were evaluated by PCR on whole sperm, within one week after collection.

Approximately 100 male white leghorn chickens, in groups of 5-26, at ages 4,
10 6, 8, 10, 12, and 14 weeks, were used as this is the age range in which it is expected that the testes are likely to be most "receptive." In this age range, the blood/testis barrier has not yet formed, and there is a relatively high number of spermatogonia relative to the numbers of other cell types, e.g., spermatids, etc. See J. Kumaran et al., 1949. Poultry Sci., vol. 29, pp. 511-520. See also E. Oakberg, 1956. Am. J. Anatomy,
15 vol. 99, pp. 507-515; and P. Kluin et al., 1984. Anat. Embryol., vol. 169, pp. 73-78.

The experimental and control males were obtained from commercial sources at one day of age, and maintained in brooders until used. The male birds were housed in temperature-controlled spaces in individual standard caging as they approached maturity. They were given water and standard commercial feed ad lib. They were
20 kept initially in a 23:1 hour light/dark cycle, stepped down at approximately weekly intervals to a 15:8 hour light/dark cycle, as this regimen has been reported to optimize sexual maturity and fertility.

Surgical and DNA Injection Procedures

At the appropriate ages, groups of individual males were starved overnight and
25 then subjected to transgene delivery by direct intratesticular injection of DNA by experienced animal surgeons. Each male was anesthetized with isoflurane via a simplified gas machine.

Various devices and anesthesia machines have previously been described for administering isoflurane (and other gaseous anesthetics) to birds. See Alsage et al.,
30 Poultry Sci., 50:1876-1878 (1971); Greenlees et al., Am. J. Vet. Res., vol. 51, pp. 757-758 (1990). However, these prior techniques are somewhat cumbersome and complex to implement. A novel and much simpler system to administer isoflurane (or other gaseous) anesthesia was developed due to the deficiencies in the prior art, a

system that we found worked well on all ages of chicks. A standard nose cone was placed over the chick's head, similar to the system that has been used for decades to administer ether to mice. A plastic tube approximately 3.5 cm in diameter and 12 cm long was filled with cotton, into which was poured approximately 2 mL isoflurane (Abbott Laboratories, Chicago). The chick's head was placed partially into the cylinder, and was held in place there intermittently throughout the surgery as required to maintain the proper plane of anesthesia, without overdosing.

Each anesthetized bird was positioned on its side on an animal board with cords tractioning the wings and feet to allow access to the testes area. The area was swabbed with 0.5% chlorhexidine, and a 2 cm dorsolateral incision was made in the skin over the testis (similar to the procedure commonly used for caponization). A small-animal retractor was used to spread the last two ribs, exposing the testis. The DNA solution was then mixed with SUPERFECT® (Qiagen) according to the manufacturer's protocol, approximately a 1:6 wt/vol ratio, to a final concentration of 0.01 - 0.05 µg/µl. This resulted in 1 - 5 µg total DNA (in a 150-200 µl volume) being injected into each testis, spread over three injection sites: one at each end of the testis, and one in the middle.

The injection device was a standard 25 gauge, 1/2 inch (1.27 cm) hypodermic needle, attached to a 50, 100, or 200 µl syringe. Approximately 5 mm of the needle tip was bent at a 90 degree angle, to facilitate insertion into the testes. Approximately 50 - 70 µl of the DNA-SUPERFECT® solution was injected into each of three sites per testis. The multiple injections were calculated to suffuse the DNA throughout the whole testis, the idea being to promote contact between DNA and spermatogonia as much as feasible. We estimated that our procedure resulted in the injection of about 100,000 DNA molecules per spermatogonium. The construct used in these tests was a highly potent constitutive modified CMV promoter, operatively linked to the dsRed gene as shown in SEQ ID NO:2.

Following injection, the incision was closed in two layers with 4-0 absorbable suture, and then the contralateral testis was similarly exposed and injected. Following surgery, each bird was returned to its cage to recover. One hundred thirteen males were ultimately used in the experimental regimen to increase the overall likelihood of success, along with 4 control birds (16 weeks 20 old) subjected to sham surgery (with injections containing only the transfection reagent).

Evaluation of Birds

Thus, a total of 113 white leghorn chickens were injected with the DNA vector in groups of 5-26 at varying ages. Fourteen birds were transformed at 4 weeks, 23 birds at 6 weeks; 26 birds at 8 weeks; 23 birds at 10 weeks; 5 birds at 12 weeks; and 22 birds at 14 weeks. Sixteen birds died before they could be sampled, so to date, 97 roosters have been sampled, plus the four controls. Birds were evaluated at 18-24 weeks of age for (a) potential transformation in the sperm, and (b) successful testis transfection. Sperm samples were obtained from each rooster by manual manipulation using standard techniques. The sperm were washed, and their DNA was extracted following the techniques of G. Mann et al., 1993. J. Reprod. Fert., 99:505-12. The samples were then frozen until analyzed. Evaluation was conducted by PCR analysis to detect DNA integration into the sperm, or into any of the testicular cells. Additionally, selected testes were harvested at the end of the sperm sampling period.

Of 97 birds tested, at least 22 showed probable positive results. Positive results were observed at all transformation ages, except for 4 weeks, which was not tested. At least two birds were confirmed positive by PCR of sperm, conducted four months after the initial injection. These results were transient in many cases, however since it was believed that the DsRed gene product used in these initial proof of concept experiments was toxic. Nevertheless, the positive PCR results presumptively demonstrated that the transgene was incorporated into spermatogonia (before puberty), and that it was carried in transgenic sperm. Such sperm could then transmit the gene to subsequent generations, resulting in the production of true, germ-line transgenic "founder" birds.

To further confirm that the DNA had been incorporated into the sperm, and that contaminating vector was not being detected from other sources, it was confirmed through PCR on sperm of experimental birds, and on positive and negative controls that the sperm of the experimental birds lacked DNA encoding the transposase. The design of the preferred transposon-based vector is such that the sequence encoding the transposase is contained in the vector, but is not incorporated into the transformed chromosome. Thus, presence of the exogenous coding sequence, coupled with absence of the transposase gene, is strong evidence for incorporation of the exogenous coding sequence, or transgene.

These results demonstrated proof of concept, as positive PCR results were obtained from the sperm of treated birds. Interpretation of these preliminary results was made more difficult by the fact that the modified CMV promoter used in the experiment was probably too "hot." As the DsRed product is not secreted from the cells, the product built up intracellularly to levels that were toxic, frequently killing the cells. Even this result, of course, means that the transformation was successful. The transgene could not have killed the cells otherwise.

In order to resolve to the problem with toxicity of the DsRed gene product, experiments were conducted using a different reporter gene operably linked to the ovalbumin promoter, so that the transgene was expressed in the egg white. These experiments are provided in Examples 12-15 below.

EXAMPLE 7

Transfection of Male White Leghorn Chickens Using the Vector pTnMod(Oval/Red) – Quail (SEQ ID NO:4) via Testicular Injections

In further experiments conducted on leghorn chickens, it was demonstrated that chickens injected intratesticularly at 8, 10, 12, or 14 weeks of age, had, on average, approximately 40% positive sperm between 6 and 8 months after injection. In other experiments, successful transfection was achieved with chickens injected at 13 weeks of age.

Forty-nine white leghorn roosters approximately 8, 10, 12, or 14 weeks of age were obtained and housed. Birds were identified, wing banded, and assigned to a treatment group. If appropriate (based on testes size and vascularization), one testis was caponized and the entire DNA injection volume was delivered to the remaining testis. Thirty-two males received DNA injections of 5µg DNA/testis at a 1:3 ratio of DNA to SUPERFECT®. The remaining birds were used as controls. After injection, all birds were mated with at least 5 females and observed until sexual maturity and egg-laying began. All eggs collected prior to peak egg production (approximately 24 weeks of age for the hens) were incubated and candled to determine embryo presence. Any embryos identified were incubated to hatch to extract DNA, PCR was conducted, and transgene presence was determined.

Roosters positive for the pTnMod(Oval/Red) – Quail construct were kept to produce F1 offspring (eggs collected at peak production). Offspring from this hatch

were bled, DNA extracted from the blood, and PCR conducted using primers specific for the DsRed gene. It was determined that 77% of the offspring were transgenic.

EXAMPLE 8

- 5 *Transfection of Mature Male Japanese Quail using the vector pTnMod(Oval/Red) – Quail (SEQ ID NO:4) via Testicular Injections*

Twelve sexually mature males (at approximately 13 weeks of age) underwent surgery for testicular injection as described above for chickens. At 21-28 days of age, the birds were identified, leg banded, debeaked, and separated based on sex.

- 10 Injections comprised 5 µg/testes of the vector in concentrations 1:3 or 1:10 for SUPERFECT® or a 1:1 ratio with Mirrus. The study consisted of 3 treatment groups with 5 males in the 1:3 DNA:SUPERFECT® group, 3 males in the 1:10 DNA:SUPERFECT® group, and 4 males in the 1:1 Mirrus group. All surgeries were conducted in one day.

- 15 Any unincorporated DNA was allowed to clear from the testes by holding the birds for 19 days before mating with females. At 15 weeks of age, 2 age-matched females were housed with each treated male. The presence of the transfected DNA was determined in the fertilized eggs during the second week of egg lay. The subsequent eggs collected from parents producing positively identified transgenic
20 eggs were collected and stored until taken to hatch.

PCR performed on the sperm of quail injected at three months of age indicated successful incorporation of the DsRed transgene into the quail sperm.

EXAMPLE 9

- 25 *Transfection of Immature Male Japanese Quail using the vector pTnMod(Oval/Red) – Quail (SEQ ID NO:4) via Testicular Injections*

Approximately 450 quail eggs were set and hatched. At 21-28 days of age, the birds were identified, wingbanded, debeaked, and separated based on sex. At 4 weeks of age, 65 male birds underwent surgery and testicular injections as described above.

- 30 Injections comprised a control and 2 µg/testes of the vector in varying concentrations (0, 1/3, 1/5, and 1/10) of three different transfection reagents: 1) SUPERFECT®, 2) Mirus/Panvera and 3) Dosper. The study comprised 13 treatment groups with 5 males per group. One transfection reagent was administered per day.

At 7 weeks of age, 2 age-matched females were housed with each treated male. The presence of the transfected DNA was determined in the fertilized eggs during the second week of egg lay. The subsequent eggs collected from parents producing positively identified transgenic eggs were collected and stored until taken to hatch. PCR performed on the sperm of quail injected at four and five weeks of age indicated successful incorporation of the DsRed transgene into the quail sperm.

EXAMPLE 10

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/p146/PA) -

10 *Chicken*

A vector is designed for inserting a p146 gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:29.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

20 Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 - 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 - 3718 are non coding DNA that is residual from vector pNK2859.

25 Base pairs 3719 - 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 - 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

30 Base pairs 4050 - 4951 are a chicken ovalbumin promoter (including SDRE) that corresponds to base pairs 431-1332 of the chicken ovalbumin promoter in GenBank Accession Number J00895 M24999.

Base pairs 4958 - 6115 are a chicken ovalbumin signal sequence and Ovalbumin gene that correspond to base pairs 66-1223 of GenBank Accession Number V00383.1 (The STOP codon being omitted).

Base pairs 6122 - 6271 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6272 - 6316 are a p146 sequence (synthetic) with 2 added stop codons.

Base pairs 6324 - 6676 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6682 - 7114 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7120- 7189 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7190 - 7231 are λ DNA that is residual from pNK2859.

Base pairs 7232 - 8096 are non coding DNA that is residual from pNK2859.

Base pairs 8097 - 10297 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

EXAMPLE 11

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/p146/PA) - Quail

A vector is designed for inserting a p146 gene under the control of a quail ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:30.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922-2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector pNK2859.

5 Base pairs 3719 – 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

10 Base pairs 4050 - 4938 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332).

15 Bp 4945 - 6092 are a quail ovalbumin signal sequence and ovalbumin gene that corresponds to base pairs 54 – 1201 of GenBank accession number X53964.1. (The STOP codon being omitted).

Base pairs 6097 - 6246 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

20 Base pairs 6247 – 6291 are a p146 sequence (synthetic) with 2 added stop codons.

Base pairs 6299 – 6651 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6657 - 7089 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

25 Base pairs 7095- 7164 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7165 - 7206 are λ DNA that is residual from pNK2859.

Base pairs 7207 – 8071 are non coding DNA that is residual from pNK2859.

30 Base pairs 8072 - 10272 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

5

EXAMPLE 12

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/ProIns/PA) – Chicken

A vector is designed for inserting a proinsulin gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:31.

10

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

15

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 - 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

20

Base pairs 3415 - 3718 are non coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

25

Base pairs 3838 - 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

Base pairs 4050 - 4951 are a chicken ovalbumin promoter (including SDRE) that corresponds to base pairs 431-1332 of the chicken ovalbumin promoter in GenBank Accession Number J00895 M24999.

30

Base pairs 4958 - 6115 are a chicken ovalbumin signal sequence and ovalbumin gene that correspond to base pairs 66-1223 of GenBank Accession Number V00383.1. (The STOP codon being omitted).

Base pairs 6122 - 6271 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6272 - 6531 are a proinsulin gene.

Base pairs 6539 - 6891 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6897 - 7329 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7335- 7404 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7405 - 7446 are λ DNA that is residual from pNK2859.

Base pairs 7447 - 8311 are non coding DNA that is residual from pNK2859.

Base pairs 8312 - 10512 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

EXAMPLE 13

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/ProIns/PA) - Quail

A vector is designed for inserting a proinsulin gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:32.

Base pairs 1 -130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector pNK2859.

5 Base pairs 3719 – 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

10 Base pairs 4050 - 4938 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332). Some deletions were noted in the quail sequence, as compared to the chicken sequence.

15 Base pairs 4945 - 6092 are a quail ovalbumin signal sequence and ovalbumin gene that corresponds to base pairs 54 – 1201 of GenBank accession number X53964.1. (The STOP codon being omitted).

Base pairs 6093 - 6246 are a TAG sequence containing a gp41 hairpin loop from HIV I an enterokinase cleavage site and a spacer (synthetic).

20 Base pairs 6247 – 6507 are a proinsulin gene.

Base pairs 6514 – 6866 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6867 - 7303 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

25 Base pairs 7304- 7379 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7380 - 7421 are λ DNA that is residual from pNK2859.

Base pairs 7422 – 8286 are non coding DNA that is residual from pNK2859.

30 Base pairs 8287 - 10487 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

5 EXAMPLE 14

Transfection of Immature Leghorn Roosters using a Transposon-based Vector containing a Proinsulin Gene via Testicular Injections

Vectors containing the elements Oval promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:31) and CMV promoter/Oval gene/GP41
10 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:42) were each injected into the testes of 11 week old white leghorn roosters. These birds were held under normal conditions until sexual maturity was reached.

At the time of sexual maturity, each bird was handled and manipulated to obtain sperm. Sperm samples were collected in Hank's Buffered Salt Solution
15 (HBSS) and stored at either -20° C or 4° C until needed. DNA was extracted from sperm using a MoBio Ultra Clean DNA Bloodspin Kit (MoBio laboratories, Solana Beach CA). Fifty microliters of sperm was used in the DNA extraction protocol and the purified genomic DNA eluted in 100 µl of water. In each PCR reaction, approximately 0.5 – 0.75 µg of genomic DNA was used with primers anchored in the
20 entag-1 (5') and the synthetic polyA-2 (3'), which amplify a 685 bp fragment. Five of nine birds gave positive reactions for the presence of the appropriate vector construct. These birds were then mated with normal females.

Birds that did not yield positive results with PCR on the sperm were sacrificed, their testes removed, and DNA extracted using an approximately 25 mg
25 piece of tissue in a Qiagen DNEasy Tissue Kit; purified DNA was eluted in 200 µl water and PCR conducted as described above. Two of these birds gave a very strong, positive PCR reaction.

EXAMPLE 15

30 *Transfection of Japanese Quail using a Transposon-based Vector containing a Proinsulin Gene via Oviduct Injections*

Two experiments were conducted in Japanese quail using transposon-based vectors containing either Oval promoter/Oval gene/GP41 Enterokinase

TAG/Proinsulin/Poly A (SEQ ID NO:31) or CMV promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:42).

In the first experiment, the Oval promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A containing construct was injected into the oviduct of sexually mature quail; three hens received 5 µg at a 1:3 Superfect ratio and three received 10 µg at a 1:3 Superfect ratio. As of the writing of the present application, at least one bird that received 10 µg of DNA was producing human proinsulin in egg white (other birds remain to be tested). This experiment indicates that 1) the DNA has been stable for at least 3 months; 2) protein levels are comparable to those observed with a constitutive promoter such as the CMV promoter; and 3) sexually mature birds can be injected and results obtained without the need for cell culture.

In the second experiment, the transposon-based vector containing CMV promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A was injected into the oviduct of sexually immature Japanese quail. A total of 9 birds were injected. Of the 8 survivors, 3 produced human proinsulin in the white of their eggs for over 6 weeks. An ELISA assay described in detail below was developed to detect GP41 in the fusion peptide (Oval gene/GP41 Enterokinase TAG/Proinsulin) since the GP41 peptide sequence is unique and not found as part of normal egg white protein. In all ELISA assays, the same birds produced positive results and all controls worked as expected.

ELISA Procedure: Individual egg white samples were diluted in sodium carbonate buffer, pH 9.6, and added to individual wells of 96 well microtiter ELISA plates at a total volume of 0.1 ml. These plates were then allowed to coat overnight at 4°C. Prior to ELISA development, the plates were allowed warm to room temperature. Upon decanting the coating solutions and blotting away any excess, non-specific binding of antibodies was blocked by adding a solution of phosphate buffered saline (PBS), 1% (w/v) BSA, and 0.05% (v/v) Tween 20 and allowing it to incubate with shaking for a minimum of 45 minutes. This blocking solution was subsequently decanted and replaced with a solution of the primary antibody (Goat Anti-GP41 TAG) diluted in fresh PBS/BSA/Tween 20. After a two hour period of incubation with the primary antibody, each plate was washed with a solution of PBS and 0.05% Tween 20 in an automated plate washer to remove unbound antibody. Next, the secondary antibody, Rabbit anti-Goat Alkaline Phosphatase-conjugated, was diluted in PBS/BSA/Tween 20 and allowed to incubate 1 hour. The plates were then

subjected to a second wash with PBS/Tween 20. Antigen was detected using a solution of *p*-Nitrophenyl Phosphate in Diethanolamine Substrate Buffer for Alkaline Phosphatase and measuring the absorbance at 30 minutes and 1 hour.

5

EXAMPLE 16

Optimization of Intra-oviduct and Intra-ovarian Arterial Injections

Overall transfection rates of oviduct cells in a flock of chicken or quail hens are enhanced by synchronizing the development of the oviduct and ovary within the flock. When the development of the oviducts and ovaries are uniform across a group of hens and when the stage of oviduct and ovarian development can be determined or predicted, timing of injections is optimized to transfect the greatest number of cells. Accordingly, oviduct development is synchronized as described below to ensure that a large and uniform proportion of oviduct secretory cells are transfected with the gene of interest.

Hens are treated with estradiol to stimulate oviduct maturation as described in Oka and Schimke (T. Oka and RT Schimke, J. Cell Biol., 41, 816 (1969)), Palmiter, Christensen and Schimke (J Biol. Chem. 245(4):833-845, 1970). Specifically, repeated daily injections of 1 mg estradiol benzoate are performed sometime before the onset of sexual maturation, a period ranging from 1 – 14 weeks of age. After a stimulation period sufficient to maximize development of the oviduct, hormone treatment is withdrawn thereby causing regression in oviduct secretory cell size but not cell number. At an optimum time after hormone withdrawal, the oviducts of treated hens are injected with the transposon-based vector. Hens are subjected to additional estrogen stimulation after an optimized time during which the transposon-based vector is taken up into oviduct secretory cells. Re-stimulation by estrogen activates the transposon mechanism of the transposon-based vector, causing the integration of the gene of interest into the host genome. Estrogen stimulation is then withdrawn and hens continue normal sexual development. If a developmentally regulated promoter such as the ovalbumin promoter is used, expression of the transposon-based vector initiates in the oviduct at the time of sexual maturation. Intra-ovarian artery injection during this window allows for high and uniform transfection efficiencies of ovarian follicles to produce germ-line transfections and possibly oviduct expression.

Other means are also used to synchronize the development, or regression, of the oviduct and ovary to allow high and uniform transfection efficiencies. Alterations of lighting and/or feed regimens, for example, cause hens to 'molt' during which time the oviduct and ovary regress. Molting is used to synchronize hens for transfection, and may be used in conjunction with other hormonal methods to control regression and/or development of the oviduct and ovary.

EXAMPLE 17

Isolation of Human Proinsulin Using Anti-TAG Column Chromotography

A HiTrap NHS-activated 1 mL column (Amersham) was charged with a 30 amino acid peptide that contained the gp-41 epitope containing gp-41's native disulfide bond that stabilizes the formation of the gp-41 hairpin loop. The 30 amino acid gp41 peptide is provided as SEQ ID NO:23. Approximately 10 mg of the peptide was dissolved in coupling buffer (0.2 M NaHCO₃, 0.5 M NaCl, pH 8.3 and the ligand was circulated on the column for 2 hours at room temperature at 0.5 mL/minute. Excess active groups were then deactivated using 6 column volumes of 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 and the column was washed alternately with 6 column volumes of acetate buffer (0.1 M acetate, 0.5 M NaCl, pH 4.0) and ethanolamine (above). The column was neutralized using 1 X PBS. The column was then washed with buffers to be used in affinity purification: 75 mM Tris, pH 8.0 and elution buffer, 100 mM glycine-HCl, 0.5 M NaCl, pH 2.7. Finally, the column was equilibrated in 75 mM Tris buffer, pH 8.0.

Antibodies to gp-41 were raised in goats by inoculation with the gp-41 peptide described above. More specifically, goats were inoculated, given a booster injection of the gp-41 peptide and then bled. Serum was harvested by centrifugation. Approximately 30 mL of goat serum was filtered to 0.45 uM and passed over a TAG column at a rate of 0.5 mL/min. The column was washed with 75 mM Tris, pH 8.0 until absorbance at 280 nm reached a baseline. Three column volumes (3 mL) of elution buffer (100 mM glycine, 0.5 M NaCl, pH 2.7) was applied, followed by 75 mM Tris buffer, pH 8.0, all at a rate of 0.5 mL/min. One milliliter fractions were collected. Fractions were collected into 200 uL 1 M Tris, pH 9.0 to neutralize acidic fractions as rapidly as possible. A large peak eluted from the column, coincident with the application the elution buffer. Fractions were pooled. Analysis by SDS-PAGE

showed a high molecular weight species that separated into two fragments under reducing condition, in keeping with the heavy and light chain structure of IgG.

Pooled antibody fractions were used to charge two 1 mL HiTrap NHS-activated columns, attached in series. Coupling was carried out in the same manner as that used for charging the TAG column.

Isolation of Ovalbumin-TAG-Proinsulin from Egg White

Egg white from quail and chickens treated by intra-oviduct injection of the CMV-ovalbumin-TAG-proinsulin construct were pooled. Viscosity was lowered by subjecting the allantoic fluid to successively finer pore sizes using negative pressure filtration, finishing with a 0.22 μ m pore size. Through the process, egg white was diluted approximately 1:16. The clarified sample was loaded on the Anti-TAG column and eluted in the same manner as described for the purification of the anti-TAG antibodies. A peak of absorbance at 280 nm, coincident with the application of the elution buffer, indicated that protein had been specifically eluted from the Anti-TAG column. Fractions containing the eluted peak were pooled for analysis.

The pooled fractions from the Anti-TAG affinity column were characterized by SDS-PAGE and western blot analysis. SDS-PAGE of the pooled fractions revealed a 60 kDal molecular weight band not present in control egg white fluid, consistent with the predicted molecular weight of the transgenic protein. Although some contaminating bands were observed, the 60 kDal species was greatly enriched compared to the other proteins. An aliquot of the pooled fractions was cleaved overnight at room temperature with the protease, enterokinase. SDS-PAGE analysis of the cleavage product, revealed a band not present in the uncut material that co-migrated with a commercial human proinsulin positive control. Western blot analysis showed specific binding to the 60 kDal species under non-reducing condition (which preserve the hairpin epitope of gp-41 by retaining the disulfide bond). Western analysis of the low molecular weight species that appeared upon cleavage with an anti-human proinsulin antibody, conclusively identified the cleaved fragment as human proinsulin.

30

EXAMPLE 18

Construction of a Transposon-based Transgene for the Expression of a Monoclonal Antibody

5 Production of a monoclonal antibody using transposon-based transgenic methodology is accomplished in a variety of ways.

1) two vectors are constructed: one that encodes the light chain and a second vector that encodes the heavy chain of the monoclonal antibody. These vectors are then incorporated into the genome of the target animal by at least one of two methods: a) direct transfection of a single animal with both vectors (simultaneously or as separate
10 events); or, b) a male and a female of the species carry in their germline one of the vectors and then they are mated to produce progeny that inherit a copy of each.

2) the light and heavy chains are included on a single DNA construct, either separated by insulators and expression is governed by the same (or different) promoters, or by using a single promoter governing expression of both transgenes with the inclusion of
15 elements that permit separate transcription of both transgenes, such as an internal ribosome entry site.

The following example describes the production of a transposon-based DNA construct that contains both the coding region for a monoclonal light chain and a heavy chain on a single construct. Beginning with the vector pTnMod, the coding
20 sequences for the heavy and light chains are added, each preceded by an appropriate promoter and signal sequence. Using methods known to one skilled in the art, approximately 1 Kb of the proximal elements of the ovalbumin promoter are linked to the signal sequence of ovalbumin or some other protein secreted from the target tissue. Two copies of the promoter and signal sequence are added to the multiple
25 cloning site of pTnMod, leaving space and key restriction sites between them to allow the subsequent addition of the coding sequences of the light and heavy chains of the monoclonal antibody. Methods known to one skilled in the art allow the coding sequences of the light and heavy chains to be inserted in-frame for appropriate expression. For example, the coding sequence of light and heavy chains of a murine
30 monoclonal antibody that show specificity for human seminoprotein have recently been disclosed (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively). The light chain cDNA sequence is provided in SEQ

ID NO:34, whereas the cDNA of the heavy chain is reported as provided in SEQ ID NO:35.

Thus one skilled in the art can produce both the heavy and light chains of a monoclonal antibody in a single cell within a target tissue and species. If the modified cell contained normal posttranslational modification capabilities, the two chains would form their native configuration and disulfide attachments and be substrates for glycosylation. Upon secretion, then, the monoclonal antibody is accumulated, for example, in the egg white of a chicken egg, if the transgenes are expressed in the magnum of the oviduct.

It should also be noted that, although this example details production of a full-length murine monoclonal antibody, the method is quite capable of producing hybrid antibodies (e.g. a combination of human and murine sequences; 'humanized' monoclonal antibodies), as well as useful antibody fragments, known to one skilled in the art, such as Fab, Fc, F(ab) and Fv fragments. This method can be used to produce molecules containing the specific areas thought to be the antigen recognition sequences of antibodies (complementarity determining regions), linked, modified or incorporated into other proteins as desired.

EXAMPLE 19

Treatment of rats with a transposon-based vector for tissue-specific insulin gene incorporation

Rats are made diabetic by administering the drug streptozotocin (Zanosar; Upjohn, Kalamazoo, MI) at approximately 200 mg/kg. The rats are bred and maintained according to standard procedures. A transposon-based vector containing a proinsulin gene, an appropriate carrier, and, optionally, a transfection agent, are injected into rats' singhepatic (if using G6P) artery with the purpose of stable transformation. Incorporation of the insulin gene into the rat genome and levels of insulin expression are ascertained by a variety of methods known in the art. Blood and tissue samples from live or sacrificed animals are tested. A combination of PCR, Southern and Northern blots, *in-situ* hybridization and related nucleic acid analysis methods are used to determine incorporation of the vector-derived proinsulin DNA and levels of transcription of the corresponding mRNA in various organs and tissues of the rats. A combination of SDS-PAGE gels, Western Blot analysis, radioimmunoassay, and ELISA and other methods known to one of ordinary skill in

the art are used to determine the presence of insulin and the amount produced. Additional transfections of the vector are used to increase protein expression if the initial amounts of the expressed insulin are not satisfactory, or if the level of expression tapers off. The physiological condition of the rats is closely examined post-transfection to register positive or any negative effects of the gene therapy. Animals are examined over extended periods of time post-transfection in order to monitor the stability of gene incorporation and protein expression.

EXAMPLE 20

Exemplary Transposon-Based Vectors

The following example provides a description of various transposon-based vectors of the present invention and several constructs for insertion into the transposon-based vectors of the present invention. These examples are not meant to be limiting in any way. The constructs for insertion into a transposon-based vector are provided in a cloning vector labeled pTnMCS.

pTnMCS (base vector)

Bp 1 – 130 Remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp1-130

Bp 133 – 1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp2 29-1873

Bp 1783 – 2991 Transposase, from Tn10 (GenBank accession #J01829) bp 108-1316

Bp 2992 – 3344 Non coding DNA from vector pNK2859

Bp 3345 – 3387 Lambda DNA from pNK2859

Bp 3388 – 3457 70 bp of IS10 left from Tn10

Bp 3464 – 3670 Multiple cloning site from pBluescriptII sk(-), thru the XmaI site bp924-718

Bp 3671 - 3715 Multiple cloning site from pBluescriptII sk(-), from the XmaI site thru the XhoI site. These base pairs are usually lost when cloning into pTnMCS.bp

717-673

Bp 3716 – 4153 Multiple cloning site from pBluescriptII sk(-), from the XhoI site bp672-235

Bp 4159 - 4228 70 bp of IS10 left from Tn10

Bp 4229 - 4270 Lambda DNA from pNK2859

Bp 4271 – 5114 Non-coding DNA from pNK2859

Bp 5115 - 7315 pBluescript sk (-) base vector (Stratagene, Inc.) bp 761-2961

pTnMCS (CMV-prepro-ent-hGH-CPA)

5 Bp 1 – 3670 from vector PTnMCS, bp 1 - 3670

Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864

Bp 5326 - 5496 Capsite/Prepro taken from GenBank accession # X07404, bp 563 – 733

10 Bp 5504 - 5652 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 5653 – 6306 Human growth hormone taken from GenBank accession # V00519, bp 1-654

Bp 6313 – 6720 Conalbumin polyA taken from GenBank accession # Y00407, bp

15 10651-11058

Bp 6722 –10321 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-CHOVg-ent-ProInsulin-synPA) (SEQ ID NO:41)

Bp 1 – 3670 from vector PTnMCS, bp 1 - 3670

20 Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864

Bp 5327 –6480 Chicken ovalbumin gene taken from GenBank accession # V00383, bp 66-1219

25 Bp 6487 - 6636 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6637 – 6897 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

Bp 6898 – 6942 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

30 Bp 6943 - 7295 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 7296 – 10895 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-prepro-ent-ProInsulin-synPA)

- Bp 1 – 3670 from vector pTnMCS, bp 1 - 3670
- Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864
- 5 Bp 5326 - 5496 Capsite/Prepro taken from GenBank accession # X07404, bp 563 – 733
- Bp 5504 - 5652 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 5653 – 5913 Human Proinsulin taken from GenBank accession # NM000207, bp
- 10 117-377
- Bp 5914 – 5958 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)
- Bp 5959 - 6310 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271
- 15 Bp 6313 – 9912 from cloning vector pTnMCS, bp 3716-7315

pTnMCS(Chicken OVep+OVg'+ENT+proins+syn polyA)

- Bp 1 – 3670 from vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4350 Chicken Ovalbumin enhancer taken from GenBank accession
- 20 #S82527.1 bp 1-675
- Bp 4357 – 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00895M24999 bp 1-1336
- Bp 5699 – 6917 Chicken Ovalbumin gene from GenBank Accession # V00383.1 bp 2-1220. (This sequence includes the 5'UTR, containing putative cap site, bp 5699-
- 25 5762.)
- Bp 6924 - 7073 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7074 - 7334 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 7335 - 7379 Spacer DNA, derived as an artifact from the cloning vectors pTOPO
- 30 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 7380 - 7731 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7733 – 11332 from vector pTnMCS, bp 3716 - 7315

pTnMCS(Chicken OVep+prepro+ENT+proins+syn polyA)

- Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4350 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1 bp 1-675
- 5 Bp 4357 – 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00895-M24999 bp 1-1336
- Bp 5699 – 5869 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733
- 10 Bp 5876 - 6025 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6026 - 6286 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6287 - 6331 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- 15 Bp 6332 - 6683 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 6685 – 10284 from cloning vector pTnMCS, bp 3716 - 7315

pTnMCS(Quail OVep+OVg'+ENT+proins+syn polyA)

- 20 Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4333 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession # S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of
- 25 bases does not correspond exactly.)
- Bp 4340 – 5705 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of
- 30 bases does not correspond exactly.)
- Bp 5712 – 6910 Quail Ovalbumin gene, EMBL accession # X53964, bp 1-1199. (This sequence includes the 5'UTR, containing putative cap site bp 5712-5764.)

- Bp 6917 - 7066 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7067 - 7327 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 7328 - 7372 Spacer DNA, derived as an artifact from the cloning vectors pTOPO
- 5 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 7373 - 7724 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7726 - 11325 from cloning vector pTnMCS, bp 3716 - 7315
- 10 pTnMCS (CHOVep-prepro-ent-hGH-CPA)
- Bp 1 - 3670 from vector PTnMCS, bp 1-3670
- Bp 3676 - 4350 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1-675
- Bp 4357 - 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- 15 Bp 5699 - 5869 Capsite/Prepro taken from GenBank accession # X07404, bp 563-733
- Bp 5877 - 6025 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6026 - 6679 Human growth hormone taken from GenBank accession # V00519, bp 1-654
- 20 Bp 6686 - 7093 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058
- Bp 7095 - 10694 from cloning vector pTnMCS, bp 3716-7315
- 25 pTnMCS(Quail OVep+prepro+ENT+proins+syn polyA)
- Bp 1 - 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 - 4333 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far- upstream chicken ovalbumin enhancer, GenBank accession #S82527.1, bp 1-675. (There are multiple base pair
- 30 substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- Bp 4340 - 5705 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter,

- GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- Bp 5712 – 5882 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733
- Bp 5889 - 6038 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6039 - 6299 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6300 - 6344 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 6345 - 6696 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 6698 – 10297 from cloning vector pTnMCS, bp 3716 - 7315
- 15 PtTnMOD
- Bp 1 - 130 remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp1-130
- Bp 133 - 1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp229-1873
- Bp 1783 - 2991 Transposase, modified from Tn10 (GenBank accession #J01829) bp 108-1316
- Bp 2992 - 2994 Engineered stop codon
- Bp 2996 - 3411 Synthetic polyA from gWIZ (Gene Therapy Systems) bp 1922 - 2337
- Bp 3412 - 3719 Non-coding DNA from vector pNK2859
- Bp 3720 - 3762 Lambda DNA from pNK2859
- 25 Bp 3763 - 3832 70 bp of IS10 left from Tn10
- Bp 3839 – 4045 Multiple cloning site from pBluescriptII sk(-), thru the XmaI site bp 924-718
- Bp 4046 - 4090 Multiple cloning site from pBluescriptII sk(-), from the XmaI site thru the XhoI site. These base pairs are usually lost when cloning into pTnMCS. bp 717-673
- 30 Bp 4091 – 4528 Multiple cloning site from pBluescriptII sk(-), from the XhoI site bp 672-235

Bp 4534 - 4603 70 bp of IS10 left from Tn10

Bp 4604 - 4645 Lambda DNA from pNK2859

Bp 4646 - 5489 Non-coding DNA from pNK2859

Bp 5490 - 7690 pBluescript sk (-) base vector (Stratagene, INC) bp 761-2961

5

pTnMOD (CHOVep-prepro-ent-hGH-CPA)

Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

Bp 4051 - 4725 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1 - 675

10 Bp 4732 - 6067 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336

Bp 6074 - 6245 Capsite/Prepro taken from GenBank accession # X07404, bp 563 - 733

15 Bp 6252 - 6400 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6401 - 7054 Human growth hormone taken from GenBank accession # V00519, bp 1-654

Bp 7061 - 7468 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

20 Bp 7470 - 11069 from cloning vector pTnMCS, bp 3716-7315

pTnMOD (CMV-CHOVg-ent-ProInsulin-synPA) (SEQ ID NO:42)

Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

25 Bp 4051 - 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

Bp 5702 - 6855 Chicken ovalbumin gene taken from GenBank accession # V00383, bp 66-1219

Bp 6862 - 7011 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

30 Bp 7012 - 7272 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

Bp 7273 - 7317 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

Bp 7318 - 7670-Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 7672 -11271 from cloning vector pTnMCS, bp 3716-7315

5 pTnMOD (CMV-prepro-ent-hGH-CPA)

Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

Bp 4051 - 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

10 Bp 5701 - 5871 Capsite/Prepro taken from GenBank accession # X07404, bp 563 - 733

Bp 5879 - 6027 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6028 - 6681 Human growth hormone taken from GenBank accession # V00519, bp 1-654

15 Bp 6688 - 7095 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

Bp 7097 - 10696 from cloning vector pTnMCS, bp 3716-7315

pTnMOD (CMV-prepro-ent-ProInsulin-synPA)

20 Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

Bp 4051 - 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

Bp 5701 - 5871 Capsite/Prepro taken from GenBank accession # X07404, bp 563 - 733

25 Bp 5879 - 6027 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6028 - 6288 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

Bp 6289 - 6333 Spacer DNA, derived as an artifact from the cloning vectors pTOPO

30 Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

Bp 6334 - 6685 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 6687 -10286 from cloning vector pTnMCS, bp 3716-7315

pTnMOD(Chicken OVep+OVg'+ENT+proins+syn polyA) (SEQ ID NO:43)

Bp 1 – 4045 from cloning vector pTnMOD, bp 1 - 4045

Bp 4051 – 4725 Chicken Ovalbumin enhancer taken from GenBank accession #

5 S82527.1 bp 1-675

Bp 4732 – 6067 Chicken Ovalbumin promoter taken from GenBank accession #

J00895-M24999 bp 1-1336

Bp 6074 – 7292 Chicken Ovalbumin gene from GenBank Accession # V00383.1 bp

2-1220. (This sequence includes the 5'UTR, containing putative cap site bp 6074-

10 6137.)

Bp 7299 - 7448 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 7449 - 7709 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 7710 - 7754 Spacer DNA, derived as an artifact from the cloning vectors pTOPO

15 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

Bp 7755 - 8106 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 8108 – 11707 from cloning vector pTnMCS, bp 3716 - 7315

20 pTnMOD(Chicken OVep+prepro+ENT+proins+syn polyA)

Bp 1 – 4045 from cloning vector pTnMCS, bp 1 - 4045

Bp 4051 – 4725 Chicken Ovalbumin enhancer taken from GenBank accession #

S82527.1 bp 1-675

Bp 4732 – 6067 Chicken Ovalbumin promoter taken from GenBank accession #

25 J00895-M24999 bp 1-1336

Bp 6074 – 6244 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733

Bp 6251 - 6400 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

30 Bp 6401 - 6661 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 6662 - 6706 Spacer DNA, derived as an artifact from the cloning vectors pTOPO

Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

Bp 6707 - 7058 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 7060 - 10659 from cloning vector pTnMCS, bp 3716 - 7315

5 pTnMOD(Quail OVep+OVg'+ENT+proins+syn polyA)

Bp 1 - 4045 from cloning vector pTnMCS, bp 1 - 4045

Bp 4051 - 4708 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession # S82527.1, bp 1-675. (There are multiple base pair
10 substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)

Bp 4715 - 6080 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair
15 substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)

Bp 6087 - 7285 Quail Ovalbumin gene, EMBL accession # X53964, bp 1-1199. (This sequence includes the 5'UTR, containing putative cap site bp 6087-6139.)

Bp 7292 - 7441 Synthetic spacer sequence and hairpin loop of HIV gp41 with an
20 added enterokinase cleavage site

Bp 7442 - 7702 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 7703 - 7747 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

Bp 7748 - 8099 Synthetic polyA from the cloning vector gWIZ (Gene Therapy
25 Systems) bp 1920 - 2271

Bp 8101 - 11700 from cloning vector pTnMCS, bp 3716 - 7315

pTnMOD(Quail OVep+prepro+ENT+proins+syn polyA)

Bp 1 - 4045 from cloning vector pTnMCS, bp 1 - 4045

Bp 4051 - 4708 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession #S82527.1, bp 1-675. (There are multiple
30

- base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- Bp 4715 – 6080 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter,
- 5 GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- Bp 6087 – 6257 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733
- 10 Bp 6264 - 6413 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6414 - 6674 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6675 - 6719 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- 15 Bp 6720 - 7071 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7073 – 10672 from cloning vector pTnMCS, bp 3716 - 7315

PTnMod(CMV/Transposase/ChickOvep/prepro/ProteinA/ConpolyA)

- 20 BP 1-130 remainder of F1 (-) ori of pBluescriptII sk(-) (Stragagene) bp 1-130.
- BP 133-1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp 229-1873.
- BP 1780-2987 Transposase, modified from Tn10 (GenBank #J01829).
- BP 2988-2990 Engineered stop codon.
- 25 BP 2991-3343 non coding DNA from vector pNK2859.
- BP 3344-3386 Lambda DNA from pNK2859.
- BP 3387-3456 70bp of IS10 left from Tn10.
- BP 3457-3674 multiple cloning site from pBluescriptII sk(-) bp 924-707.
- BP 3675-5691 Chicken Ovalbumin enhancer plus promoter from a Topo Clone 10
- 30 maxi 040303 (5' XmaI, 3' BamHI)
- BP 5698-5865 prepro with Cap site amplified from cecropin of pMON200
- GenBank # X07404 (5'BamHI, 3'KpnI)

BP 5872-7338 Protein A gene from GenBank# J01786, mature peptide bp 292-1755
(5'KpnI, 3'SacII)

BP 7345-7752 ConPolyA from Chicken conalbumin polyA from GenBank # Y00407
bp 10651-11058. (5'SacII, 3'XhoI)

5 BP 7753-8195 multiple cloning site from pBluescriptII sk(-) bp 677-235.

BP 8196-8265 70 bp of IS10 left from Tn10.

BP 8266-8307 Lamda DNA from pNK2859

BP 8308-9151 noncoding DNA from pNK2859

BP 9152-11352 pBluescriptII sk(-) base vector (Stratagene, INC.) bp 761-2961

10

All patents, publications and abstracts cited above are incorporated herein by
reference in their entirety. It should be understood that the foregoing relates only to
preferred embodiments of the present invention and that numerous modifications or
alterations may be made therein without departing from the spirit and the scope of the

15 present invention as defined in the following claims.

CLAIMS

We Claim:

1. A vector comprising:
 - a) a transposase gene operably linked to a first promoter; and
 - b) one or more genes of interest operably-linked to one or more additional promoters;
 - c) wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase; and
 - d) wherein the first promoter comprises a modified Kozak sequence comprising ACCATG.
2. The vector of claim 1, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon.
3. The vector of claim 2, wherein the transposase gene is modified in its first ten codons.
4. The vector of claim 1, wherein the transposase is a Tn10 transposase.
5. The vector of claim 1, wherein the first promoter is a constitutive promoter.
6. The vector of claim 1, wherein the first promoter is an inducible promoter.
7. The vector of claim 6, wherein the inducible promoter is an ovalbumin promoter or a vitellogenin promoter.
8. The vector of claim 1, wherein one gene of interest is operably-linked to a second promoter.
9. The vector of claim 8, wherein the second promoter is a constitutive promoter.

10. The vector of claim 8, wherein the second promoter is an inducible promoter.
- 5 11. The vector of claim 10, wherein the inducible promoter is an ovalbumin promoter or a vitellogenin promoter.
12. The vector of claim 1, further comprising a polyA sequence operably-linked to the transposase gene.
- 10 13. The vector of claim 12, wherein the polyA sequence is a conalbumin polyA sequence.
14. The vector of claim 1 or claim 12, further comprising two stop codons operably-linked to the transposase gene.
- 15 15. The vector of claim 1, wherein a first gene of interest is operably-linked to a second promoter and a second gene of interest is operably-linked to a third promoter.
- 20 16. The vector of claim 1, wherein a first and a second gene of interest are operably-linked to a second promoter.
17. The vector of claim 1, further comprising an enhancer operably-linked to the one or more genes of interest.
- 25 18. The vector of claim 17, wherein the enhancer comprises at least a portion of an ovalbumin enhancer.
19. The vector of claim 1, further comprising an egg directing sequence operably-linked to the one or more genes of interest.
- 30 20. The vector of claim 19, wherein the egg directing sequence is an ovalbumin signal sequence or an ovomucoid signal sequence.
- 35 21. The vector of claim 19, wherein the egg directing sequence is a vitellogenin targeting sequence.

22. A method for producing a transgenic animal comprising administering to the animal a vector comprising:
- a) a modified transposase gene operably linked to a first promoter; and
 - b) one or more genes of interest operably-linked to one or more additional promoters;
 - c) wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase; and
 - d) wherein the first promoter comprises a modified Kozak sequence comprising ACCATG.
23. The method of claim 22, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon.
24. The method of claim 23, wherein the transposase gene is modified in its first ten codons.
25. The method of claim 22, wherein the vector is administered via an intratesticular, intraarterial, intraoviductal or intraembryonic route.
26. The method of claim 22, wherein the transposase is a Tn10 transposase.
27. The method of claim 22, wherein the first promoter is a constitutive promoter.
28. The method of claim 22, wherein the first promoter is an inducible promoter.
29. The method of claim 28, wherein the inducible promoter is selected from the group consisting of an ovalbumin promoter, an ovomucoid promoter and a vitellogenin promoter.
30. The method of claim 22, wherein one gene of interest is operably linked to a second promoter.


31. The method of claim 30, wherein the second promoter is an inducible promoter.
- 5 32. The method of claim 31, wherein the inducible promoter is an ovalbumin promoter or a vitellogenin promoter.
33. The method of claim 22, wherein the vector further comprises a polyA sequence operably-linked to the transposase gene.
- 10 34. The method of claim 33, wherein the polyA sequence is a conalbumin polyA sequence.
35. The method of claim 22 or claim 33, wherein the vector further comprises two stop codons operably-linked to the transposase gene.
- 15 36. The method of claim 22, wherein a first gene of interest is operably-linked to a second promoter and a second gene of interest is operably-linked to a third promoter.
- 20 37. The method of claim 22, wherein a first and second gene of interest are operably linked to a second promoter.
38. The method of claim 22, further comprising an enhancer operably-linked to the one or more genes of interest.
- 25 39. The method of claim 38, wherein the enhancer comprises at least a portion of an ovalbumin enhancer.
- 30 40. The method of claim 22, wherein the animal is an avian animal.
41. The method of claim 40, wherein the avian animal is a chicken or a quail.
- 35 42. An egg produced by the avian animal of claim 40, wherein the egg contains one or more desired proteins encoded by the one or more genes of interest.

43. A transgenic sperm produced by the animal of claim 22.
44. A method of producing a desired protein comprising:
- 5 a) administering to an animal a vector comprising a modified transposase gene operably linked to a first promoter, and a gene of interest encoding the desired protein operably-linked to a second promoter; and
- b) isolating the desired protein produced in the animal; wherein
- c) the gene of interest and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase; and
- 10 d) the first promoter comprises a modified Kozak sequence comprising ACCATG.
45. The method of claim 44, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon.
- 15 46. The method of claim 44, wherein the animal is an egg-laying animal and the desired protein is isolated from an egg white.
- 20 47. The method of claim 44, wherein the vector further comprises a TAG sequence and wherein the desired protein is purified using the TAG sequence.
48. The method of claim 47, wherein the TAG sequence comprises a polynucleotide sequence encoding an antigenic portion of a gp41 protein, an enterokinase cleavage site and a spacer polynucleotide sequence.
- 25 49. The method of claim 47, wherein the TAG sequence comprises a polynucleotide sequence shown in SEQ ID NO:22.
- 30 50. The method of claim 44, wherein the desired protein is a lytic protein.
51. The method of claim 44, wherein the vector further comprises a second gene of interest operably-linked to a third promoter and wherein the genes of interest encode antibody polypeptides.
- 35

FIGURE 1




FIGURE 2



3/7

FIGURE 3



4/7

FIGURE 4




FIGURE 5

IS	Oval Pro	prepro	Heavy chain	pro	Light chain	polyA	IS
----	----------	--------	-------------	-----	-------------	-------	----

FIGURE 6

IS	Oval Pro	prepro	Light chain	ent	Heavy chain	polyA	IS
----	----------	--------	-------------	-----	-------------	-------	----

7/7

FIGURE 7

A.

Tail-to-Tail

IS	Oval Pro	Oval SS	Light chain	Poly A	Spacer DNA	Poly A	Heavy chain	Oval SS	Oval Pro	IS
----	----------	---------	-------------	--------	------------	--------	-------------	---------	----------	----

B.

Tail-to-Head

IS	Oval Pro	Oval SS	Light chain	Poly A	Spacer DNA	Oval Pro	Oval SS	Heavy chain	Poly A	IS
----	----------	---------	-------------	--------	------------	----------	---------	-------------	--------	----

Appendix A

SEQ ID NO:1 (pTnMod)

5 CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCC CTCCTTTCGC 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTCCG CGGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 10 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGGTGACCG CCCAACGACC 350
 CCCGCCCAT TACGTCATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGCCCA 450
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 15 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
 20 CCCATTGACG CAAATGGGCG GTAGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTGGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 CCGCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 25 CTGTTTTTGG CTTGGGGCCT ATACACCCCT GCTTCCTTAT GCTATAGGTG 1050
 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTGAGAGAC 1200
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
 30 AATTACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 CTCCAGCGGC TCATGGTCCG TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
 CCAGACTTAG GCACAGCACA ATGCCCACCA CCACCAAGTGT GCCGCACAAG 1500
 35 GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550
 CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
 GCAGCTGAGT TGTGTATTTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
 GTGCTGTTAA CGGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700
 CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCTTTT 1750
 40 CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
 TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850
 CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
 CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAAGCGGAG AACAAAACAT 1950
 AACTCAAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000
 45 GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050
 GATGCCCCATT GACTTGTGTT ACTGGTCTGA TATTCGTGAG CAAAAACGAC 2100
 TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGGTGCTTC TGTTACTCTT 2150
 TATGAGAAAG CGTTCCCGCT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200
 CCAATTTCTA GCCGACCTTG CGAGCATTCT ACCGAGTAAC ACCACACCGC 2250
 50 TCATTGTGAG TGATGCTGGC TTAAAGTGC CATGGTATAA ATCCGTTGAG 2300
 AAGCTGGGTT GGTACTGGTT AAGTCGAGTA AGAGGAAAAG TACAATATGC 2350
 AGACCTAGGA GCGGAAAACCT GGAACCTAT CAGCAACTTA CATGATATGT 2400
 CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450
 CCAATCTCAT GCCAAATTCT ATTGTATAAA TCTCGCTCTA AAGGCCGAAA 2500
 55 AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCCGTCA CCTAAAATCT 2550
 ACTCAGCGTC GGCAAAGGAG CCATGGGTTT TAGCAACTAA CTTACCTGTT 2600
 GAAATTCGAA CACCCAAACA ACTTGTTAAT ATCTATTGCA AGCGAATGCA 2650
 GATTGAAGAA ACCTTCCGAG ACTTGAAAAG TCCTGCCTAC GGACTAGGCC 2700
 TACGCCATAG CCGAACGAGC AGCTCAGAGC GTTTTGATAT CATGCTGCTA 2750
 60 ATCGCCCTGA TGCTTCAACT AACATGTTGG CTTGCGGGCG TTCATGCTCA 2800
 GAAACAAGGT TGGGACAAGC ACTTCCAGGC TAACACAGTC AGAAATCGAA 2850

ACGTACTCTC AACAGTTCGC TTAGGCATGG AAGTTTGGC GCATTCTGGC 2900
 TACACAATAA CAAGGGAAGA CTTACTCGTG GCTGCAACCC TACTAGCTCA 2950
 AAATTTATTC ACACATGGTT ACGCTTTGGG GAAATTATGA TAATGATCCA 3000
 5 GATCACTTCT GGCTAATAAA AGATCAGAGC TCTAGAGATC TGTGTGTTGG 3050
 TTTTGTGG ATCTGCTGTG CCTTCTAGTT GCCAGCCATC TGTGTTTGC 3100
 CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CACTGTCTCT 3150
 TTCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 3200
 CTATTCTGGG GGTGGGGTG GGCAGCACA GCAAGGGGGA GGATTGGGAA 3250
 10 GACAATAGCA GGCATGCTGG GGATGCGGTG GGCTCTATGG GTACCTCTCT 3300
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CTCTCGGTAC CTCTCTCTCT 3350
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CGGTACCAGG TGCTGAAGAA 3400
 TTGACCCCGT GACCAAAGGT GCCTTTTATC ATCACTTTAA AAATAAAAAA 3450
 CAATTACTCA GTGCCTGTTA TAAGCAGCAA TTAATTATGA TTGATGCCTA 3500
 15 CATCACAACA AAAACTGATT TAACAAATGG TTGGTCTGCC TTAGAAAGTA 3550
 TATTTGAACA TTATCTTGAT TATATTATG ATAATAATAA AAACCTTATC 3600
 CCTATCCAAG AAGTGATGCC TATCATTGGT TGAATGAAC TTGAAAAAAA 3650
 TTAGCCTTGA ATACATTACT GGTAAGGTAA ACGCCATTGT CAGCAAATTG 3700
 ATCCAAGAGA ACCAACTTAA AGCTTTCCTG ACGGAATGTT AATTCTCGTT 3750
 GACCCTGAGC ACTGATGAAT CCCCTAATGA TTTTGGTAAA AATCATTAAAG 3800
 20 TTAAGGTGGA TACACATCTT GTCATATGAT CCCGGTAATG TGAGTTAGCT 3850
 CACTCATTAG GCACCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT 3900
 TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA CAGCTATGAC 3950
 CATGATTACG CCAAGCGCGC AATTAACCCT CACTAAAGGG AACAAAAGCT 4000
 GGAGCTCCAC CGCGGTGGCG GCCGCTCTAG AACTAGTGGA TCCCCGGGC 4050
 25 TGCAGGAATT CGATATCAAG CTTATCGATA CCGCTGACCT CGAGGGGGGG 4100
 CCCGGTACCC AATTGCGCCT ATAGTGAGTC GTATTACGCG CGCTCACTGG 4150
 CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT TACCCAATT 4200
 AATCGCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA ATAGCGAAGA 4250
 GGCCCGCACC GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT 4300
 30 GGAAATTGTA AGCGTTAATA TTTTGTAAA ATTGCGGTTA AATTTTGT 4350
 AAATCAGCTC ATTTTAAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT 4400
 AAATCAAAAG AATAGACCGA GATAGGGTTG AGTGTGTTC CAGTTTGGA 4450
 CAAGAGTCCA CTATTAAAGA ACGTGGACTC CAACGTCAAA GGGCGAAAAA 4500
 CCGTCTATCA GGGCGATGGC CCACTACTCC GGGATCATAT GACAAGATGT 4550
 35 GTATCCACCT TAACTTAATG ATTTTACCA AAATCATTAG GGGATTTCAT 4600
 AGTGCTCAGG GTCAACGAGA ATTAACATTC CGTCAGGAAA GCTTATGATG 4650
 ATGATGTGCT TAAAACTTA CTCAATGGCT GGTATGCAT ATCGCAATAC 4700
 ATGCGAAAAA CCTAAAAGAG CTTGCCGATA AAAAAGGCCA ATTTATTGCT 4750
 ATTTACCGCG GCTTTTATT GAGCTTGAAA GATAAATAAA ATAGATAGGT 4800
 40 TTTATTGAA GCTAAATCTT CTTTATCGTA AAAAATGCCC TCTTGGGTTA 4850
 TCAAGAGGGT CATTATATTT CGCGGAATAA CATCATTTGG TGACGAAATA 4900
 ACTAAGCACT TGTCTCCTGT TTAATCCCCT GAGCTTGAGG GGTAAACATG 4950
 AAGGTCATCG ATAGCAGGAT AATAATACAG TAAAACGCTA AACCAATAAT 5000
 CCAATCCAG CCATCCCAA TTGGTAGTGA ATGATTATAA ATAACAGCAA 5050
 45 ACAGTAATGG GCCAATAACA CCGGTTGCAT TGGTAAGGCT CACCAATAAT 5100
 CCCTGTAAAG CACCTTGCTG ATGACTCTTT GTTTGGATAG ACATCACTCC 5150
 CTGTAATGCA GGTAAAGCGA TCCCACCACC AGCCAATAAA ATTAAAACAG 5200
 GGAAAACTAA CCAACCTTCA GATAAAACG CTAAAAGGC AAATGCACTA 5250
 CTATCTGCAA TAAATCCGAG CAGTACTGCC GTTTTTTCGC CCATTTAGTG 5300
 50 GCTATTCTTC CTGCCACAAA GGCTTGAAT ACTGAGTGTA AAAGACCAAG 5350
 ACCCGTAATG AAAAGCCAAC CATCATGCTA TTCATCATCA CGATTCTGT 5400
 AATAGCACC AACCCTGCTG GATTGGCTAT CAATGCGCTG AAATAATAAT 5450
 CAACAAATGG CATCGTTAAA TAAGTGATGT ATACCGATCA GCTTTGTTC 5500
 CCTTAGTGA GGGTTAATTG CGCGCTTGGC GTAATCATGG TCATAGCTGT 5550
 55 TTCTGTGTG AAATGTATT CCGCTCACAA TTCCACACAA CATACGAGCC 5600
 GGAAGCATAA AGTGTAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAC 5650
 ATTAATTGCG TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT 5700
 GCCAGCTGCA TTAATGAATC GGCCAACGCG CGGGGAGAGG CGGTTTGCCT 5750
 ATTGGGCGCT CTTCCGCTTC CTCGCTCACT GACTCGCTGC GCTCGGTCGT 5800
 60 TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGTTAT 5850
 CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG 5900

CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG 5950
 GCTCCGCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA AGTCAGAGGT 6000
 GGCGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC 6050
 TCCCTCGTGC GCTCTCTGT TCCGACCCTG CCGCTTACCG GATACCTGTG 6100
 5 CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA 6150
 GGTATCTCAG TTCGGTGTAG GTCGTTGCGT CCAAGCTGGG CTGTGTGCAC 6200
 GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT 6250
 TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG 6300
 GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCCTG 6350
 10 AAGTGTGTGG CTAACCTACG CTACACTAGA AGGACAGTAT TTGGTATCTG 6400
 CGCTCTGTCT AAGCCAGTTA CCTTCGGAAG AAGAGTTGGT AGCTCTTGAT 6450
 CCGGCAAAACA AACCCCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG 6500
 CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC 6550
 TACGGGTCTT GACGCTCAGT GGAACGAAAA CTCACGTAA GGGATTTTGG 6600
 15 TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAAGAA 6650
 TGAAGTTTAA ATCAATCTA AAGTATATAT GAGTAACTT GGTCTGACAG 6700
 TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTT 6750
 GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAAGATAAC TACGATACGG 6800
 GAGGGCTTAC CATCTGCCCC CAGTGCTGCA ATGATACCGC GAGACCCACG 6850
 20 CTCACCGGCT CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG 6900
 AGCGCAGAAG TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAA 6950
 TGTTGCCGGG AAGCTAGAGT AAGTAGTTCG CCAGTTAATA GTTTGCGCAA 7000
 CGTTGTGTCC ATTGCTACAG GCATCGTGGT GTCACGCTCG TCGTTTGGA 7050
 TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT TACATGATCC 7100
 25 CCCATGTTGT GCAAAAAAGC GGTAGTCTCC TTCGGTCTC CGATCGTTGT 7150
 CAGAAAGTAA TGGCCGCGAG TGTTATCACT CATGGTTATG GCAGCACTGC 7200
 ATAATTTCTT TACTGTCTAG CCATCCGTAA GATGCTTTTC TGTGACTGGT 7250
 GAGTACTCAA CCAAGTCATT CTGAGAATAG TGTATGCGGC GACCGAGTTG 7300
 CTCTTGCCCC GCGTCAATAC GGGATAATAC CGCGCCACAT AGCAGAACTT 7350
 30 TAAAAGTGCT CATCATTTGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG 7400
 ATCTTACCGC TGTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA 7450
 CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA 7500
 CAGGAAGGCA AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT 7550
 TGAATACTCA TACTCTTCCT TTTTCAATAT TATTGAAGCA TTTATCAGGG 7600
 35 TTATTGTCTC ATGAGCGGAT ACATATTGTA ATGTATTAG AAAAATAAAC 7650
 AAATAGGGGT TCCGCGCACA TTTCCCGGAA AAGTGCCAC 7689

SEQ ID NO:2 (PTnMod (CMV/Red))

40 CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTTCG 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTTCG CGGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 45 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGAGATTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
 CCCGCCCAT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAATGCCCCA 450
 50 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
 TGGGACTTTC TCACTTGCCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 55 TTTTGGCACC AAAATCAACG GGAATTTCCA AAATGTCGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCGC 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 60 CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050

ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 GCCACAACTA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTCAGAGAC 1200
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATT TTTATTTACA 1250
 5 AATTCACATA TACAACAACG CCGTCCCCCG TGCCCCGAGT TTTTATTAAA 1300
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTC CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
 CCAGACTTAG GCACAGCACA ATGCCACCA CCACCAGTGT GCCGCACAAG 1500
 10 GCCGTGGCGG TAGGGTATGT GTCTGAAAT GAGCGTGGAG ATTGGGCTCG 1550
 CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
 GCAGCTGAGT TGTTGTATTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
 GTGCTGTAA CCGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700
 CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCCCTT 1750
 15 CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
 TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAAAGACT 1850
 CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
 CTCTTACCGA ACTTGGCGGT AACCTGCCAA CCAAAGCGAG AACAAAACAT 1950
 AACATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000
 20 GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050
 GATGCCCAT TACTTTGTTG ACTGGTCTGA TATTCGTGAG CAAAAACGAC 2100
 TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGGTCGTTT TGTTACTCTT 2150
 TATGAGAAAG CGTTCCCGCT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200
 CCAATTTCTA GCCGACCTTG CGAGCATTTCT ACCGAGTAAC ACCACACCGC 2250
 25 TCATTGTCTAG TGATGCTGGC TTAAAGTGC CATGGTATAA ATCCGTTGAG 2300
 AAGCTGGGTT GGTACTGGTT AAGTCGAGTA AGAGGAAAAG TACAATATGC 2350
 AGACCTAGGA GCGGAAAACCT GGAACCTAT CAGCAACTTA CATGATATGT 2400
 CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450
 CCAATCTCAT GCCAAATTCT ATTGTATAAA TCTCGCTCTA AAGGCCGAAA 2500
 30 AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCCGTCA CCTAAAATCT 2550
 ACTCAGCGTC GGCAAAGGAG CCATGGGTTT TAGCAACTAA CTTACCTGTT 2600
 GAAATTGAA CACCCAAACA ACTTGTTAAT ATCTATTCTGA AGCGAATGCA 2650
 GATTGAAGAA ACCTTCCGAG ACTTGAAAAG TCCTGCCTAC GGACTAGGCC 2700
 TACGCCATAG CCGAACGAGC AGCTCAGAGC GTTTTGATAT CATGCTGCTA 2750
 35 ATCGCCCTGA TGCTTCAACT AACATGTTGG CTTGCGGGCG TTCATGCTCA 2800
 GAAACAAGGT TGGGACAAGC ACTTCCAGGC TAACACAGTC AGAAATCGAA 2850
 ACGTACTCTC AACAGTTCGC TTAGGCATGG AAGTTTTCG GCATTCTGGC 2900
 TACACAATA CAAGGGAAGA CTTACTCGTG GCTGCAACCC TACTAGCTCA 2950
 AAATTTATT ACACATGGTT ACGCTTTGGG GAAATTATGA TAATGATCCA 3000
 40 GATCACTTCT GGCTAATAAA AGATCAGAGC TCTAGAGATC TGTGTGTTGG 3050
 TTTTTTGTGG ATCTGCTGTG CTTCTAGTT GCCAGCCATC TGTTGTTTGC 3100
 CCCTCCCCCG TGCCTTCTT GACCCTGGAA GGTGCCACTC CCACTGTCTT 3150
 TTCTTAATA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 3200
 CTATTCTGGG GGGTGGGGTG GGGCAGCACA GCAAGGGGGA GGATTGGGAA 3250
 45 GACAATAGCA GGCATGCTGG GGATGCGGTG GGCTCTATGG GTACCTCTCT 3300
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CTCTCGGTAC CTCTCTCTCT 3350
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CGGTACCAGG TGCTGAAGAA 3400
 TTGACCCGGT GACCAAAGGT GCCTTTTATC ATCACTTTAA AAATAAAAAA 3450
 CAATTACTCA GTGCCTGTTA TAAGCAGCAA TTAATTATGA TTGATGCCTA 3500
 50 CATCACAACA AAAACTGATT TAACAAATGG TTGGTCTGCC TTAGAAAGTA 3550
 TATTTGAACA TTATCTTGAT TATATTATTG ATAATAATAA AAACCTTATC 3600
 CCTATCCAAG AAGTGATGCC TATCATTGGT TGGAATGAAC TTGAAAAAAA 3650
 TTAGCCTTGA ATACATTACT GGTAAGGTAA ACGCCATTGT CAGCAAATTG 3700
 ATCCAAGAGA ACCAACTTAA AGCTTTCCTG ACGGAATGTT AATTCTCGTT 3750
 55 GACCCTGAGC ACTGATGAAT CCCCTAATGA TTTTGGTAAA AATCATTAAAG 3800
 TTAAGGTGGA TACACATCTT GTCATATGAT CCCGGTAATG TGAGTTAGCT 3850
 CACTCATTAG GCACCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT 3900
 TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA CAGCTATGAC 3950
 CATGATTACG CCAAGCGCGC AATTAACCTT CACTAAAGGG AACAAAAGCT 4000
 60 GGAGCTCCAC CGCGGTGGCG GCCGCTCTAG AACTAGTGGA TCCCCGGGCG 4050
 ATCAGATTGG CTATTGGCCA TTGCATACGT TGTATCCATA TCATAATATG 4100

	TACATTTATA	TTGGCTCATG	TCCAACATTA	CCGCCATGTT	GACATTGATT	4150
	ATTGACTAGT	TATTAATAGT	AATCAATTAC	GGGGTCATTA	GTTCATAGCC	4200
	CATATATGGA	GTTCCGCGTT	ACATAACTTA	CGGTAAATGG	CCCGCCTGGC	4250
	TGACCGCCCA	ACGACCCCG	CCCATGACG	TCAATAATGA	CGTATGTTC	4300
5	CATAGTAACG	CCAATAGGGA	CTTTCATTG	ACGTCAATGG	GTGGAGTATT	4350
	TACGGTAAAC	TGCCCACTTG	GCAGTACATC	AAGTGTATCA	TATGCCAAGT	4400
	ACGCCCCCTA	TTGACGTCAA	TGACGGTAAA	TGGCCCGCCT	GGCATTATGC	4450
	CCAGTACATG	ACCTTATGGG	ACTTTCCTAC	TTGGCAGTAC	ATCTACGTAT	4500
	TAGTCATCGC	TATTACCATG	GTGATGCGGT	TTTGGCAGTA	CATCAATGGG	4550
10	CGTGGATAGC	GGTTTGACTC	ACGGGGATT	CCAAGTCTCC	ACCCCATTGA	4600
	CGTCAATGGG	AGTTTGT	GGCACCAAAA	TCAACGGGAC	TTTCCAAAAT	4650
	GTCGTAACAA	CTCCGCCCA	TTGACGCAAA	TGGGCGGTAG	GCGTGTACGG	4700
	TGGGAGGTCT	ATATAAGCAG	AGCTCGTTTA	GTGAACCGTC	AGATCGCCTG	4750
	GAGACGCCAT	CCACGCTGTT	TTGACCTCCA	TAGAAGACAC	CGGGACCGAT	4800
15	CCAGCCTCCG	CGGCCGGGAA	CGGTGCATTG	GAACGCGGAT	TCCCCGTGCC	4850
	AAGAGTGACG	TAAGTACCGC	CTATAGACTC	TATAGGCACA	CCCCTTTGGC	4900
	TCTTATGCAT	GCTATACTGT	TTTTGGCTTG	GGGCCTATAC	ACCCCCGCTT	4950
	CCTTATGCTA	TAGGTGATGG	TATAGCTTAG	CCTATAGGTG	TGGGTTATTG	5000
	ACCATTATTG	ACCACTCCCC	TATTGGTGAC	GATACTTTCC	ATTACTAATC	5050
20	CATAACATGG	CTCTTTGCCA	CAACTATCTC	TATTGGCTAT	ATGCCAATAC	5100
	TCTGTCCCTC	AGAGACTGAC	ACGGACTCTG	TATTTTACA	GGATGGGGTC	5150
	CCATTTATTA	TTTACAAATT	CACATATACA	ACAACGCCGT	CCCCCGTGCC	5200
	CGCAGTTTTT	ATTAAACATA	GCGTGGGATC	TCCACGCGAA	TCTCGGGTAC	5250
	GTGTTCCGGA	CATGGGCTCT	TCTCCGGTAG	CGGCGGAGCT	TCCACATCCG	5300
25	AGCCCTGGTC	CCATGCCTCC	AGCGGCTCAT	GGTCGCTCGG	CAGCTCCTTG	5350
	CTCCTAACAG	TGGAGGCCAG	ACTTAGGCAC	AGCACAATGC	CCACCACCAC	5400
	CAGTGTGCCG	CACAAGGCCG	TGGCGGTAGG	GTATGTGTCT	GAAAATGAGC	5450
	GTGGAGATTG	GGCTCGCACG	GCTGACGCAG	ATGGAAGACT	TAAGGCACGG	5500
	GCAGAAGAAG	ATGCAGGCAG	CTGAGTTGTT	GTATTCTGAT	AAGAGTCAGA	5550
30	GGTAACCTCC	GTTGCGGTGC	TGTTAACGGT	GGAGGGCAGT	GTAGTCTGAG	5600
	CAGTACTCGT	TGCTGCCCGC	CGCGCCACCA	GACATAATAG	CTGACAGACT	5650
	AACAGACTGT	TCCTTTCCAT	GGGTCTTTTC	TGCAGTCACC	GTCTCGCGAC	5700
	AGGGATCCAC	CGGTCGCCAC	CATGGTGCGC	TCCTCCAAGA	ACGTCATCAA	5750
	GGAGTTCATG	CGCTTCAAGG	TGCGCATGGA	GGGCACCGTG	AACGGCCACG	5800
35	AGTTCGAGAT	CGAGGGCGAG	GGCGAGGGCC	GCCCCACGA	GGGCCACAAC	5850
	ACCGTGAAGC	TGAAGGTGAC	CAAGGGCGGC	CCCCTGCCCT	TCGCCTGGGA	5900
	CATCCTGTCC	CCCCAGTTCC	AGTACGGCTC	CAAGGTGTAC	GTGAAGCACC	5950
	CCGCCGACAT	CCCCGACTAC	AAGAAGCTGT	CCTTCCCCGA	GGGCTTCAAG	6000
	TGGGAGCGCG	TGATGAACTT	CGAGGACGGC	GGCGTGTTGA	CCGTGACCCA	6050
40	GGACTCCTCC	CTGCAGGACG	GCTGCTTCAT	CTACAAGGTG	AAGTTCATCG	6100
	GCGTGAACTT	CCCCTCCGAC	GGCCCCGTAA	TGCAGAAGAA	GACCATGGGC	6150
	TGGGAGGCCT	CCACCAGCG	CCTGTACCCC	CGCGACGGCG	TGCTGAAGGG	6200
	CGAGATCCAC	AAGGCCCTGA	AGCTGAAGGA	CGGCGGCCAC	TACCTGGTGG	6250
	AGTTCAGATC	CATCTACATG	GCCAAGAAGC	CCGTGCAGCT	GCCCCGGTAC	6300
45	TACTACGTGG	ACTCCAAGCT	GGACATCACC	TCCCACAACG	AGGACTACAC	6350
	CATCGTGGAG	CAGTACGAGC	GCACCGAGGG	CCGCCACCAC	CTGTTCCCTG	6400
	AGCGGCCGCG	ACTCTAGATC	ATAATCAGCC	ATACCACATT	TGTAGAGGTT	6450
	TTACTTGCTT	TAAAAAACCT	CCCACACCTC	CCCCTGAACC	TGAAACATAA	6500
	AATGAATGCA	ATTGTTGTTG	TTAACTTGTT	TATTGCAGCT	TATAATGGTT	6550
50	ACAAATAAAG	CAATAGCATC	ACAAATTTCA	CAAATAAAGC	ATTTTTTTCA	6600
	CTGCATTCTA	GTTGTGGCCC	GGGCTGCAGG	AATTTCGATAT	CAAGCTTATC	6650
	GATACCGCTG	ACCTCGAGGG	GGGGCCCGGT	ACCCAATTCT	CCCTATAGTG	6700
	AGTCGTATTA	CGCGCGCTCA	CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	6750
	GAAAACCCCTG	CGGTTACCCA	ACTTAATCGC	CTTGCAGCAC	ATCCCCCTTT	6800
55	CGCCAGCTGG	CGTAATAGCG	AAGAGGCCCG	CACCGATCGC	CCTTCCCAAC	6850
	AGTTGCGCAG	CCTGAATGGC	GAATGGAAAT	TGTAAGCGTT	AATATTTTGT	6900
	TAAAAATTCGC	GTTAAATTTT	TGTTAAATCA	GCTCATTTT	TAACCAATAG	6950
	GCCGAAATCG	GCAAAATCCC	TTATAAATCA	AAAGAATAGA	CCGAGATAGG	7000
	GTTGAGTGTT	GTTCCAGTTT	GGAACAAGAG	TCCACTATTA	AAGAACGTGG	7050
60	ACTCCAACGT	CAAAGGGCGA	AAAACCGTCT	ATCAGGGCGA	TGGCCCACTA	7100
	CTCCGGGATC	ATATGACAAG	ATGTGTATCC	ACCTTAACTT	AATGATTTTT	7150

ACCAAAATCA TTAGGGGATT CATCAGTGCT CAGGGTCAAC GAGAATTAAC 7200
 ATTCCTGTCAG GAAAGCTTAT GATGATGATG TGCTTAAAAA CTTACTCAAT 7250
 GGCTGGTTAT GCATATCGCA ATACATGCGA AAAACCTAAA AGAGCTTGCC 7300
 GATAAAAAAG GCCAATTTAT TGCTATTTAC CGCGGCTTTT TATTGAGCTT 7350
 5 GAAAGATAAA TAAATAGAT AGGTTTTATT TGAAGCTAAA TCTTCTTTAT 7400
 CGTAAAAAAT GCCCTCTTGG GTTATCAAGA GGGTCATTAT ATTTCGCGGA 7450
 ATAACATCAT TTGGTGACGA AATAACTAAG CACTTGCTC CTGTTTACTC 7500
 CCCTGAGCTT GAGGGGTAA CATGAAGGTC ATCGATAGCA GGATAATAAT 7550
 ACAGTAAAC GCTAAACCA TAATCCAAAT CCAGCCATCC CAAATTGGTA 7600
 10 GTGAATGATT ATAAATAACA GCAAACAGTA ATGGGCCAAT AACACCGGTT 7650
 GCATTGTTAA GGCTCACCA TAATCCCTGT AAAGCACCTT GCTGATGACT 7700
 CTTTGTGTTG ATAGACATCA CTCCCTGTAA TGCAGGTAAA GCGATCCAC 7750
 CACCAGCCAA TAAATTTAAA ACAGGGAAAA CTAACCAACC TTCAGATATA 7800
 AACGCTAAAA AGGCAATGTC ACTACTATCT GCAATAAATC CGAGCAGTAC 7850
 15 TGCCGTTTTT TCGCCCATTT AGTGGCTATT CTTCTGCGCA CAAAGGCTTG 7900
 GAATACTGAG TGTAAAAGAC CAAGACCCGT AATGAAAAGC CAACCATCAT 7950
 GCTATTCATC ATCAGGATTT CTGTAATAGC ACCACACCGT GCTGGATTGG 8000
 CTATCAATGC GCTGAAATA TAATCAACAA ATGGCATCGT TAAATAAGTG 8050
 ATGTATACCG ATCAGCTTTT GTTCCCTTTA GTGAGGGTTA ATTGCGCGCT 8100
 20 TGGCGTAATC ATGGTCATAG CTGTTTCCTG TGTGAAATG TTATCCGCTC 8150
 ACAATTCCAC ACAACATACG AGCCGGAAGC ATAAAGTGTA AAGCCTGGGG 8200
 TGCCTAATGA GTGAGCTAAC TCACATTAAT TCGGTTGCGC TCACTGCCCG 8250
 CTTTCCAGTC GGGAAACCTG TCGTGCCAGC TGCAATTAATG AATCGGCCAA 8300
 CGCGCGGGGA GAGGCGGTTT GCGTATTGGG CGCTCTTCCG CTTCTCGCT 8350
 25 CACTGACTCG CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG GTATCAGCTC 8400
 ACTCAAAGGC GGTAAATACG TTATCCACAG AATCAGGGGA TAACGCAGGA 8450
 AAGAACATGT GAGCAAAAGG CCAGCAAAAG GCCAGGAACC GTAAAAAGGC 8500
 CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC GAGCATCACA 8550
 AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA 8600
 30 TACCAAGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC 8650
 CCTGCCGCTT ACCGATACC TGTCCGCTT TCTCCCTTCG GGAAGCGTGG 8700
 CGCTTTCTCA TAGCTCACGC TGTAGGTATC TCAGTTCGGT GTAGGTCGTT 8750
 CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTACG CCGACCGCTG 8800
 CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGTA AGACACGACT 8850
 35 TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT 8900
 GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCTAACT ACGCTACAC 8950
 TAGAAGGACA GTATTTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG 9000
 GAAAAAGAGT TGGTAGCTCT TGATCCGGCA AACAAACCAC CGCTGGTAGC 9050
 40 GGTGGTTTTT TTGTTTGCAA GCAGCAGATT ACGCGCAGAA AAAAAAGTAC 9100
 TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT CAGTGAACG 9150
 AAAACTCAGC TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC 9200
 ACCTAGATCC TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT 9250
 ATATGAGTAA ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC 9300
 CTATCTCAGC GATCTGTCTA TTTGCTTCAT CCATAGTTGC CTGACTCCCC 9350
 45 GTCGTGTAGA TAACTACGAT ACGGGAGGGC TTACCATCTG GCGGAGTGC 9400
 TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT TTATCAGCAA 9450
 TAAACCAGCC AGCCGGAAGG GCGGAGCGCA GAAGTGGTCC TGCAACTTTA 9500
 TCCGCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG 9550
 TTCGCCAGTT AATAGTTTGC GCAACGTTGT TGCCATTGCT ACAGGCATCG 9600
 50 TGGTGTACG CTGTCGTTT GGTATGGCTT CATTCAGCTC CGGTTCCCAA 9650
 CGATCAAGGC GAGTTACATG ATCCCCATG TTGTGCAAAA AAGCGGTTAG 9700
 CTCTTCCGCT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC GCAGTGTTAT 9750
 CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC 9800
 GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA 9850
 55 ATAGTGTATG CCGCGACCGA GTTGCTCTTG CCCGGCGTCA ATACGGGATA 9900
 ATACCGCGCC ACATAGCAGA ACTTTAAAAG TGCTCATCAT TGGAAAACGT 9950
 TCTTCGGGCG GAAAACTCTC AAGGATCTTA CCGCTGTTGA GATCCAGTTC 10000
 GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT TTTACTTTCA 10050
 CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG 10100
 60 GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTCA 10150
 ATATTATTGA AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT 10200

TTGAATGTAT TTAGAAAAAT AAACAAATAG GGGTTCGCG CACATTTCCC 10250
CGAAAAGTGC CAC 10263

5 SEQ ID NO:3 (PTnMod (Oval/Red) Chicken)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCCG 100
TTTCTTCCCT TCCTTTCTCG CCACGTTCCG CGGCATCAGA TTGGCTATTG 150
10 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
CCCGCCCAT TACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
15 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA 450
CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550
TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGTATTAC 600
CATGGTGATG CCGTTTGGC AGTACATCAA TGGCGTGGTA TAGCGGTTTG 650
20 ACTCAGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
25 GGAACGGTGC ATTGGAACGC GGATTCCCG TGCCAAGAGT GACGTAAGTA 950
CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
CTGTTTTTGG CTTGGGGCCT ATACACCCCG GCTTCCTTAT GCTATAGGTG 1050
ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
GCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
30 GCCACAAC TA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTACAGAGC 1200
TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
AATTCACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CCGACATGGG 1350
CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
35 CTCCAGCGGC TCATGGTCCG TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGACAAG 1500
GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550
CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
GCAGCTGAGT TGTTGTATTG TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
40 GTGCTGTAA CCGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700
CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCCCTT 1750
CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
TTACATGATT CTCTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850
CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
45 CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAAAGCGAG AACAAAACAT 1950
AACAATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000
GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050
GATGCCCCAT GTACTTGTTG ACTGGTCTGA TATTCGTGAG CAAAACGAC 2100
TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGGTCGTTT TGTTACTCTT 2150
50 TATGAGAAAG CGTTCCTCGT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200
CCAAATTTCTA GCCGACCTTG CGAGCATTCT ACCGAGTAAC ACCACACCGC 2250
TCATTGTCTAG TGATGCTGGC TTTAAAGTGC CATGGTATAA ATCCGTTGAG 2300
AAGTGGGTT GGTACTGGTT AAGTCGAGTA AGAGGAAAAG TACAATATGC 2350
AGACCTAGGA GCGGAAAAC GGAACCTAT CAGCAACTTA CATGATATGT 2400
55 CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450
CCAAATCTCAT GCCAAATCT ATTGTATAA TCTCGCTCTA AAGGCCGAAA 2500
AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCCGTCA CCTAAAATCT 2550
ACTCAGCGTC GGCAAAGGAG CCATGGGTTT TAGCAACTAA CTTACCTGTT 2600
GAAATTCGAA CACCCAAACA ACTTGTTAAT ATCTATTCTA AGCGAATGCA 2650
60 GATTGAAGAA ACCTTCCGAG ACTTGAAAAG TCCTGCCTAC GGAAGTAGGC 2700
TACGCCATAG CCGAACGAGC AGCTCAGAGC GTTTTGATAT CATGCTGCTA 2750

	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTCGC	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
5	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
10	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
15	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATACAACA	AAAACCTGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
20	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCGTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACCTATTAG	GCACCCCAAG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
25	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTGAGAAT	GGTTCTTTTA	CTGTTGTGCA	ATTCTATTAT	TTCAATACAG	4100
	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTCAACA	TTCTCTGTCT	4200
30	ATCTGCCAGG	CCATTAAAGTT	ATTCATGGAA	GATCTTTGAG	GAACACTGCA	4250
	AGTTCATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTTA	TAAAGCATTG	4350
	ACACCCATAA	AAAGATAGAT	TTAAATATTC	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
35	TTATTTCTCC	TATTTTGTCA	AGAAAATAAT	AGGTCACGTC	TTGTTCTCAC	4500
	TTATGTCTCG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
	TCAAATGAAA	CAGACTTCTG	GTCTGTTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTCATTAAT	AATTGCTAAT	TATGTTTTCC	ATCTTAAGG	TTCCCAATT	4650
	TTTTCTGTTT	CTTAAAGATC	CCATTATCTG	GTTGTAAGT	AAGCTCAATG	4700
40	GAACATGAGC	AATATTTCCC	AGTCTTCTCT	CCCATCCAAC	AGTCCTGATG	4750
	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAATCTAA	4850
	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACTGTG	GGTGGGTCAC	AATTCAGGCT	ATATATTCCC	CAGGGCTCAG	4950
45	CGGATCTCCA	TGGGCTCCAT	CGGTGCAGCA	AGCATGGAAT	TTTGTTTTGA	5000
	TGTATTCAG	GAGCTCAAAG	TCCACCATGC	CAATGAGAAC	ATCTTCTACT	5050
	GCCCCATTGC	CATCATGTCA	GCTCTAGCCA	TGGTATACCT	GGGTGCAAAA	5100
	GACAGCACCA	GGGAATTTCGT	GCGCTCCTCC	AAGAACGTCA	TCAAGGAGTT	5150
	CATGCGCTTC	AAGGTGCGCA	TGGAGGGCAC	CGTGAACGGC	CACGAGTTCT	5200
50	AGATCGAGGG	CGAGGGCGAG	GGCCGCCCTC	ACGAGGGCCA	CAACACCGTG	5250
	AAGTGAAGG	TGACCAAGGG	CGGCCCTCTG	CCCTTCGCCT	GGGACATCCT	5300
	GTCCCCCAG	TTCCAGTACG	GCTCCAAGGT	GTACGTGAAG	CACCCGCGCG	5350
	ACATCCCCGA	CTACAAGAAG	CTGTCCTTCC	CCGAGGGCTT	CAAGTGGGAG	5400
	CGCGTGATGA	ACTTCGAGGA	CGGCGGCGTG	GTGACCGTGA	CCCAGGACTC	5450
55	CTCCCTGCAG	GACGGCTGCT	TCATCTACAA	GGTGAAGTTC	ATCGGCGTGA	5500
	ACTTCCCTCT	CGACGGCCCC	GTAATGCAGA	AGAAGACCAT	GGGCTGGGAG	5550
	GCCTCCACCG	AGCGCCTGTA	CCCCCGCGAC	GGCGTGCTGA	AGGGCGAGAT	5600
	CCACAAGGCC	CTGAAGCTGA	AGGACGGCGG	CCACTACCTG	GTGGAGTTCA	5650
	AGTCCATCTA	CATGGCCAAAG	AAGCCCGTGC	AGCTGCCCGG	CTACTACTAC	5700
60	GTGGACTCCA	AGCTGGACAT	CACCTCCAC	AACGAGGACT	ACACCATCGT	5750
	GGAGCAGTAC	GAGCGCACCG	AGGGCCGCCA	CCACCTGTTC	CTGTAGCGGC	5800

	CGCGACTCTA	GATCATAATC	AGCCATACCA	CATTTGTAGA	GGTTTTACTT	5850
	GCTTTAAAAA	ACCTCCCACA	CCTCCCCTG	AACCTGAAAC	ATAAAATGAA	5900
	TGCAATTGTT	GTTGTAACT	TGTTTATTGC	AGCTTATAAT	GGTTACAAAT	5950
	AAAGCAATAG	CATCACAAT	TTCACAAATA	AAGCATTTTT	TTCAGTGCAT	6000
5	TCTAGTTGTG	GCTCGAGAAG	GGCGAATTCT	GCAGATATCC	ATCACACTGG	6050
	CGGCGGCTCG	AGGGGGGGCC	CGGTACCCAA	TTGCGCCTAT	AGTGAGTCGT	6100
	ATTACGCGCG	CTCACTGGCC	GTCGTTTAC	AACGTCGTGA	CTGGGAAAAAC	6150
	CCTGGCGTTA	CCCAACTTAA	TCGCCTTGCA	GCACATCCCC	CTTTCGCCAG	6200
	CTGGCGTAAT	AGCGAAGAGG	CCCGCACCGA	TCGCCCTTCC	CAACAGTTGC	6250
10	GCAGCTGAA	TGGCGAATGG	AAATGTAAAG	CGTTAATATT	TTGTTAAAAAT	6300
	TCGCGTTAAA	TTTTTGTTAA	ATCAGCTCAT	TTTTTAACCA	ATAGGCCGAA	6350
	ATCGGCAAAA	TCCCTTATAA	ATCAAAAGAA	TAGACCGAGA	TAGGGTTGAG	6400
	TGTTGTTCCA	GTTTGAACA	AGAGTCCACT	ATTAAAGAAC	GTGGACTCCA	6450
	ACGTCAAAGG	GCGAAAAACC	GTCTATCAGG	GCGATGGCCC	ACTACTCCGG	6500
15	GATCATATGA	CAAGATGTGT	ATCCACCTTA	ACTTAATGAT	TTTTACCAAA	6550
	ATCATTAGGG	GATTTCATCAG	TGCTCAGGGT	CAACGAGAAT	TAACATTCGG	6600
	TCAGGAAAGC	TTATGATGAT	GATGTGCTTA	AAAACCTACT	CAATGGCTGG	6650
	TTATGCATAT	CGCAATACAT	GCGAAAAACC	TAAAAGAGCT	TGCCGATAAA	6700
	AAAGGCCAAT	TTATTGCTAT	TTACCGCGGC	TTTTTATTGA	GCTTGAAGA	6750
20	TAAATAAAAT	AGATAGGTTT	TATTTGAAGC	TAAATCTTCT	TTATCGTAAA	6800
	AAATGCCCTC	TTGGGTTATC	AAGAGGGTCA	TTATATTTTCG	CGGAATAACA	6850
	TCATTTGGTG	ACGAAATAAC	TAAGCACTTG	TCTCCTGTTT	ACTCCCCTGA	6900
	GCTTGAGGGG	TTAACATGAA	GGTCATCGAT	AGCAGGATAA	TAATACAGTA	6950
	AAACGCTAAA	CCAATAATCC	AAATCCAGCC	ATCCCAAATT	GGTAGTGAAT	7000
25	GATTATAAAT	AACAGCAAAAC	AGTAATGGGC	CAATAACACC	GGTTGCATTG	7050
	GTAAGGCTCA	CCAATAATCC	CTGTAAAGCA	CCTTGCTGAT	GACTCTTTGT	7100
	TTGGATAGAC	ATCACTCCCT	GTAATGCAGG	TAAAGCGATC	CCACCACCAG	7150
	CCAATAAAAT	TAAACAGGG	AAAACCTAAC	AACCTTCAGA	TATAAACGCT	7200
	AAAAAGGCAA	ATGCACTACT	ATCTGCAATA	AATCCGAGCA	GTAAGTCCGT	7250
30	TTTTTCGCCC	CATTTAGTGG	CTATTCTTCC	TGCCACAAAG	GCTTGGAATA	7300
	CTGAGTGTA	AAGACCAAGA	CCCGCTAATG	AAAAGCCAAC	CATCATGCTA	7350
	TTCCATCCAA	AACGATTTTC	GGTAAATAGC	ACCCACACCG	TTGCGGGAAT	7400
	TTGGCCTATC	AATTGCGCTG	AAAAATAAAT	AATCAACAAA	ATGGCATCGT	7450
35	TTTAAATAAA	GTGATGTATA	CCGAATTCAG	CTTTTGTTCC	CTTTAGTGAG	7500
	GGTTAATTGC	GCGCTTGCGG	TAATCATGGT	CATAGCTGTT	TCCTGTGTGA	7550
	AATTGTTATC	CGCTCACAAT	TCCACACAAC	ATACGAGCCG	GAAGCATAAA	7600
	GTGTAAAGCC	TGGGGTGCCT	AATGAGTGAG	CTAACTCACA	TTAATTGCGT	7650
	TGCGCTCACT	GCCCGCTTTC	CAGTCGGGAA	ACCTGTCGTG	CCAGCTGCAT	7700
	TAATGAATCG	GCCAACGCGC	GGGGAGAGGC	GGTTTGCGTA	TTGGGCGCTC	7750
40	TTCCGCTTCC	TCGCTCACTG	ACTCGCTGCG	CTCGGTCGTT	CGGCTGCGGC	7800
	GAGCGGTATC	AGCTCACTCA	AAGGCGGTAA	TACGGTTATC	CACAGAATCA	7850
	GGGGATAACG	CAGGAAAGAA	CATGTGAGCA	AAAGGCCAGC	AAAAGGCCAG	7900
	GAACCGTAAA	AAGGCGCGT	TGCTGGCGTT	TTTCATAGG	CTCCGCCCTC	7950
	CTGACGAGCA	TCACAAAAAT	CGACGCTCAA	GTCAGAGGTG	GCGAAACCCG	8000
45	ACAGGACTAT	AAAGATACCA	GGCGTTTCCC	CCTGGAAGCT	CCCTCGTGCG	8050
	CTCTCCTGTT	CCGACCCTGC	CGCTTACCGG	ATACCTGTCC	GCCTTTCTCC	8100
	CTTCGGGAAG	CGTGGCGCTT	TCTCATAGCT	CACGCTGTAG	GTATCTCAGT	8150
	TCGGTGTAGG	TCGTTGCTC	CAAGCTGGGC	TGTGTGCACG	AACCCCCCGT	8200
	TCAGCCCGAC	CGCTGCGCCT	TATCCGGTAA	CTATCGTCTT	GAGTCCAACC	8250
50	CGGTAAGACA	CGACTTATCG	CCACTGGCAG	CAGCCACTGG	TAACAGGATT	8300
	AGCAGAGCGA	GGTATGTAGG	CGGTGCTACA	GAGTTCCTGA	AGTGGTGGCC	8350
	TAACTACGGC	TACACTAGAA	GGACAGTATT	TGGTATCTGC	GCTCTGCTGA	8400
	AGCCAGTTAC	CTTCGGAAAA	AGAGTTGGTA	GCTCTTGATC	CGGCAAAACA	8450
	ACCACCGCTG	GTAGCGGTGG	TTTTTTTGTT	TGCAAGCAGC	AGATTACGCG	8500
55	CAGAAAAAAA	GGATCTCAAG	AAGATCCTTT	GATCTTTTCT	ACGGGCTCTG	8550
	ACGCTCAGTG	GAACGAAAAAC	TCACGTTAAG	GGATTTTGGT	CATGAGATTA	8600
	TCAAAAAGGA	TCTTCACCTA	GATCCTTTTA	AATTAATAAT	GAAGTTTAA	8650
	ATCAATCTAA	AGTATATATG	AGTAAACTTG	GTCTGACAGT	TACCAATGCT	8700
	TAATCAGTGA	GGCACCTATC	TCAGCGATCT	GTCTATTTTCG	TTTATCCATA	8750
60	GTTGCGTGAC	TCCCCGTCGT	GTAAGATACT	ACGATACGGG	AGGGCTTACC	8800
	ATCTGGCCCC	AGTGCTGCAA	TGATACCGCG	AGACCCACGC	TCACCGGCTC	8850

CAGATTTATC AGCAATAAAC CAGCGAGCCG GAAGGGCCGA GCGCAGAAGT 8900
 GGTCCCTGCAA CTTTATCCGC CTCCATCCAG TCTATTAATT GTTGCCGGA 8950
 AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTGCGCA 9000
 TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC 9050
 5 AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG 9100
 CAAAAAAGCG GTTAGCTCCT TCGGTCTCTC GATCGTTGTC AGAAGTAAGT 9150
 TGGCCGCAGT GTTATCACTC ATGGTTATGG CAGCACTGCA TAATTCCTT 9200
 ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG AGTACTCAAC 9250
 CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG 9300
 10 CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC 9350
 ATCATTTGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT 9400
 GTTGAGATCC AGTTCGATGT AACCCACTCG TGCACCAAC TGATCTTCAG 9450
 CATCTTTTAC TTTCACCAGC GTTCTTGGGT GAGCAAAAAC AGGAAGGCAA 9500
 AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT GAATACTCAT 9550
 15 ACTCTTCCTT TTTCATATT ATTGAAGCAT TTATCAGGT TATTGTCTCA 9600
 TGAGCGGATA CATATTGAA TGTATTAGA AAAATAAACA AATAGGGGT 9650
 CCGCGCACAT TTCCCCGAAA AGTGCCAC 9678

20 SEQ ID NO:4 (PTnMod (Oval/Red) Quail)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCC CTCCTTTCGC 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTTCG CGGCATCAGA TTGGCTATTG 150
 25 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACCGCCA TGTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
 CCCGCCCAT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 30 GGGACTTTCC ATTGACGTC ATGGGTGGAG TATTTACGGT AAACCTGCCA 450
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGGA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTGGC AGTACATCAA TGGGCGTGA TAGCGGTTTG 650
 35 ACTCACGGG ATTTCCAAGT CTCCACCCCA TTGACGTC AAGGAGTTTG 700
 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACG 850
 TGTTTTGACC TCCATAGAAG ACACCGGAC CGATCCAGCC TCCGCGGCG 900
 40 GGAACGGTGC ATTGGAACG GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 CCGCTATAG ACTCTATAG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCT GCTTCCTTAT GCTATAGGTG 1050
 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 45 GCCACAAC TA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTCAGAGAC 1200
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTACA 1250
 AATTACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 50 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTGCTCCTA ACAGTGGAGG 1450
 CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCACAAG 1500
 GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550
 CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
 GCAGCTGAGT TGTGTATTTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
 55 GTGCTGTAA CGGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGTGTC 1700
 CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCTTT 1750
 CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
 TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850
 CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
 60 CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAAAGCGAG AACAAAACAT 1950
 AACATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000

	CGGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCAT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
5	CCAAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTGCTAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
10	CCAAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATGTGCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTC	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
15	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	GATCGCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTCGC	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
20	AAATTTATT	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GACACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCTTGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTAATAA	AATGAGGAAA	TTGCATCGCA	TTGCTGAGT	AGGTGTCATT	3200
25	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
30	CAATTAFTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAACGTATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTTGG	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAAATTG	3700
35	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCCGTAATG	TGAGTTAGCT	3850
	CACCTATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTTGTGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
40	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGTCCAC	CGCGTGCGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCGGGG	4050
	AGGTGAGAAT	GGTTTCTTTA	CTGTTGTGCA	ATTCTATTAT	TTCAATACAG	4100
	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTCACAA	TTCCTCTGTC	4200
45	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
	CATACCATAA	ACTCATTTGG	AATTGAGTAT	TATTTTGCTT	TGAATGGAGC	4300
	TATGTTTTGC	AGTTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
	CCATCAAAAAG	ATATATTTAA	ATATTCCAAC	TACAGAAAAG	TTTTGTCTGC	4400
	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTG	4450
50	CCTATTTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTTCTC	ACTTATCTCC	4500
	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAATGA	4550
	AACAGACTTC	TGGTCTGTTA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600
	ATAATTGCTA	ATTATGTTTT	CCATCTCTAA	GGTTCCCAAC	TTTTTCTGTT	4650
	TTAAGATCCC	ATTATCTGGT	TGTAACGTAA	GCTCAATGGA	ACATGAACAG	4700
55	TATTTCTCAG	TCTTTTCTCC	AGCAATCCTG	ACGGATTAGA	AGAACTGGCA	4750
	GAAAACACTT	TGTTACCCAG	AATTAATAAC	TAATATTTGC	TCTCCCTTCA	4800
	ATCCAAAATG	GACCTATTGA	AACTAAAATC	TGACCCAATC	CCATTAAATT	4850
	ATTTCTATGG	CGTCAAAGGT	CAAACCTTTG	AAGGGAACCT	GTGGGTGGGT	4900
	CCCAATTCAG	GCTATATATT	CCCCAGGGCT	CAGCGGATCT	CCATGGGCTC	4950
60	CTCGTGCAGC	AAGCATGGAA	TTTTGCCTTG	ATGTATTCAA	GGAGCTCAAA	5000
	GTCCACCATG	CCAATGACAA	CATGCTCTAC	TCCCCCTTTG	CCATCTGTCA	5050

ACTCTGGCCA TGGTCTCCCT GGGTGCAAAA GACAGCACCA GGGAAATTCGT 5100
 GCGTCTCTCC AAGAAGCTCA TCAAGGAGTT CATGCGCTTC AAGGTGCGCA 5150
 TGGAGGGCAC CGTGAACGGC CACGAGTTCC AGATCGAGGG CGAGGGCGAG 5200
 GGGCGCCCCCT ACGAGGGCCA CAACACCGTG AAGCTGAAGG TGACCAAGGG 5250
 5 CCGCCCCCTG CCCTTCGCCT GGGACATCCT GTCCCCCAG TTCCAGTACG 5300
 GCTCCAAGGT GTACGTGAAG CACCCCGCCG ACATCCCCGA CTACAAGAAG 5350
 CTGTCCTTCC CCGAGGGCTT CAAGTGGGAG CGCGTGATGA ACTTCGAGGA 5400
 CGGCGGCGTG GTGACCGTGA CCCAGGACTC CTCCTGCGAG GACGGCTGCT 5450
 TCATCTACAA GGTGAAGTTC ATCGGCGTGA ACTTCCCCTC CGACGGCCCC 5500
 10 GTAATGCAGA AGAAGACCAT GGGCTGGGAG GCCTCCACCG AGCGCTGTGA 5550
 CCCCCGCGAC GCGTGCTGA AGGGCGAGAT CCACAAGGCC CTGAAGCTGA 5600
 AGGACGGCGG CCACTACCTG GTGGAGTTCA AGTCCATCTA CATGGCCAAG 5650
 AAGCCCGTGC AGCTGCCCGG CTACTACTAC GTGGACTCCA AGCTGGACAT 5700
 CACCTCCCAC AACGAGGACT ACACCATCGT GGAGCAGTAC GAGCGCACCG 5750
 15 AGGGCCGCCA CCACCTGTTC CTGTAGCGGC CGCGACTCTA GATCATAATC 5800
 AGGCATACCA CATTGTAGA GGTTTTACTT GCTTTAAAAA ACCTCCCACA 5850
 CCTCCCCCTG AACCTGAAAC ATAAATGAA TGCAATTGTT GTTGTTAACT 5900
 TGTTTATTGC AGCTTATAAT GGTTACAAAT AAAGCAATAG CATCACAAT 5950
 TTCACAAATA AAGCATTTTT TTCCTGTCAT TCTAGTTGTG GCTCGAGAAG 6000
 20 GCGCAATTC TGCAGATATCC ATCACACTGG CGGCCGCTCG AGGGGGGGCC 6050
 CCGTACCCAA TTCGCCCTAT AGTGAGTCGT ATTACGCGCG CTCACTGGCC 6100
 GTCGTTTTAC AACGTCGTGA CTGGGAAAAC CCTGGCGTTA CCCAACTTAA 6150
 TCGCCTTGCA GCACATCCCC CTTTCGCCAG CTGGCGTAAT AGCGAAGAGG 6200
 CCGCACCCGA TCGCCCTTCC CAACAGTTGC GCAGCCTGAA TGGCGAATGG 6250
 25 AAATGTGAAG CGTTAATATT TTGTTAAAT TCGCGTTAAA TTTTGTAA 6300
 ATCAGCTCAT TTTTAAACCA ATAGGCCGAA ATCGGCAAAA TCCCTTATAA 6350
 ATCAAAAGAA TAGACCGAGA TAGGGTTGAG TGTTGTTCCA GTTTGGAACA 6400
 AGAGTCCACT ATTAAGAAGC GTGGACTCCA ACGTCAAAGG GCGAAAAACC 6450
 GTCTATCAGG GCGATGGCCC ACTACTCCGG GATCATATGA CAAGATGTGT 6500
 30 ATCCACCTTA ACTTAATGAT TTTTACCAA ATCATTAGGG GATTTCATCAG 6550
 TGCTCAGGGT CAACGAGAAT TAACATTCCG TCAGGAAAGC TTATGATGAT 6600
 GATGTGCTTA AAAACTTACT CAATGGCTGG TTATGCATAT CGCAATACAT 6650
 GCGAAAAACC TAAAAGAGCT TGCCGATAAA AAAGGCCAAT TTATTGCTAT 6700
 TTACCGCGGC TTTTATTGA GCTTGAAAGA TAAATAAAAT AGATAGGTTT 6750
 35 TATTGAAGC TAAATCTTCT TTATCGTAAA AAATGCCCTC TTGGGTATC 6800
 AAGAGGTCA TTATATTTCC CGGAATAACA TCATTGGTG ACGAAATAAC 6850
 TAAGCACTTG TCTCCTGTTT ACTCCCTGA GCTTGAGGGG TTAACATGAA 6900
 GGTTCATCGAT AGCAGGATAA TAATACAGTA AAACGCTAAA CCAATAATCC 6950
 40 AAATCCAGCC ATCCCAAATT GGTAGTGAAT GATTATAAAT AACAGCAAAAC 7000
 AGTAATGGGC CAATAACACC GGTTCGATTG GTAAGGCTCA CCAATAATCC 7050
 CTGTAAGCA CCTTGCTGAT GACTCTTGT TTGGATAGAC ATCACTCCCT 7100
 GTAATGCAGG TAAAGCGATC CCACCACCAG CCAATAAAAT TAAAACAGGG 7150
 AAACTAACCC AACCTTCAGA TATAACGCT AAAAAGGCAA ATGCACTACT 7200
 ATCTGCAATA AATCCGAGCA GTACTGCCGT TTTTTCGCC CATTTAGTGG 7250
 45 CTATTCTTCC TGCCACAAAG GCTTGGAATA CTGAGTGTA AAGACCAAGA 7300
 CCGGCTAATG AAAAGCCAAC CATCATGCTA TTCCATCCAA AACGATTTTC 7350
 GGTAATAGC ACCCACACCG TTGCGGGAAT TTGGCCTATC AATTGCGCTG 7400
 AAAATAAAAT AATCAACAAA ATGGCATCGT TTTAAATAAA GTGATGTATA 7450
 CCGAATTCAG CTTTTGTTCC CTTTAGTGAG GGTAAATTGC GCGCTTGGCG 7500
 50 TAATCATGGT CATAGCTGTT TCCTGTGTGA AATTGTTATC CGCTCACAAT 7550
 TCCACACAAC ATACGAGCCG GAAGCATAAA GTGTAAGGCC TGGGGTGCTT 7600
 AATGAGTGAG CTAATCACA TTAATTGCGT TGCCTCACT GCCCGCTTTC 7650
 CAGTCGGGAA ACCTGTCGTG CCAGCTGCAT TAATGAATCG GCCAACGCGC 7700
 GGGGAGAGGC GGTGTCGTA TTGGGCGCTC TTCGCTTCC TCGCTCACTG 7750
 55 ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC GAGCGGTATC AGCTCACTCA 7800
 AAGGCGGTAA TACGGTTATC CACAGAATCA GGGGATAACG CAGGAAAGAA 7850
 CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA AAGGCCGCTT 7900
 TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA TCACAAAAAT 7950
 60 CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA 8000
 GGCGTTTCCC CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCTGCG 8050
 CGCTTACCGG ATACCTGTCC GCCTTTCTCC CTTGCGGAAG CGTGCGCTT 8100

TCTCATAGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG TCGTTCGCTC 8150
 CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC CGGTGCGCCT 8200
 TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG 8250
 CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG 8300
 5 CCGTGCTACA GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA 8350
 GGACAGTATT TGGTATCTGC GCTCTGCTGA AGCCAGTTAC CTTGCGAAAA 8400
 AGAGTTGGTA GCTCTTGATC CGGCAAAACA ACCACCGCTG GTAGCGGTGG 8450
 TTTTTTGTG TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG 8500
 AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC 8550
 10 TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA 8600
 GATCCTTTTA AATTAAAAAT GAAGTTTAA ATCAATCTAA AGTATATATG 8650
 AGTAAACTTG GTCTGACAGT TACCAATGCT TAATCAGTGA GGCACCTATC 8700
 TCAGCGATCT GTCTATTTCG TTCATCCATA GTTGCCTGAC TCCCCGTCGT 8750
 GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA 8800
 15 TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC 8850
 CAGCCAGCCG GAAGGGCCGA GCGCAGAAGT GGTCCCTGCA CTTTATCCGC 8900
 CTCCATCCAG TCTATTAATT GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC 8950
 CAGTTAATAG TTTGCGCAAC GTTGTGCGCA TTGCTACAGG CATCGTGGTG 9000
 TCACGCTCGT CGTTTGGTAT GGCTTCATTC AGCTCCGGTT CCCAACGATC 9050
 20 AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG GTTAGCTCCT 9100
 TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCGAGT GTTATCACTC 9150
 ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG 9200
 ATGCTTTTCT GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT 9250
 GTATGCGGCG ACCGAGTTGC TCTTGCCCGG CGTCAATACG GGATAATACC 9300
 25 GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA AACGTTCTTC 9350
 GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTCGATGT 9400
 AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC 9450
 GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT 9500
 AAGGGCGACA CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT 9550
 30 ATTGAAGCAT TTATCAGGGT TATTGTCTCA TGAGCGGATA CATATTTGAA 9600
 TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT TTCCCCGAAA 9650
 AGTGCCAC 9658

35 SEQ ID NO:5 (spacer)
 (GPGG)_x

SEQ ID NO:6 (spacer)
 GPGGGPGGPGG

40

SEQ ID NO:7 (spacer)
 GGGSGGGSGGGGS

45

SEQ ID NO:8 (spacer)
 GGGSGGGSGGGSGGGGS

50 SEQ ID NO:9 (enterokinase cleavage site)
 DDDDK

55 SEQ ID NO:10 (altered transposase Hef forward primer)
 ATCTCGAGACCATGTGTGAACCTGATATTTACATGATTCTCTTACC

60 SEQ ID NO:11 (altered transposase Her reverse primer)
 GATTGATCATATCATAATTTCCCAAAGCGTAACC

- SEQ ID NO:12 (Xho I restriction site)
CTCGAG
- 5 SEQ ID NO:13 (modified Kozak sequence)
ACCATG
- 10 SEQ ID NO:14 (Bcl I restriction site)
TGATCA
- 15 SEQ ID NO:15 (CMVf-NgoM IV primer)
TTGCCGGCATCAGATTGGCTAT
- 20 SEQ ID NO:16 (Syn-polyAr-BstE II primer)
AGAGGTCACCGGGTCAATTCTTCAGCACCTGGTA
- 25 SEQ ID NO:17 (vitellogenin promoter)
- TGAATGTGTT CTTGTGTTAT CAATATAAAT CACAGTTAGT GATGAAGTTG GCTGCAAGCC
TGCATCAGTT CAGCTACTTG GCTGCATTTT GTATTGTTT CTGTAGGAAA TGCAAAAGGT
TCTAGGCTGA CCTGCACTTC TATCCCTCTT GCCTTACTGC TGAGAATCTC TGCAGGTTTT
AATTGTTTAC ATTTTGCTCC CATTACTTTT GGAAGATAAA ATATTTACAG AATGCTTATG
AAACCTTTGT TCATTAAAA ATATTCCTGG TCAGCGTGAC CGGAGCTGAA AGAACACATT
GATCCCGTGA TTTCAATAAA TACATATGTT CCATATATTG TTTCTCAGTA GCCTCTTAAA
TCATGTGCGT TGGTGACAT ATGAATACAT GAATAGCAAA GGTTTATCTG GATTACGCTC
TGGCCTGCAG GAATGGCCAT AAACCAAAGC TGAGGGAAGA GGGAGAGTAT AGTCAATGTA
30 GATTATACTG ATTGCTGATT GGGTTATTAT CAGCTAGATA ACAACTTGGG TCAGGTGCCA
GGTCAACATA ACCTGGGCAA AACCAGTCTC ATCTGTGGCA GGACCATGTA CCAGCAGCCA
GCCGTGACCC AATCTAGGAA AGCAAGTAGC ACATCAATTT TAAATTTATT GTAAATGCCG
TAGTAGAAGT GTTTTACTGT GATACATTGA AACTTCTGGT CAATCAGAAA AAGGTTTTTT
ATCAGAGATG CCAAGGTATT ATTTGATTTT CTTTATTCGC CGTGAAGAGA ATTTATGATT
35 GCAAAAAGAG GAGTGTTTAC ATAACTGAT AAAAACTTG AGGAATTCAG CAGAAAACAG
CCACGTGTTT CTGAACATTC TTCCATAAAA GTCTCACCAT GCCTGGCAGA GCCCTATTCA
CCTTCGCT
- 40 SEQ ID NO:18 (vitellogenin targeting sequence)
- ATGAGGGGGATCATACTGGCATTAGTGCTCACCTTGTAGGCAGCCAGAAGTTTGACATTGGT
- 45 SEQ ID NO:19 (p146 protein)
KYKKALKKLAKLL
- 50 SEQ ID NO:20 (p146 coding sequence)
AAATACAAAAAGCACTGAAAAAAGTGGCAAACTGCTG
- 55 SEQ ID NO:21 (pro-insulin sequence)
- TTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAAGCTCTCTACCTAGTGTGCGGGGAACGAGGC
TTCTTCTACACACCAAGACCCGCGGGAGGCAGAGGACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGG
GGCCCTGGTGAGGCAGCCTGCAGCCCTTGGCCCTGGAGGGGTCCCTGCAGAAGCGTGCCATTGTGGAA
CAATGCTGTACCAGCATCTGCTCCCTTACCAGCTGGAGAACTCTGCAACTAG
- 60 SEQ ID NO:22 (TAG sequence)

5 SEQ ID NO:23 (gp41 epitope)
Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys Gly Trp Ile Gly Leu Leu

10 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly
Ser Cys Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys

SEQ ID NO:26 (TAG spacer sequence)
Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
20 Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp

[illegible]

117

SEQ ID NO:29 (pTnMod(Oval/ENT tag/P146/PA) - Chicken)

5	CTGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT	GGTGGTTACG	50
	CGCAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCGCCCG	CTCCTTTCGC	100
	TTTCTTCCCT	TCCTTTCTCG	CCACGTTCCG	CGGCATCAGA	TTGGCTATTG	150
	GCCATTGCAT	ACGTTGTATC	CATATCATAA	TATGTACATT	TATATTGGCT	200
	CATGTCCAAC	ATTACCGCCA	TGTTGACATT	GATTATTGAC	TAGTTATTAA	250
	TAGTAATCAA	TTACGGGGTC	ATTAGTTCAT	AGCCCATATA	TGGAGTTCCG	300
10	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	350
	CCCCCCATT	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	400
	GGGACTTTCC	ATTGACGTCA	ATGGGTGGAG	TATTTACGGT	AAACTGCCCA	450
	CTTGGCAGTA	CATCAAGTGT	ATCATATGCC	AAGTACGCCC	CCTATTGACG	500
	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCAGTA	CATGACCTTA	550
15	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	600
	CATGGTGTATG	CGGTTTGGC	AGTACATCAA	TGGGCGTGA	TAGCGGTTTG	650
	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
	TTTTGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTCGTA	ACAACTCCGC	750
	CCCATTGACG	CAAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATAA	800
20	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGGCCG	900
	GGAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
	CCGCCTATAG	ACTCTATAGG	CACACCCTT	TGGCTCTTAT	GCATGTCTATA	1000
	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCC	GCTTCCTTAT	GCTATAGGTG	1050
25	ATGGTATAGC	TAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCATTGGG	TGACGATACT	TCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAACATA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATTT	ATTATTTACA	1250
	AATTACACATA	TACAACAACG	CCGTCCCCCG	TGCCCCGAGT	TTTTATTAAA	1300
30	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTT	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTCGC	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
	CCAGACTTAG	GCACAGCACA	ATGCCACCCA	CCACCACTGT	GCCGCACAAG	1500
	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
35	CACGCGTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTG	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCCCTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
40	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
45	GATGCCCAT	GTAATTGTTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCTCGT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTCTTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTCTAG	TGATGTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
50	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
55	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTC	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTGTATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
60	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900

	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTATTTC	ACACATGGTT	ACGCTTTGGG	GAAATATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTGTTG	3100
5	CCCTCCCCCG	TGCCTTCCTT	GACCTTGGA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
10	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTAGCCGGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAACGTATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
15	CCTATCCAAG	AAGTGATGCC	TATCATTTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCTTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
20	CATCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCCCT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTC	ATTCTATTAT	TTCAATACAG	4100
25	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTCACAA	TTCTCTGTGC	4200
	ATCTGCCAGG	CCATTAAGTT	ATTCATGGAA	GATCTTTGAG	GAACACTGCA	4250
	AGTTCATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTTA	TAAAGCATTG	4350
30	ACACCCATAA	AAAGATAGAT	TTAAATATTT	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACTCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
	TTATTTCTCC	TATTTTGTC	AGAAAATAAT	AGGTCACGTC	TTGTTCTCAC	4500
	TTATGTCCTG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
35	TTCAAATGAAA	CAGACTTCTG	GTCTGTTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTAACTAAT	AATTGCTAAT	TATGTTTTCC	ATCTCTAAGG	TTCCACATT	4650
	TTTCTGTTTT	CTTAAAGATC	CCATTATCTG	GTTGTAAGTG	AAGCTCAATG	4700
	GAACATGAGC	AATATTTCCC	AGTCTTCTCT	CCCATCCAAC	AGTCCTGATG	4750
	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAAACTAA	4850
40	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACTGTG	GGTGGGTGAC	AATTGAGGCT	ATATATTCCC	CAGGGCTCAG	4950
	CGGATCCATG	GGCTCCATCG	GCGCAGCAAG	CATGGAATTT	TGTTTTGATG	5000
	TATTCAGGA	GCTCAAAGTC	CACCATGCCA	ATGAGAACAT	CTTCTACTGC	5050
	CCCATTGCCA	TCATGTCAGC	TCTAGCCATG	GTATACCTGG	GTGCAAAAGA	5100
45	CAGCACCAGG	ACACAGATAA	ATAAGGTTGT	TCGCTTTGAT	AACTTCCAG	5150
	GATTGCGAGA	CAGTATTGAA	GCTCAGTGTG	GCACATCTGT	AAACGTTTCC	5200
	TCTTCACTTA	GAGACATCCT	CAACCAAATC	ACCAAACCAA	ATGATGTTTA	5250
	TTCCGTTGAGC	CTTGCCAGTA	GACTTTATGC	TGAAGAGAGA	TACCCAATCC	5300
	TGCCAGAATA	CTTGCAAGT	GTGAAGGAAC	TGTATAGAGG	AGGCTTGGA	5350
50	CCTATCAACT	TTCAAACAGC	TGCAGATCAA	GCCAGAGAGC	TCATCAATTC	5400
	CTGGGTAGAA	AGTCAGACAA	ATGGAATTAT	CAGAAATGTC	CTTCAGCCAA	5450
	GCTCCGTGGA	TTCTCAAAC	GCAATGGTTC	TGTTAATGTC	CATTGTCTTC	5500
	AAAGGACTGT	GGGAGAAAAC	ATTTAAGGAT	GAAGACACAC	AAGCAATGCC	5550
	TTTCAGAGTG	ACTGAGCAAG	AAAGCAAACC	TGTGCAGATG	ATGTACCAGA	5600
55	TTGGTTTATT	TAGAGTGGCA	TCAATGGCTT	CTGAGAAAAT	GAAGATCCTG	5650
	GAGCTTCCAT	TTGCCAGTGG	GACAATGAGC	ATGTTGGTGC	TGTTGCCTGA	5700
	TGAAGTCTCA	GGCCTTGAGC	AGCTTGAGAG	TATAATCAAC	TTTGAAAAAC	5750
	TGACTGAATG	GACCAGTTCT	AATGTTATGG	AAGAGAGGAA	GATCAAAGTG	5800
	TACTTACCTC	GCATGAAGAT	GGAGAAAAAA	TACAACCTCA	CATCTGTCTT	5850
60	AATGGCTATG	GGCATTACTG	ACGTGTTTAG	CTCTTCAGCC	AATCTGTCTG	5900
	GCATCTCCTC	AGCAGAGAGC	CTGAAGATAT	CTCAAGCTGT	CCATGCAGCA	5950

	CATGCAGAAA	TCAATGAAGC	AGGCAGAGAG	GTGGTAGGGT	CAGCAGAGGC	6000
	TGGAGTGGAT	GCTGCAAGCG	TCTCTGAAGA	ATTTAGGGCT	GACCATCCAT	6050
	TCCTCTTCTG	TATCAAGCAC	ATCGCAACCA	ACGCCGTTCT	CTTCTTTGGC	6100
	AGATGTGTTT	CCCCTCCGCG	GCCAGCAGAT	GACGCACCAG	CAGATGACGC	6150
5	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	6200
	CAGATGACGC	AACAACATGT	ATCCTGAAAG	GCTCTTGTTG	CTGGATCGGC	6250
	CTGCTGGATG	ACGATGACAA	AAAATACAAA	AAAGCACTGA	AAAAACTGGC	6300
	AAAACTGCTG	TAATGAGGGC	GCCTGGATCC	AGATCACTTC	TGGCTAATAA	6350
	AAGATCAGAG	CTCTAGAGAT	CTGTGTGTTG	GTTTTTTGTG	GATCTGCTGT	6400
10	GCCTTCTAGT	TGCCAGCCAT	CTGTTGTTTG	CCCCTCCCCC	GTGCCTTCCT	6450
	TAGCCCTGGA	AGGTGCCACT	CCCCTGTCC	TTTCCTAATA	AAATGAGGAA	6500
	ATTGCATCGC	ATTGTCTGAG	TAGGTGTCAT	TCTATTCTGG	GGGGTGGGGT	6550
	GGGGCAGCAC	AGCAAGGGGG	AGGATTGGGA	AGACAATAGC	AGGCATGCTG	6600
	GGGATCGGGT	GGGCTCTATG	GGTACCTCTC	TCTCTCTCTC	TCTCTCTCTC	6650
15	TCTCTCTCTC	TCTCTCGGTA	CCTCTCTCGA	GGGGGGGGCC	GGTACCCCAAT	6700
	TCGCCCTATA	GTGAGTCGTA	TTACGCGCGC	TCACTGGCCG	TCGTTTTTACA	6750
	ACGTCGTGAC	TGGGAAAACC	CTGGCGTTAC	CCAACTTAAT	CGCCTTGACG	6800
	CACATCCCCC	TTTCGCCAGC	TGGCGTAATA	GCGAAGAGGC	CCGCACCGAT	6850
	CGCCCTTCCC	AACAGTTGCG	CAGCCTGAAT	GGCGAATGGA	AATTGTAAAGC	6900
20	GTTAATATTT	TGTTAAAATT	CGCGTTAAAT	TTTTGTAAAT	TCAGCTCATT	6950
	TTTTAACCAA	TAGGCCGAAA	TCGGCAAAAT	CCCTTATAAA	TCAAAAGAAAT	7000
	AGACCGAGAT	AGGGTTGAGT	GTTGTTCCAG	TTTGGAACAA	GAGTCCACTA	7050
	TTAAAGAACG	TGGACTCCAA	CGTCAAAGGG	CGAAAACCCG	TCTATCAGGG	7100
	CGATGGCCCA	CTACTCCGGG	ATCATATGAC	AAGATGTGTA	TCCACCTTAA	7150
25	CTTAATGATT	TTTACCAAAA	TCATTAGGGG	ATTCATCAGT	GCTCAGGGTC	7200
	AACGAGAATT	AACATTCCGT	CAGGAAAGCT	TATGATGATG	ATGTGCTTAA	7250
	AAACTTACTC	AATGGCTGGT	TATGCATATC	GCAATACATG	CGAAAAACCT	7300
	AAAAGAGCTT	GCCGATAAAA	AAGGCCAATT	TATTGCTATT	TACCGCGGCT	7350
	TTTTATTGAG	CTTGAAAGAT	AAATAAAATA	GATAGGTTTT	ATTTGAAGCT	7400
30	AAATCTTCTT	TATCGTAAAA	AATGCCCTCT	TGGGTATCA	AGAGGGTCAT	7450
	TATATTTCGC	GGAATAACAT	CATTTGGTGA	CGAAATAACT	AAGCACTTGT	7500
	CTCCTGTTTA	CTCCCTGAG	CTTGAGGGGT	TAACATGAAG	GTCATCGATA	7550
	GCAGGATAAT	AATACAGTAA	AACGCTAAAC	CAATAATCCA	AATCCAGCCA	7600
	TCCCAAAATTG	GTAGTGAATG	ATTATAAATA	ACAGCAAAACA	GTAATGGGCC	7650
35	AATAACACCG	GTTGCATTGG	TAAGGCTCAC	CAATAATCCC	TGTAAAGCAC	7700
	CTTGCTGATG	ACTCTTTGTT	TGGATAGACA	TCACTCCCTG	TAATGCAGGT	7750
	AAAGCGATCC	CACCACCAGC	CAATAAAATT	AAAACAGGGA	AAACTAACCA	7800
	ACCTTCAGAT	ATAAACGCTA	AAAAGGCAAA	TGCACTACTA	TCTGCAATAA	7850
	ATCCGAGCAG	TACTGCCGTT	TTTTCGCCCC	ATTTAGTGGC	TATTCTTCTT	7900
40	GCCACAAAGG	CTTGGAATAC	TGAGTGTAAT	AGACCAAGAC	CCGCTAATGA	7950
	AAAGCCAACC	ATCATGCTAT	TCCATCCAAA	ACGATTTTCG	GTAATAGCA	8000
	CCCACACCGT	TGCGGGAATT	TGGCCTATCA	ATTGCGCTGA	AAAATAAATA	8050
	ATCAACAAAA	TGGCATCGTT	TTAAATAAAG	TGATGTATAC	CGAATTCAGC	8100
	TTTTGTTCCT	TTTAGTGAGG	GTTAATTGCG	CGCTTGGCGT	AATCATGGTC	8150
45	ATAGCTGTTT	CCTGTGTGAA	ATTGTTATCC	GCTCACAATT	CCACACAACA	8200
	TACGAGCCCG	AAGCATAAAG	TGTAAAGCCT	GGGGTGCCCTA	ATGAGTGAGC	8250
	TAACTCACAT	TAATTGCGTT	GCGCTCACTG	CCCGCTTTCC	AGTCGGGAAA	8300
	CCTGTGCTGC	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	8350
	GTTTGCGTAT	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	8400
50	TCGGTCGTTT	GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	8450
	ACGGTTATCC	ACAGAATCAG	GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	8500
	AAGGCCAGCA	AAAGGCCAGG	AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	8550
	TTCCATAGGC	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	GACGCTCAAG	8600
	TCAGAGGTGG	CGAAACCCGA	CAGGACTATA	AAGATACCAG	GCGTTTCCCC	8650
55	CTGGAAGCTC	CCTCGTGCGC	TCTCCTGTTT	CGACCTGCCC	GCTTACCGGA	8700
	TACCTGTCCG	CCTTTCTCCC	TTCGGGAAGC	GTGGCGCTTT	CTCATAGCTC	8750
	ACGCTGTAGG	TATCTCAGTT	CGGTGTAGGT	CGTTTCGCTCC	AAGCTGGGCT	8800
	GTGTGCACGA	ACCCCCCGTT	CAGCCCGACC	GCTGCGCCTT	ATCCGGTAAC	8850
	TATCGTCTTG	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	CACTGGCAGC	8900
60	AGCCACTGGT	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	8950
	AGTTCTTGAA	GTGGTGGCCT	AACTACGGCT	ACACTAGAAG	GACAGTATTT	9000

5 GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG 9050
 CTCTTGATCC GGCAAAACAAA CCACCGCTGG TAGCGGTGGT TTTTGTGTTT 9100
 GCAAGCAGCA GATTACGCGC AGAAAAAAG GATCTCAAGA AGATCCTTTG 9150
 ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAAACT CACGTTAAGG 9200
 GATTTTGGTC ATGAGATTAT CAAAAGGAT CTTACCTAG ATCCTTTTAA 9250
 ATTAAAAATG AAGTTTAA TCAATCTAAA GTATATATGA GTAAACTTGG 9300
 TCTGACAGTT ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG 9350
 TCTATTTCGT TCATCCATAG TTGCCTGACT CCCCCTCGTG TAGATAACTA 9400
 10 CGATACGGGA GGGCTTACCA TCTGGCCCA GTGCTGCAAT GATACCGCGA 9450
 GACCCACGCT CACCGCTCC AGATTATCA GCAATAAACC AGCCAGCCG 9500
 AAGGGCCGAG CGCAGAAGTG GTCTGCAAC TTTATCCGCC TCCATCCAGT 9550
 CTATTAAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT 9600
 TTGCGCAACG TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC 9650
 GTTTGGTATG GCTTCATTCA GCTCCGGTTC CCAACGATCA AGGCGAGTTA 9700
 15 CATGATCCCC CATGTTGTGC AAAAAAGCGG TTAGCTCCTT CGGTCTCTCCG 9750
 ATCGTTGTCA GAAGTAAGTT GGCCGAGTG TTATCACTCA TGGTTATGGC 9800
 AGCACTGCAT AATTCTCTTA CTGTATGCC ATCCGTAAGA TGCTTTTCTG 9850
 TGACTGGTGA GACTCAACC AAGTCATTCT GAGAAATAGT TATGCGGCGA 9900
 CCGAGTTGCT CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG 9950
 20 CAGAACTTTA AAAGTGCTCA TCATTGAAA ACGTTCTTCG GGGCGAAAAAC 10000
 TCTCAAGGAT CTTACCGCTG TTGAGATCCA GTTCGATGTA ACCCACTCGT 10050
 GCACCCAACT GATCTTCAGC ATCTTTTACT TTCACCAGCG TTTCTGGGTG 10100
 AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC 10150
 GGAAATGTTG AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT 10200
 25 TATCAGGGTT ATTGTCTCAT GAGCGGATAC ATATTGAA GTATTTAGAA 10250
 AAATAAACAA ATAGGGTTT CGCGCACATT TCCCCGAAAA GTGCCAC 10297

30 SEQ ID NO:30 (pTnMod(Oval/ENT tag/P146/PA) - QUAIL)
 CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 TTTCTTCCCT TCCTTCTCG CCACGTTGCG CGGCATCAGA TTGGCTATTG 150
 35 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTA 250
 TAGTAATCAA TTACGGGGT ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCAACGACC 350
 CCGGCCCAT TACGTCATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA 450
 40 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTGGC AGTACATCAA TGGGCGTGA TAGCGGTTTG 650
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 45 TTTTGGCACC AAAATCAACG GGAATTTCCA AAATGTCGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGAC CGATCCAGCC TCCGCGGCCG 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 50 CCGCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTGTG CTTGGGGCCT ATACACCCCT GCTTCTTAT GCTATAGGTG 1050
 ATCGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTAGAGAC 1200
 55 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTACA 1250
 AATTACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTA 1300
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
 60 CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCAACG 1500
 GCGGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550

	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATT	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTCTT	1750
5	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
10	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCAT	GTACTTGTTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAG	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTC	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTCTTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
15	TCATTGTCTAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
20	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
25	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTCGC	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATT	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
30	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCCTGGA	GGTGCCACTC	CCACTGTCTT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCTAT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
35	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
40	CATCACAACA	AAAACGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
45	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACCTATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
50	GGAGTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAAA	TTCTCTGTCT	4200
	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
55	CATACCATAA	ACTCATTTGG	AATTGAGTAT	TATTTTGCTT	TGAATGGAGC	4300
	TATGTTTTGC	AGTTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
	CCATCAAAAAG	ATATATTTAA	ATATTCCAAC	TACAGAAAAG	TTTTGTCTGC	4400
	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTGT	4450
	CCTATTTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTCTCT	ACTTATCTCC	4500
60	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAATGA	4550
	AACAGACTTC	TGGTCTGTGA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600

5 ATAATTGCTA ATTATGTTTT CCATCTCTAA GGTTCCACACA TTTTCTGT 4650
 TTAAGATCCC ATTATCTGGT TGTAAC TGAA GCTCAATGGA ACATGAACAG 4700
 TATTTCTCAG TCTTTCTTCC AGCAATCCTG ACGGATTAGA AGAACTGGCA 4750
 GAAAACACTT TGTTACCCAG AATTA AAAAC TAATATTTGC TCTCCCTTCA 4800
 ATCCAAAATG GACCTATTGA AACTAAAATC TGACCCAATC CCATTAAAT 4850
 ATTTCTATGG CGTCAAAGGT CAAACTTTTG AAGGGAACCT GTGGGTGGGT 4900
 CCCAATTCAG GCTATATATT CCCAGGGCT CAGCCAGTGG ATCCATGGGC 4950
 TCCATCGGTG CAGCAAGCAT GGAATTTTGT TTTGATGTAT TCAAGGAGCT 5000
 CAAAGTCCAC CATGCCAATG ACAACATGCT CTACTCCCC TTTGCCATCT 5050
 10 TGTCAACTCT GGCCATGGTC TTCTTAGGTG CAAAAGACAG CACCAGGACC 5100
 CAGATAAATA AGGTTGTTCA CTTTGATAAA CTTCAGGAT TCGGAGACAG 5150
 TATTGAAGCT CAGTGTGGCA CATCTGTAAA TGTTCACTCT TCACTTAGAG 5200
 ACATACTCAA CCAAATCACC AAACAAAATG ATGCTTATTC GTTCAGCCTT 5250
 GCCAGTAGAC TTTATGTCTA AGAGACATAC ACAGTCGTGC CGGAATACCT 5300
 15 GCAATGTGTG AAGGAACTGT ATAGAGGAGG CTTAGAATCC GTCAACTTTC 5350
 AAACAGCTGC AGATCAAGCC AGAGGCCTCA TCAATGCCTG GGTAGAAAGT 5400
 CAGACAAACG GAATTATCAG AAACATCCTT CAGCCAAGCT CCGTGGATT 5450
 TCAAAGTCA ATGGTCTGG TTAATGCCAT TGCCTTCAAG GGAAGTGGG 5500
 AGAAAGCATT TAAGGCTGAA GACACGCAA CAATACCTT CAGAGTGA 5550
 20 GAGCAAGAAA GCAAACCTGT GCAGATGATG TACCAGATTG GTTCATTTA 5600
 AGTGGCATCA ATGGCTTCTG AGAAAATGAA GATCCTGGAG CTTCATTG 5650
 CCAGTGGAA CAGATGATG TGGGTGCTGT TGCCTGATGA TGTCTCAGGC 5700
 CTTGAGCAGC TTGAGAGTAT AATCAGCTT GAAAACCTGA CTGAATGGAC 5750
 CAGTTCTAGT ATTATGGAAG AGAGGAAGGT CAAAGTGTAC TTACCTCGCA 5800
 25 TGAAGATGGA GGAGAAATAC AACCTCACAT CTCTCTTAAT GGCTATGGGA 5850
 ATTACTGACC TGTTGAGCTC TTCAGCCAAT CTGTCTGGCA TCTCTCAGT 5900
 AGGGAGCCTG AAGATATCTC AAGCTGTCCA TGCAGCACAT GCAGAAATCA 5950
 ATGAAGCGGG CAGAGATGTG GTAGGCTCAG CAGAGGCTGG AGTGGATGCT 6000
 ACTGAAGAAT TTAGGGCTGA CCATCCATTC CTCTTCTGTG TCAAGCACAT 6050
 30 GAAACCAAC GCCATTCTCC TCTTTGGCAG ATGTGTTTCT CCGCGGCCAG 6100
 CAGATGACGC ACCAGCAGAT GACGCACCAG CAGATGACGC ACCAGCAGAT 6150
 GACGCACCAG CAGATGACGC ACCAGCAGAT GACGCAACAA CATGTATCCT 6200
 GAAAGGCTCT TGTGGCTGGA TCGGCCTGCT GGATGACGAT GACAAAAAAT 6250
 ACAAAAAAGC ACTGAAAAA CTGGCAAAAC TGCTGTAATG AGGGCGCCTG 6300
 35 GATCCAGATC ACTTCTGGCT AATAAAAGAT CAGAGCTCTA GAGATCTGTG 6350
 TGTTGGTTTT TTGTGGATCT GCTGTGCCTT CTAGTTGCCA GCCATCTGTT 6400
 GTTTGCCCTT CCCCCGTGCC TTCTTGACC CTGGAAGGTG CCACTCCAC 6450
 TGTCTTTTCC TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT 6500
 40 GTCATTCTAT TCTGGGGGGT GGGGTGGGGC AGCACAGCAA GGGGAGGAT 6550
 TGGGAAGACA ATAGCAGGCA TGCTGGGGAT GCGGTGGGCT CTATGGGTAC 6600
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CCGTACCTCT 6650
 CTCGAGGGGG GGCCCGTAC CCAATTCGCC CTATAGTGAG TCGATTACG 6700
 CGCGCTCACT GGCCGTGCTT TTACAACGTC GTGACTGGGA AAACCTGGC 6750
 GTTACCCAAC TTAATCGCCT TGCAGCACAT CCCCCTCTCG CCAGCTGGCG 6800
 45 TAATAGCGAA GAGGCCCGCA CCGATCGCCC TTCCAACAG TTGCGCAGCC 6850
 TGAATGGCGA ATGGAATTG TAAGCGTTAA TATTTTGTTA AAATTCGCGT 6900
 TAAATTTTTG TTAATCAGC TCATTTTTTA ACCAATAGGC CGAAATCGGC 6950
 AAAATCCCTT ATAAATCAAA AGAATAGACC GAGATAGGGT TGAGTGTGT 7000
 50 TCCAGTTTGG AACAAGAGTC CACTATTAAA GAACGTGGAC TCCAACGTCA 7050
 AAGGGCGAAA AACCGTCTAT CAGGGCGATG GCCCACTACT CCGGGATCAT 7100
 ATGACAAGAT GTGTATCCAC CTTAACCTAA TGATTTTAC CAAATCATT 7150
 AGGGGATTCA TCAGTGCTCA GGGTCAACGA GAATTAACAT TCCGTCAGGA 7200
 AAGCTTATGA TGATGATGTG CTTAAAAACT TACTCAATGG CTGGTTATGC 7250
 55 ATATCGCAAT ACATGCGAAA AACCTAAAAG AGCTTGCCGA TAAAAAAGGC 7300
 CAATTTATTG CTATTTACCG CGGCTTTTA TTGAGCTGA AAGATAAATA 7350
 AAATAGATAG GTTTTATTTG AAGCTAAATC TTCTTTATCG TAAAAAATGC 7400
 CCTCTTGGGT TATCAAGAGG GTCATTATAT TTCGCGGAAT AACATCATTT 7450
 GGTGACGAAA TAACTAAGCA CTTGTCTCCT GTTTACTCCC CTGAGCTTGA 7500
 60 GGGGTTAACA TGAAGGTCAT CGATAGCAGG ATAATAATAC AGTAAAACGC 7550
 TAAACCAATA ATCCAAATCC AGCCATCCCA AATTGGTAGT GAATGATTAT 7600
 AAATAACAGC AAACAGTAAT GGGCCAATAA CACCGGTTGC ATTGGTAAGG 7650

CTCACCAATA ATCCCTGTAA AGCACCTTGC TGATGACTCT TTGTTTGGAT 7700
 AGACATCACT CCCTGTAATG CAGGTAAAGC GATCCACCA CCAGCCAATA 7750
 AAATTAAC AGGGAACCTT AACCAACCTT CAGATATAAA CGCTAAAAAG 7800
 5 GCAATGCAC TACTATCTGC AATAAATCCG AGCAGTACTG CCGTTTTC 7850
 GCCCCATTTA GTGGCTATTC TTCTGCCAC AAAGGCTTGG AATACTGAGT 7900
 GTAAAGACC AAGACCCGCT AATGAAAAGC CAACCATCAT GCTATTCCAT 7950
 CCAAAACGAT TTTCGGTAAA TAGCACCCAC ACCGTGCGG GAATTGGCC 8000
 TATCAATTGC GCTGAAAAAT AAATAATCAA CAAAATGGCA TCGTTTAAA 8050
 TAAAGTGATG TATACCGAAT TCAGCTTTTG TTCCCTTTAG TGAGGGTTAA 8100
 10 TTGCGCGCTT GCGTAATCA TGGTCATAGC TGTTCCTGT GTGAAATTGT 8150
 TATCCGCTCA CAATCCACA CAACATACGA GCCGAAGCA TAAAGTGTA 8200
 AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT 8250
 CACTGCCCCG TTTCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA 8300
 ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTCCGC 8350
 15 TTCTCGCTC ACTGACTCGC TCGCTCGGT CGTTCGGCTG CGGCGAGCGG 8400
 TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT 8450
 AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG 8500
 TAAAGAGGCC GCGTTGCTGG CGTTTTCCA TAGGCTCCGC CCCCTGACG 8550
 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA 8600
 20 CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TCGCTCTCC 8650
 TGTTCGACC CTGCGGCTTA CCGGATACCT GTCCGCTTT CTCCCTTCG 8700
 GAAGCGTGGC GCTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG 8750
 TAGTTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC 8800
 CGACCGCTGC GCCTATCCG GTAATATCG TCTTGAGTCC AACCCGGTAA 8850
 25 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA 8900
 GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA 8950
 CCGGTACACT AGAAGGACAG TATTGGTAT CTGCGCTCTG CTGAAGCCAG 9000
 TTACCTTCGG AAAAGAGATT GGTAGCTCTT GATCCGGCAA ACAACACCACC 9050
 CTGGGTAGCG GTGGTTTTT TGTGTGCAAG CAGCAGATTA CGCGCAGAAA 9100
 30 AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC 9150
 AGTGAACGA AAATCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA 9200
 AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT 9250
 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA 9300
 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTATC CATAGTTGCC 9350
 35 TGAATCCCG TCCTGTAGAT AACTACGATA CCGGAGGGCT TACCATCTGG 9400
 CCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT 9450
 TATCAGCAAT AAACAGCCA GCCGAAGGG CCGAGCGCAG AAGTGGTCCT 9500
 GCAACTTTAT CCGCTCCAT CCAGTCTATT AATTGTTGCC GGAAGCTAG 9550
 AGTAAGTAGT TCGCCAGTTA ATAGTTTGGC CAACGTTGTT GCCATTGCTA 9600
 40 CAGGCATCGT GGTGTACGC TCGTCGTTTG GTATGGCTTC ATTACAGCTCC 9650
 GGTTCCTAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAA 9700
 AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTGCAAGT AAGTTGGCCG 9750
 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATT TCTTACTGTC 9800
 ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC 9850
 45 ATTCTGAGAA TAGTGATGC GCGACCGAG TTGCTCTTGC CCGCGCTCAA 9900
 TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAGT GCTCATCATT 9950
 GGAACCGTT CTTCGGGGCG AAACTCTCA AGGATCTTAC CGCTGTTGAG 10000
 ATCCAGTTTC ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT 10050
 50 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC 10100
 GCAAAAAGG GAAATAAGGC GACACGGAAG TGTGAAATC TCATACTCTT 10150
 CCTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG 10200
 GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC 10250
 ACATTTCCCC GAAAAGTGCC AC 10272

55

SEQ ID NO:31 (pTnMod(Oval/ENT tag/Proins/PA) - Chicken)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 60 TTCTTCCCT TCCTTCTCG CCACGTTTCG CCGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200

	CATGTCCAAC	ATTACCGCCA	TGTTGACATT	GATTATTGAC	TAGTTATTAA	250
	TAGTAATCAA	TTACGGGGTC	ATTAGTTCAT	AGCCCATATA	TGGAGTTCCG	300
	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	350
	CCCGCCCAT	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	400
5	GGGACTTTCC	ATTGACGTCA	ATGGGTGGAG	TATTTACGGT	AAACTGCCCCA	450
	CTTGGCAGTA	CATCAAGTGT	ATCATATGCC	AAGTACGCCC	CCTATTGACG	500
	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCCAGTA	CATGACCTTA	550
	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	600
	CATGGTGATG	CGGTTTGGC	AGTACATCAA	TGGGCGTGGA	TAGCGGTTTG	650
10	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
	TTTTGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTCGTA	ACAACTCCGC	750
	CCCATTTGACG	CAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATAA	800
	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTGACC	TCCATAGAAG	ACACGGGGAC	CGATCCAGCC	TCCGCGGCCG	900
15	GGAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
	CCGCCTATAG	ACTCTATAGG	CACACCCCTT	TGGCTCTTAT	GCATGCTATA	1000
	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCC	GCTTCCTTAT	GCTATAGGTG	1050
	ATGGTATAGC	TTAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCATTGG	TGACGATACT	TTCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
20	GCCACAATA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATTT	ATTATTTACA	1250
	AATTCACATA	TACAACAACG	CCGTCCCCCG	TGCCCGCAGT	TTTTATTAAA	1300
	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTC	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
25	CTCCAGCGGC	TCATGGTTCG	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
	CCGACTTAG	GCACAGCACA	ATGCCACCCA	CCACCAAGTGT	GCCGCACAAG	1500
	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
30	GTCTGTTTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCCCTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
35	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATAACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCAT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCCGACTAC	ACGGTCGTTC	TGTTACTCTT	2150
40	TATGAGAAAG	CGTTCCCGCT	TTGAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTGAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
45	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTGTA	AGCGAATGCA	2650
50	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTGATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTCGC	GCATTCTGGC	2900
55	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATATGTA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
60	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250

	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
5	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAACGTATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
10	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCAATGAT	CCCGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
15	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAAA	TTCTCTGTGC	4200
20	ATCTGCCAGG	CCATTAAGTT	ATTCATGGAA	GATCTTTGAG	GAACACTGCA	4250
	AGTTCATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTTA	TAAAGCATTG	4350
	ACACCCATAA	AAAGATAGAT	TTAAATATTC	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACTCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
25	TTATTTCTCC	TATTTTGTCA	AGAAAATAAT	AGGTACGTC	TTGTTCTCAC	4500
	TTATGTCTCTG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
	TCAAATGAAA	CAGACTTCTG	GTCTGTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTAACTAAT	AATTGCTAAT	TATGTTTTC	ATCTCTAAGG	TTCCACATT	4650
	TTTCTGTTTT	CTTAAAGATC	CCATTATCTG	GTTGTAAGTG	AAGCTCAATG	4700
30	GAACATGAGC	AATATTTCCC	AGTCTTCTCT	CCCATCCAAC	AGTCCTGATG	4750
	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAATCTAA	4850
	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACTGTG	GGTGGGTAC	AATTCAGGCT	ATATATTTCC	CAGGGCTCAG	4950
35	CGGATCCATG	GGCTCCATCG	GCGCAGCAAG	CATGGAATTT	TGTTTTGATG	5000
	TATTTCAAGGA	GCTCAAAGTC	CACCATGCCA	ATGAGAACAT	CTTCTACTGC	5050
	CCCATTGCCA	TCATGTCAGC	TCTAGCCATG	GTATACCTGG	GTGCAAAAGA	5100
	CAGCACCAGG	ACACAGATAA	ATAAGGTTGT	TCGCTTTGAT	AAACTTCCAG	5150
	GATTCGGAGA	CAGTATTGAA	GCTCAGTGTG	GCACATCTGT	AAACGTTTAC	5200
40	TCTTCACTTA	GAGACATCCT	CAACCAAAATC	ACCAAAACCA	ATGATGTTTA	5250
	TTGCTTCAGC	CTTGCCAGTA	GACTTTATGC	TGAAGAGAGA	TACCCAATCC	5300
	TGCCAGAATA	CTTGCACTGT	GTGAAGGAAC	TGTATAGAGG	AGGCTTGGAA	5350
	CCTATCAACT	TTCAAACAGC	TGCAGATCAA	GCCAGAGAGC	TCATCAATTC	5400
	CTGGGTAGAA	AGTCAGACAA	ATGGAATTAT	CAGAAATGTC	CTTCAGCCAA	5450
45	GCTCCGTGGA	TTCTCAAAC	GCAATGGTTC	TGGTTAATGC	CATTGTCTTC	5500
	AAAGGACTGT	GGGAGAAAAC	ATTTAAGGAT	GAAGACACAC	AAGCAATGCC	5550
	TTTCAGAGTG	ACTGAGCAAG	AAAGCAAACC	TGTGCAGATG	ATGTACCAGA	5600
	TTGGTTTATT	TAGAGTGGCA	TCAATGGCTT	CTGAGAAAAT	GAAGATCCTG	5650
	GAGCTTCCAT	TTGCCAGTGG	GACAATGAGC	ATGTTGGTGC	TGTTGCCTGA	5700
50	TGAAGTCTCA	GGCCTTGAGC	AGCTTGAGAG	TATAATCAAC	TTTGAAAAAC	5750
	TGACTGAATG	GACCAGTTCT	AATGTTATGG	AAGAGAGGAA	GATCAAAGTG	5800
	TACTTACCTC	GCATGAAGAT	GGAGGAAAAA	TACAACCTCA	CATCTGTCTT	5850
	AATGGCTATG	GGCATTACTG	ACGTGTTTAG	CTCTTCAGCC	AATCTGTCTG	5900
	GCATCTCCTC	AGCAGAGAGC	CTGAAGATAT	CTCAAGCTGT	CCATGCAGCA	5950
55	CATGCAGAAA	TCAATGAAGC	AGGCAGAGAG	GTGGTAGGGT	CAGCAGAGGC	6000
	TGGAGTGGAT	GCTGCAAGCG	TCTCTGAAGA	ATTTAGGGCT	GACCATCCAT	6050
	TCCTCTTCTG	TATCAAGCAC	ATCGCAACCA	ACGCCGTTCT	CTTCTTTGGC	6100
	AGATGTGTTT	CCCCTCCGCG	GCCAGCAGAT	GACGCACCAG	CAGATGACGC	6150
	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	6200
60	CAGATGACGC	AACAACATGT	ATCCTGAAAG	GCTCTGTGG	CTGGATCGGC	6250
	CTGCTGGATG	ACGATGACAA	ATTTGTGAAC	CAACACCTGT	GCGGCTCACA	6300

	CCTGGTGGAA	GCTCTCTACC	TAGTGTGCGG	GGAACGAGGC	TTCTTCTACA	6350
	CACCCAAGAC	CCGCCGGGAG	GCAGAGGACC	TGCAGGTGGG	GCAGGTGGAG	6400
	CTGGGCGGGG	GCCCTGGTGC	AGGCAGCCTG	CAGCCCTTGG	CCCTGGAGGG	6450
	GTCCCTGCAG	AAGCGTGGCA	TTGTGGAACA	ATGCTGTACC	AGCATCTGCT	6500
5	CCCTCTACCA	GCTGGAGAAC	TACTGCAACT	AGGGCGCCTG	GATCCAGATC	6550
	ACTTCTGGCT	AATAAAAAGAT	CAGAGCTCTA	GAGATCTGTG	TGTTGGTTTT	6600
	TTGTGGATCT	GCTGTGCCTT	CTAGTTGCCA	GCCATCTGTT	GTTTGGCCCT	6650
	CCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCAC	TGTCCTTTCC	6700
	TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	GTCATTCTAT	6750
10	TCTGGGGGT	GGGGTGGGGC	AGCACAGCAA	GGGGGAGGAT	TGGGAAGACA	6800
	ATAGCAGGCA	TGCTGGGGAT	GCGGTGGGCT	CTATGGGTAC	CTCTCTCTCT	6850
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCTCT	CTCGAGGGGG	6900
	GGCCCGGTAC	CCAATTCGCC	CTATAGTGAG	TCGTATTACG	CGCGCTCACT	6950
	GGCCGTCGTT	TTACAACGTC	GTGACTGGGA	AAACCCTGGC	GTTACCCAAC	7000
15	TTAATCGCCT	TGCAGCACAT	CCCCCTTTCG	CCAGCTGGCG	TAATAGCGAA	7050
	GAGGCCGCA	CCGATCGCCC	TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	7100
	ATGGAATG	TAAGCGTTAA	TATTTTGTTA	AAATTCGCGT	TAAATTTTTG	7150
	TTAAATCAGC	TCATTTTTTA	ACCAATAGGC	CGAAATCGGC	AAAAATCCCTT	7200
	ATAAATCAAA	AGAATAGACC	GAGATAGGGT	TGAGTGTGT	TCCAGTTTGG	7250
20	AACAAGAGTC	CACTATTAAA	GAACGTGGAC	TCCAACGTCA	AAGGGCGAAA	7300
	AACCGTCTAT	CAGGGCGATG	GCCCACTACT	CCGGGATCAT	ATGACAAGAT	7350
	GTGTATCCAC	CTTAACCTAA	TGATTTTAC	CAAAATCATT	AGGGGATTCA	7400
	TCAGTGCTCA	GGGTCAACGA	GAATTAACAT	TCCGTCAGGA	AAGCTTATGA	7450
	TGATGATGTG	CTTAAAACT	TACTCAATGG	CTGGTTATGC	ATATCGCAAT	7500
25	ACATGCGAAA	AACCTAAAAAG	AGCTTGCCGA	TAAAAAAGGC	CAATTTATTG	7550
	CTATTTACCG	CGGCTTTTTA	TTGAGCTTGA	AAGATAAATA	AAATAGATAG	7600
	GTTTTATTG	AAGCTAAATC	TTCTTTATCG	TAAAAATGC	CCTCTGGGT	7650
	TATCAAGAGG	GTCATTATAT	TTGCGGAAT	AACATCATTT	GGTGACGAAA	7700
	TAACCTAAGCA	CTTGCTCCT	GTTTACTCCC	CTGAGCTTGA	GGGGTTAACA	7750
30	TGAAGGTCAT	CGATAGCAGG	ATAATAATAC	AGTAAACGC	TAAACCAATA	7800
	ATCCAAATCC	AGCCATCCCA	AATTGGTAGT	GAATGATTAT	AAATAACAGC	7850
	AAACAGTAAT	GGGCCAATAA	CACCGGTTGC	ATTGTAAGG	CTCACCATAA	7900
	CCCTCTGTA	AGCACCTTGC	TGATGACTCT	TTGTTGGAT	AGACATCACT	7950
	CCCTGTAATG	CAGGTAAAGC	GATCCACCA	CCAGCCAATA	AAATTAATAA	8000
35	AGGGAAAACT	AACCAACCTT	CAGATATAAA	CGCTAAAAAG	GCAATGCAC	8050
	TACTATCTGC	AATAAATCCG	AGCAGTACTG	CCGTTTTTTC	GCCCCATTTA	8100
	TGGGCTATT	TTCCTGCCAC	AAAGGCTTGG	AATACTGAGT	GTAAAGAGCC	8150
	AAGACCCGCT	AATGAAAAGC	CAACCATCAT	GCTATTCCAT	CCAAAACGAT	8200
	TTTCGGTAAA	TAGCACCCAC	ACCGTTGCGG	GAATTGGCC	TATCAATTGC	8250
40	GCTGAAAAAT	AAATAATCAA	CAAAATGGCA	TCGTTTTAAA	TAAAGTGATG	8300
	TATACCGAAT	TCAGCTTTTG	TTCCCTTTAG	TGAGGGTTAA	TTGCGCGCTT	8350
	GGCGTAATCA	TGGTCATAGC	TGTTTCCTGT	GTGAAATTGT	TATCCGCTCA	8400
	CAATTCCACA	CAACATACGA	GCCGGAAGCA	TAAAGTGTA	AGCCTGGGGT	8450
	GCCTAATGAG	TGAGCTAACT	CACATTAATT	GCGTTGCGCT	CACTGCCCCG	8500
45	TTTCCAGTCG	GGAAACCTGT	CGTGCCAGCT	GCATTAATGA	ATCGGCCAAC	8550
	GCGCGGGGAG	AGGCGGTTTG	CGTATTGGGC	GCTCTTCCGC	TTCTCGCTC	8600
	ACTGACTCG	TGCGCTCGGT	CGTTCGGCTG	CGGCGAGCGG	TATCAGTCA	8650
	CTCAAAGGCG	GTAATACGGT	TATCCACAGA	ATCAGGGGAT	AACGCAGGAA	8700
	AGAACATGTG	AGCAAAAGGC	CAGCAAAAGG	CCAGGAACCG	TAAAAAGGCC	8750
50	GCGTTGCTGG	CGTTTTTCCA	TAGGCTCCGC	CCCCCTGACG	AGCATCACAA	8800
	AAATCGACGC	TCAAGTCAGA	GGTGCGGAAA	CCCCGACAGGA	CTATAAAGAT	8850
	ACCAGGCGTT	TCCCCCTGGA	AGCTCCCTCG	TGCGCTCTCC	TGTTCCGACC	8900
	CTGCCGCTTA	CCGGATACCT	GTCCGCCTTT	CTCCCTTCGG	GAAGCGTGGC	8950
	GCTTTCTCAT	AGCTCACGCT	GTAGGTATCT	CAGTTCGGTG	TAGGTCGTTT	9000
55	GCTCCAAGCT	GGGCTGTGTG	CACGAACCCC	CCGTTACAGC	CGACCGCTGC	9050
	GCTTATCCG	GTAACATCG	TCTTGAGTCC	AACCGGTAA	GACACGACTT	9100
	ATCGCCACTG	GCAGCAGCCA	CTGGTAACAG	GATTAGCAGA	GCGAGGTATG	9150
	TAGGCGGTGC	TACAGAGTTC	TTGAAGTGGT	GGCCTAACTA	CGGCTACACT	9200
	AGAAAGGACAG	TATTTGGTAT	CTGCGCTCTG	CTGAAGCCAG	TTACCTTCGG	9250
60	AAAAAGAGTT	GGTAGCTCTT	GATCCGGCAA	ACAAACCACC	GCTGGTAGCG	9300
	GTGTTTTTTT	TGTTTGCAAG	CAGCAGATTA	CGCGCAGAAA	AAAAGGATCT	9350

CAAGPAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA 9400
 AAACACACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 9450
 CCTAGATCCT TTAAATTA AAATGAAGTT TTAATCAAT CTAAAGTATA 9500
 TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC 9550
 5 TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC TGACTCCCCG 9600
 TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT 9650
 GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT 9700
 AAACCAGCCA GCCGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 9750
 CCGCTCCAT CCAGTCTATT AATTGTTGCC GGAAGCTAG AGTAAGTAGT 9800
 10 TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT 9850
 GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCTAAC 9900
 GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAAA AGCGGTTAGC 9950
 TCCTTCGGTC CTCCGATCGT TGTCAGAAAGT AAGTTGGCCG CAGTGTATC 10000
 ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 10050
 15 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA 10100
 TAGTGTATGC GGCAGCCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA 10150
 TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT 10200
 CTTCCGGGCG AAAACTCTCA AGGATCTTAC CGCTGTGAG ATCCAGTTCG 10250
 ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTTAC 10300
 20 CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAGG 10350
 GAATAGGGC GACACGGAAG TGTGAATAC TCATACTCTT CCTTTTCAA 10400
 TATTAATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT 10450
 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC 10500
 25 GAAAAGTGCC AC 10512

SEQ ID NO:32 (pTnMod(Oval/ENT tag/Proins/PA) - QUAIL)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 30 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 TTTCTTCCCT TCCTTCTCG CCACGTTTCG CCGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCG 300
 35 CGTTACATAA CTTACGTAAT ATGGCCCGCC TGGCTGACCG CCAACGACC 350
 CCCGCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTCCCA 450
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 40 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGCCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGTGTATG CGGTTTGGC AGTACATCAA TGGGCGTGA TAGCGGTTG 650
 ACTCAAGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTG 700
 TTTTGGCACC AAAATCAACG GGAATTTCCA AAATGTCGTA ACAACTCCG 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATA 800
 45 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 CCGCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050
 50 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTAGAGAC 1200
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTACA 1250
 AATTACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTA 1300
 55 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CCGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 CTCAGCGGCG TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
 CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCACAAG 1500
 GCGGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550
 60 CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
 GCAGCTGAGT TGTGTATTTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650

	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTTTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAAAGACT	1850
5	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCATT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
10	TTATGCTATT	GCGAGCTTCA	GTGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	CTACTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2200
	CCAATTCTTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTGAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAAATATG	2350
15	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
20	GAAATTCGAA	CACCCAAACA	ACTTGTAAAT	ATCTATTCTA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
25	AGCTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTCGC	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
30	CCCTCCCCCG	TGCCTTCCCT	GACCCTGGAA	GGTGCCACTC	CCACTGTCTT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
35	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCATTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAACGTATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAAGTA	3550
	TATTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
40	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCGTGAG	ACTGATGAAT	CCCCATATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
45	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCTT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AAGTAGTGGA	TCCCCCGGGG	4050
	AGGTGAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
50	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAAA	TTCTCTGTGC	4200
	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
	CATACCATAA	ACTCATTGGG	AATTGAGTAT	TATTTTGCTT	TGAATGGAGC	4300
	TATGTTTTGC	AGTTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
55	CCATCAAAAAG	ATATATTTAA	ATATTCCAAC	TACAGAAAAG	TTTGTCTGTC	4400
	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTGT	4450
	CCTATTTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTTCTC	ACTTATCTCC	4500
	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAATGA	4550
	AACAGACTTC	TGGTCTGTTA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600
60	ATAATTGCTA	ATTATGTTTT	CCATCTCTAA	GGTCCCCACA	TTTTTCTGTT	4650
	TTAAGATCCC	ATTATCTGGT	TGTAACGTAA	GCTCAATGGA	ACATGAACAG	4700

	TATTTCTCAG	TCTTTTCTCC	AGCAATCCTG	ACGGATTAGA	AGAACTGGCA	4750
	GAAAACACTT	TGTTACCCAG	AATTAAAAAC	TAATATTTGC	TCTCCCTTCA	4800
	ATCCAAAATG	GACCTATTGA	AACTAAAAATC	TGACCCAATC	CCATTAAATT	4850
	ATTTCTATGG	CGTCAAAGGT	CAAACCTTTTG	AAGGGAACCT	GTGGGTGGGT	4900
5	CCCAATTTCAG	GCTATATATT	CCCCAGGGCT	CAGCCAGTGG	ATCCATGGGC	4950
	TCCATCGGTG	CAGCAAGCAT	GGAATTTTGT	TTTGATGTAT	TCAAGGAGCT	5000
	CAAAGTCCAC	CATGCCAATG	ACAACATGCT	CTACTCCCCC	TTTGCCATCT	5050
	TGTCAACTCT	GGCCATGGTC	TTCTAGGTG	CAAAAGACAG	CACCAGGACC	5100
	CAGATAAATA	AGGTTGTTC	CTTTGATAAA	CTTCCAGGAT	TCGGAGACAG	5150
10	TATTGAAGCT	CAGTGTGGCA	CATCTGTAAA	TGTTCACTCT	TCACTTAGAG	5200
	ACATACTCAA	CCAAATCACC	AAACAAAATG	ATGCTTATTC	GTTTCAGCCTT	5250
	GCCAGTAGAC	TTTATGCTCA	AGAGACATAC	ACAGTCGTGC	CGGAATACTT	5300
	GCAATGTGTG	AAGGAACTGT	ATAGAGGAGG	CTTAGAATCC	GTCAACTTTC	5350
	AAACAGCTGC	AGATCAAGCC	AGAGGCCTCA	TCAATGCCTG	GGTAGAAAAGT	5400
15	CAGACAAACG	GAATTATCAG	AAACATCCTT	CAGCCAAGCT	CCGTGGATTG	5450
	TCAAACCTGCA	ATGGTCCTGG	TAAATGCCAT	TGCCTTCAAG	GGACTGTGGG	5500
	AGAAAGCATT	TAAGGCTGAA	GACACGCAAA	CAATACCTTT	CAGAGTGACT	5550
	GAGCAAGAAA	GCAAACCTGT	GCAGATGATG	TACCAGATTG	GTTTCATTTAA	5600
	AGTGGCATCA	ATGGCTTCTG	AGAAAATGAA	GATCCTGGAG	CTTCCATTG	5650
20	CCAGTGGAA	AATGAGCATG	TTGGTGCTGT	TGCCTGATGA	TGTCTCAGGC	5700
	CTTGAGCAGC	TTGAGAGTAT	AATCAGCTTT	GAAAACTGA	CTGAATGGAC	5750
	CAGTTCTAGT	ATTATGGAAG	AGAGGAAGGT	CAAAGTGATC	TTACCTCGCA	5800
	TGAAGATGGA	GGAGAAATAC	AACCTCACAT	CTCTCTTAAT	GGCTATGGGA	5850
	ATTACTGACC	TGTTCAAGTC	TTCAAGCAAT	CTGTCTGGCA	TCTCCTCAGT	5900
25	AGGGAGCCTG	AAGATATCTC	AAGCTGTCCA	TGCAGCACAT	GCAGAAATCA	5950
	ATGAAGCGGG	CAGAGATGTG	GTAGGCTCAG	CAGAGGCTGG	AGTGGATGCT	6000
	ACTGAAGAAT	TTAGGGCTGA	CCATCCATTG	CTCTTCTGTG	TCAAGCACAT	6050
	CGAAACCAAC	GCCATTCTCC	TCTTTGGCAG	ATGTGTTTCT	CCGCGGCCAG	6100
	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	6150
30	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCAACAA	CATGTATCCT	6200
	GAAAGGCTCT	TGTGGCTGGA	TCGGCCTGCT	GGATGACGAT	GACAAATTTG	6250
	TGAACCAACA	CCTGTGCGGC	TCACACCTGG	TGGAAGCTCT	CTACCTAGTG	6300
	TGCGGGGAAC	GAGGCTTCTT	CTACACACCC	AAGACCCGCC	GGGAGGCAGA	6350
	GGACTGTCAG	GTGGGGCAGG	TGGAGCTGGG	CGGGGGCCCT	GGTGCAGGCA	6400
35	GCCTGCAGCC	CTTGGCCCTG	GAGGGGTCCC	TGCAGAAGCG	TGGCATTTGTG	6450
	GAACAATGCT	GTACCAGCAT	CTGCTCCCTC	TACCAGCTGG	AGAACTACTG	6500
	CAACTAGGGC	GCCTGGATCC	AGATCACTTC	TGGCTAATAA	AAGATCAGAG	6550
	CTCTAGAGAT	CTGTGTGTTG	GTTTTTGTG	GATCTGCTGT	GCCTTCTAGT	6600
	TGCCAGCCAT	CTGTTGTTTG	CCCCCCCCC	GTGCCCTTCT	TGACCTGGA	6650
40	AGGTGCCACT	CCCCTGTCC	TTTCCTAATA	AAATGAGGAA	ATTGCATCGC	6700
	ATTGTCTGAG	TAGGTGTCT	TCTATCTG	GGGGTGGGGT	GGGGCAGCAC	6750
	AGCAAGGGGG	AGGATTGGGA	AGACAATAGC	AGGCATGCTG	GGGATGCGGT	6800
	GGGCTCTATG	GGTACCTCTC	TCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTC	6850
	TCTCTCGGTA	CCTCTCTCGA	GGGGGGGCCC	GGTACCCAAT	TCGCCCTATA	6900
45	GTGAGTCGTA	TTACGCGCGC	TCCTGGCCG	TCGTTTAC	ACGTCGTGAC	6950
	TGGGAAAACC	CTGGCGTTAC	CCAACCTAAT	CGCCTTGCG	CACATCCCCC	7000
	TTTCGCCAGC	TGGCGTAATA	GCGAAGAGGC	CCGCACCGAT	CGCCCTTCCC	7050
	AACAGTTGCG	CAGCCTGAAT	GGCGAATGGA	AATTGTAAGC	GTTAATATTT	7100
	TGTTAAATTT	CGCGTTAAAT	TTTTGTAAA	TCAGCTCATT	TTTTAACCAA	7150
50	TAGGCCGAAA	TCGGCAAAAT	CCCTTATAAA	TCAAAAGAAT	AGACCGAGAT	7200
	AGGGTTGAGT	GTTGTTCAG	TTTGAACAA	GAGTCCACTA	TTAAAGAACG	7250
	TGACTCCAA	CGTCAAAGGG	CGAAAAACCG	TCTATCAGGG	CGATGGCCCC	7300
	CTACTCCGGG	ATCATATGAC	AAGATGTGTA	TCCACCTTAA	CTTAATGATT	7350
	TTTACCAAAA	TCATTAGGGG	ATTCATCAGT	GCTCAGGGTC	AACGAGAATT	7400
55	AACATTCGGT	CAGGAAAGCT	TATGATGATG	ATGTGCTTAA	AAACTTACTC	7450
	AATGGCTGGT	TATGCATATC	GCAATACATG	CGAAAAACCT	AAAAGAGCTT	7500
	GCCGATAAAA	AAGGCCAATT	TATTGCTATT	TACCGCGGCT	TTTTATTGAG	7550
	CTTGAAAGAT	AAATAAAATA	GATAGGTTTT	ATTTGAAGCT	AAATCTTCTT	7600
	TATCGTAAAA	AATGCCCTCT	TGGGTATCA	AGAGGGTCAT	TATATTTCGC	7650
60	GGATAACAT	CATTTGGTGA	CGAAATAACT	AAGCACTTGT	CTCCTGTTTA	7700
	CTCCCTGAG	CTTGAGGGGT	TAACATGAAG	GTCATCGATA	GCAGGATAAT	7750

	AATACAGTAA	AACGCTAAAC	CAATAATCCA	AATCCAGCCA	TCCCAAATTG	7800
	GTAGTGAATG	ATTATAAATA	ACAGCAAACA	GTAATGGGCC	AATAACACCG	7850
	GTTGCTATTG	TAAGGCTCAC	CAATAATCCC	TGTAAGCAC	CTTGCTGATG	7900
	ACTCTTTGTT	TGGATAGACA	TCACCTCCCTG	TAATGCAGGT	AAAGCGATCC	7950
5	CACCACCAGC	CAATAAAATT	AAAACAGGGA	AAACTAACCA	ACCTTCAGAT	8000
	ATAAACGCTA	AAAAGGCAAA	TGCACTACTA	TCTGCAATAA	ATCCGAGCAG	8050
	TACTGCCGTT	TTTTCGCCCC	ATTTAGTGGC	TATTCTTCCT	GCCACAAAGG	8100
	CTTGGAATAC	TGAGTGTAAA	AGACCAAGAC	CCGCTAATGA	AAAGCCAACC	8150
	ATCATGCTAT	TCCATCCAAA	ACGATTTTCG	GTAAATAGCA	CCCACACCGT	8200
10	TGCGGGAATT	TGGCCTATCA	ATTGCGCTGA	AAAATAAATA	ATCAACAAAA	8250
	TGGCATCGTT	TTAAATAAAG	TGATGTATAC	CGAATTCAGC	TTTGTTTCCC	8300
	TTTAGTGAGG	GTTAATTGCG	CGCTTGGCGT	AATCATGGTC	ATAGCTGTTT	8350
	CCTGTGTGAA	ATTGTTATCC	GCTCACAATT	CCACACAACA	TACGAGCCGG	8400
	AAGCATAAAG	TGTAAAGCCT	GGGGTGCCCTA	ATGAGTGAGC	TAACCTACAT	8450
15	TAATTGCGTT	GCGCTCACTG	CCCGCTTTC	AGTCGGGAAA	CCTGTCGTGC	8500
	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	GTTTGCGTAT	8550
	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	TCGGTCGTTC	8600
	GGCTCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	ACGGTTATCC	8650
	ACAGAATCAG	GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	AAGGCCAGCA	8700
20	AAAGGCCAGG	AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	TCCATAGGC	8750
	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	GACGCTCAAG	TCAGAGGTGG	8800
	CGAAACCCGA	CAGGACTATA	AAGATACCAG	GCGTTTCCCC	CTGGAAGCTC	8850
	CCTCGTGCGC	TCTCCTGTTT	CGACCCCTGCC	GCTTACCGGA	TACCTGTCCG	8900
	CCTTTCTCCC	TTCGGGAAGC	GTGGCGCTTT	CTCATAGCTC	ACGCTGTAGG	8950
25	TATCTCAGTT	CGGTGTAGGT	CGTTCGCTCC	AAGCTGGGCT	GTGTGCACGA	9000
	ACCCCCCGTT	CAGCCCGACC	GCTGCGCCTT	ATCCGGTAAC	TATCGTCTTG	9050
	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	CACTGGCAGC	AGCCACTGGT	9100
	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	AGTTCTTGAA	9150
	CTGTGGCCCT	AACTACGGCT	ACACTAGAAG	GACAGTATTT	GGTATCTGCG	9200
30	CTCTGCTGAA	GCCAGTTACC	TTCGGAAAAA	GAGTTGGTAG	CTCTTGATCC	9250
	GGCAAACAAA	CCACCGCTGG	TAGCGGTGGT	TTTTTTGTTT	GCAAGCAGCA	9300
	GATTACGCGC	AGAAAAAAAG	GATCTCAAGA	AGATCCTTTG	ATCTTTTCTA	9350
	CGGGGTCTGA	CGCTCAGTGG	AACGAAAACT	CACGTTAAGG	GATTTTGGTC	9400
	ATGAGATTAT	CAAAAAGGAT	CTTCACCTAG	ATCCTTTTAA	ATTAAAAATG	9450
35	AAGTTTAAAA	TCAATCTAAA	GTATATATGA	GTAAACTTGG	TCTGACAGTT	9500
	ACCAATGCTT	AATCAGTGAG	GCACCTATCT	CAGCGATCTG	TCTATTTCTG	9550
	TCATCCATAG	TTGCCTGACT	CCCCGTCGTG	TAGATAACTA	CGATACGGGA	9600
	GGGCTTACCA	TCTGGCCCCA	GTGCTGCAAT	GATACCGCGA	GACCCACGCT	9650
	CACCGGCTCC	AGATTTATCA	GCAATAAACC	AGCCAGCCGG	AAGGGCCGAG	9700
40	CGCAGAAGTG	GTCCTGCAAC	TTTATCCGCC	TCCATCCAGT	CTATTAATTG	9750
	TTGCCGGGAA	GCTAGAGTAA	GTAGTTCGCC	AGTTAATAGT	TTGCGCAACG	9800
	TTGTTGCCAT	TGCTACAGGC	ATCGTGGTGT	CACGCTCGTC	GTTTGGTATG	9850
	GCTTCAATTCA	GCTCCGGTTC	CCAACGATCA	AGGCGAGTTA	CATGATCCCC	9900
	CATGTTGTGC	AAAAAAGCGG	TTAGCTCCTT	CGGTCCTCCG	ATCGTTGTCA	9950
45	GAAGTAAGTT	GGCCGAGTG	TTATCACTCA	TGGTTATGGC	AGCACTGCAT	10000
	AATTCTCTTA	CTGTCAATGC	ATCCGTAAGA	TGCTTTTCTG	TGACTGGTGA	10050
	GTAATCAACC	AAGTCATTCT	GAGAATAGTG	TATGCGGCGA	CCGAGTTGCT	10100
	CTTGCCCGGC	GTCAATACGG	GATAATACCG	CGCCACATAG	CAGAACTTTA	10150
	AAAGTGCTCA	TCATTGGAAA	ACGTTCTTCG	GGGCGAAAAA	TCTCAAGGAT	10200
50	CTTACCGCTG	TTGAGATCCA	GTTTCGATGA	ACCCACTCGT	GCACCCAACT	10250
	GATCTTCAGC	ATCTTTTACT	TTCACCAGCG	TTTCTGGGTG	AGCAAAAAACA	10300
	GGAAGGCAAA	ATGCCGCAAA	AAAGGGAATA	AGGGCGACAC	GGAAATGTTG	10350
	AATACTCATA	CTCTTCCTTT	TTCAATATTA	TTGAAGCATT	TATCAGGGTT	10400
	ATTGTCTCAT	GAGCGGATAC	ATATTTGAAT	GTATTTAGAA	AAATAAACAA	10450
55	ATAGGGGTTT	CGCGCACATT	TCCCCGAAAA	GTGCCAC		10487

SEQ ID NO:33 (conalbumin polyA)

60	tctgcattg	ctgcttcctc	tgcccttcct	cgctactctg	aatgtgggctt	cttcgctact
	gccacagcaa	gaaataaaat	ctcaacatct	aaatgggttt	cctgaggttt	ttcaagagtc
	gttaagcaca	ttccttcccc	agcacccttt	gctgcaggcc	agtgccaggc	accaacttgg

ctactgctgc ccatgagaga aatccagttc aatattttcc aaagcaaaat ggattacata
 tgccctagat cctgattaac aggcgtttgt attatctagt gctttcgctt caccagatt
 atccattgc ctccc

5

SEQ ID NO:34 (exemplary antibody light chain sequence)

1 gagctcgtga tgaccagac tccatcctcc ctgtctgcct ctctgggaga cagagtcacc
 61 atcagttgca gggcaaatca ggacattagc aattatttaa actggtatca gcagaaacca
 121 gatggaactg ttaaaactct gatctactac acatcaagat tacactcagg ggtcccatca
 10 181 aggttcagtg gcagtgggtc tggacagat tattctctca ccattagcaa cctggagcaa
 241 gaagattttg ccacttactt ttgccaacag ggtaatacgc ttccgtggac gtccggtgga
 301 ggcaccaacc tggaaatcaa acgggctgat gctgcaccaa ctgtatccat ctcccacca
 361 tccagtggag agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac
 421 cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgctctg
 15 481 aacagttgga ctgatcagga cagcaagac agcacctaca gcattgagcag caccctcagc
 541 ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca
 601 tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttaa

20

SEQ ID NO:35 (exemplary antibody heavy chain sequence)

1 ctcgagtcag gacctggcct ggtggcgccc tcacagaacc tgtccatcac ttgcaactgc
 61 tctgggtttt cattaaccag ctatggtgta cactgggttc gccagcctcc aggaaagggt
 121 ctggaatggc tgggagtaat atggactggt agaagcacia cttataattc ggctctcatg
 181 tccagactga gcattcagca agacaactcc aagagccaag ttttcttaaa aatgaacagt
 25 241 ctgcaaaactg atgacacagc ctttactac tgtggcagag ggggtctgat tacgtccttt
 301 gctatggact actggggtca aggaacctca gtcaccgtct cctcagccaa aacgaccccc
 361 ccattctgtct atccactggc ccttgatct gctgcccata ctaactccat ggtgacctg
 421 ggatgcctgg tcaagggcta tttccctgag ccagtacagc tgacctggaa ctctggatcc
 481 ctgtccagcg gtgtgcacac cttcccagct gtctgcagc ctgacctcta cactctgagc
 30 541 agctcagtga ctgtcccctc cagcacctgg ccagcagaga ccgtcacctg caacgttgcc
 601 caccgggcca gcagaccaa ggtggacaag aaaattgtgc ccagggttg tactagt

SEQ ID NO:36 (pTnMCS)

35

1 ctgacgcgcc ctgtacggc gcattaagcg cggcgggtgt ggtgggtacg cgcagcgtga
 61 ccgtctacact tgccagcgcc ctacgcgccg ctcttttcgc tttcttcctc tctttctcgc
 121 ccacgttcgc cggcatcaga ttggtattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 40 241 tagttattaa tagtaataa ttacgggggc attagtctat agcccatata tggagtccg
 301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt
 361 gacgtcaata atgacgtatg tccccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggt aaactgcccc cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
 45 601 catggtgatg cggttttggc agtacatcaa tggcggtgga tagcggttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag gtaggcgtgt
 781 acgggtggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg

841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcgggccc
 901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgacctatag
 961 actctatagg cacacccctt tggctcttat gcattgctata ctgttttttg cttggggcct
 1021 atacaccccc gcttctcttat gctataggtg atgggtatagc ttagectata ggtgtggggtt
 1081 attgaccatt attgaccact cccctatttg tgacgatact ttcattact aatccataac
 1141 atgggtctttt gccacaacta tctctatttg ctatatgcc aatctctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtccccattt attatttaca aattcacata
 1261 vacaacaacg ccgtcccccg tgcggcagc ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcgcc tcatggtcgc tcggcagctc cttgtccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg tagggtagtg gtctgaaaat gagcgtggag attgggctcg caccgtgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtatc
 1621 tgataagagt cagaggtaac tcccggtgcg gtgctgttaa cgggtggaggg cagtgtatgc
 1681 tgagcagtag tctgtgtgct gcgcgcgcgc accagacata atagctgaca gactaacaga
 1741 ctgttctctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggtct gccacgcatt acttgactgt aaaactctca ctcttaccga acttggcgct
 1921 aacctgccaa ccaaaagcag aacaaaacat aacatcaaac gaatcgaccg attgttagt
 1981 aatcgtcacc tccacaaga gcgactcgct gtataccgtt ggcagcttag ctttatctgt
 2041 tcgggcaata cgatgcccatt tgtactgtgt gactggtctg atattcgtga gcaaaaacga
 2101 cttatgggtat tgcgagcttc tgcgcacta caccggtcgtt ctgttactct ttatgagaaa
 2161 gcgttcccgct tttcagagca atgttcaaag aaagctcatg accaatctct agccgacctt
 2221 gcgagcattc taccgagtaa caccacacccg ctcatgttca gtgatgctgg ctttaaaagt
 2281 ccattggtata aatccgttga gaagctgggt tggtagtggg taagtctgag aagaggtaaa
 2341 gtacaatatg cagacctagg agcggaacac tggaaaccta tcagcaactt acatgatag
 2401 tcatctagtc actcaaacag tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaattc tattgtataa atctcgctct aaaggccgaa aaaatcagcg ctgcacacgg
 2521 actcattgtc accaccgcgt accataaatc tactcagcgt cggcaaaagg gactgaggtt
 2581 ctacgaacta acttacctgt tgaattcga acacccaaac aacttggtta tatctattc
 2641 aagcgaaatg agattgaaga aaccttccga gacttgaaaa gtcttcgcta cggactagcg
 2701 ctacgcata gccgaacgag cagctcagag cgttttgata tcatgctgct aatgccttg
 2761 ctgtctcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag
 2821 gacttccagg ctacacagc cagaaatcga aacgtactct caacagttcg cttagcgatg
 2881 gaagttttgc ggcattctgg ctacacaata acaagggaag acttactcgt gggtgcaacc
 2941 ctactagctc aaaaatttatt cacacatggt tacgcttttg ggaattatg aggggactgc
 3001 tctagagcga tccgggactc cgggaaaagc gttggtgacc aaaggtgcct ttatcatca
 3061 ctttaaaaat aaaaaacaat tactcagtcg ctgttataag cagcaattaa ttatgatga
 3121 tgctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt
 3181 tgaacattat cttgattata ttattgataa taataaaaac cttatcccta tccaagaagt
 3241 gatgcctatc attgggttga atgaacttga aaaaaattag ccttgaatac attacttgga
 3301 aggttaaacg cattgtcagc aaattgatcc aagagaacca acttaagct tccctgacgg
 3361 aatgttaatt ctggttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc
 3421 attaaagttta ggtggataga catcttgtca tatgatcccg gtaattgtgag ttatgctcact
 3481 cattagggac ccagggcttt acactttatg cttccggctc gtatgttgtg tggaaattgt
 3541 agcggataac aatttcacac aggaacacag tatgacctag attacgccaag gcgcgcaatt
 3601 aacctcact aaagggaaca aaagctggag ctccaccgcg gtggcgggcg ctctagaact
 3661 agtggtatcc ccgggctgca ggaattcgat atcaagctta tcgataccgc tgacctcgag
 3721 gggggggccc gtacccaatt cgccctatag tgagtctgat tacgcgcgct cactggcgct
 3781 cgttttaca cgtcgtgact gggaaaacc tggcggtacc caacttaac gccttgacg
 3841 catccccct ttcgcccagc ggcgtaatag cgaagaggcc cgcaccgatc gcccttccca
 3901 ccagttgcgc agcctgaatg gcgaatggaa attgtaagcg ttaattttt gttaaaattc
 3961 gcgttaaat tttgttaaat cagctcattt ttttaaccaat agggccgaat cggcaaaatc
 4021 ccttataaat caaaagaata gaccgagata ggggttagtg ttgttccagt ttggaaacaag
 4081 agtccactat taaagaacgt ggactccaac gtcaaaggcg gaaaaaccgt ctatcagggc
 4141 gatggcccac tactccggga tcatatgaca agatgtgtat ccaccttaac ttaattgattt
 4201 ttacaaaat cattagggga tctatcagtg ctccagggtca acgagaatta acattccgtc
 4261 aggaagcctt atgatgatga tgtgcttaaa aacttactca atgggtggtt atgcatatcg
 4321 caatacatgc gaaaaaccta aaagagcttg ccgataaaaa agggcaattt attgtattt
 4381 accgcggctt tttattgagc ttgaaagata aataaaatag ataggtttta tttgaagcta
 4441 aatcttcttt atcgtaaaaa atgcccctct ggggttatcaa gagggctcatt atatttcgag
 4501 gaataacatc atttggtagc gaaataacta agcactgtgc tctgtttac tccccgagc
 4561 ttgagggggtt aacatgaagg tcatcgatag caggataata atacagtaaa acgctaaacc
 4621 aataatccaa atccagccat cccaaattgg tagtgaatga ttataaataa cagcaaacag
 4681 taatgggcca ataaccacgg ttgcattggt aaggctcacc aataatccct gtaaagcacc
 4741 ttgctgatga ctctttgttt ggatagacat cactccctgt aatgcaggtt aagcgatccc
 4801 accaccagcc aataaaatta aaacagggaa aactaaccac ccttcagata taaacgctaa
 4861 aaaggcaaat gcactactat ctgcaataaa tccgagcagt actgcccgtt tttcggccat

4921 ttatgggcta ttcttcctgc cacaaaggct tggaaactg agtgtaaaag accaagaccc
 4981 gtaatgaaaa gccaacatc atgctattca tcatcacgat ttctgtaata gccaccaccc
 5041 gtgctggatt ggctatcaat gcgctgaaat aataatcaac aaatggcatc gttaaaataag
 5101 gatgtatac cgatcagctt ttgttccttt tagtgagggg taattgcgcg cttggcgtaa
 5161 catgggcat agctgtttcc tgggtgaaat tggatccgc tcacaattcc acacaacata
 5221 cgagccggaa gcataaagtg taaagcctgg ggtgcctaat gagtgcgcta actcacatta
 5281 attgcgttgc gctcactgcc cgctttccag tcgggaaaacc tgcgtgcca gctgcattaa
 5341 tgaatcgccc aacgcgcggg gagaggcggg ttgcgtattg ggcgctcttc cgcttctctg
 5401 ctactgact cgctgcgcctc ggtcggttcg ctgcgcgcgag cgggtatcagc tcaactcaaag
 5461 gcggtaatac ggttatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa
 5521 ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt ccataggctc
 5581 cgccccctg acgagcatca caaaaatcga cgtcaagtc agaggtggcg aaaccgcaca
 5641 ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgcctc tctgttccg
 5701 accctgcgcg ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct
 5761 catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctggcctgt
 5821 gtgcacgaac ccccggttca gccgcaccgc tgcgccttat ccggttaacta tcgtcttgag
 5881 tccaaccggg taagacacga cttatcgcca ctggcagcag ccactgggta caggattagc
 5941 agagcgaggg atgtaggcgg tgctacagag tcttgaaagt ggtggcctaa ctacggctac
 6001 actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttaacct cggaaaaaga
 6061 gttggtagct cttgatccgg caaacaacc accgctggta cgggtgggtt ttttgtttg
 6121 aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg
 6181 ggtctcgacg ctcatgggaa cgaaaaactca cgttaaggga ttttggctat gagattatca
 6241 aagagatct tcacctagat ccttttaaat taaaaatgaa gttttaaatc aatctaaagt
 6301 atatatgagt aaacttgggt tgacagttac caatgcttaa tcagtgaggc acctatctca
 6361 gcgactctgtc tatttcgttc atccatagtt gcctgactcc cgtcgtgta gataactacg
 6421 ctacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca
 6481 cgggctccag atttatcagc aataaacagg ccagccggaa gggccgagcg cagaagtggg
 6541 cctgcaactt tatccgcctc catccagtct attaatgtt gccgggaagc tagagtaagt
 6601 agttcgccag ttaatatgtt gcgcaacgtt gttgccattg ctacaggcat cgtgggtgca
 6661 cgtcgtcgt ttggtatggc ttcatcagc tccggttccc aacgatcaag gcgagtaca
 6721 tgatccccc tggtgtgcaa aaaagcgggt agctccttcg gtctccgat cgttgtcaga
 6781 agtaagttag ccgcagtggt atcactcatg gttatggcag cactgcataa tctcttact
 6841 gtcattccat ccgtaagatg ctttctgtg actggtgagt actcaacca gtcattctga
 6901 gaattagtga tcggcgacc gagttgtctc tgcccggcgt caatacggga taataccgcg
 6961 ccacatagca gaactttaa agtgctcatc attggaatac gttcttcggg gcgaaaactc
 7021 tcaaggatct taccgctgt gagatccagt tcgatgtaac ccactcgtgc acccaactga
 7081 tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaaat
 7141 gccgcaaaaa aggggaataag ggcgacacgg aaatgttga tactcatact cttcctttt
 7201 caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatg
 7261 atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccac

SEQ ID NO:37 (chicken ovalbumin enhancer)

ccgggctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag
 cttgaactga tacctgattt tcttcaaaact ggggaaacaa cacaatccca caaaacagct
 45 cagagagaaa ccactactga tggctacagc accaagggtat gcaatggcaa tccattcgac
 attcatctgt gacctgagca aaatgattta tctctccatg aatggttgct tcttccctc
 atgaaaaggc aatttccaca ctcaaatat gcaacaaaga caaacagaga acaattaatg
 tgctcttcc taatgtcaaa attgtagtgg caaagaggag aacaaaatct caagttctga
 50 gtaggtttta gtgattggat aagaggcttt gacctgtgag ctcacctgga cttcatatcc
 ttttgataaa aaagtgtttt tataactttc aggtctccga gtctttatc atgagactgt
 tgggttaggg acagaccac aatgaaatgc ctggcatagg aaaggcgagc agagccttag
 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg acaaaaactat ttgtactgct
 ttgcacagct gtgctgggca gggcaatcca ttgccacctc tcccaggtaa ctttccaaact
 55 gcaagaagat tgttgcttac tctctctaga

SEQ ID NO:38 (5' untranslated region)

GTGGATCAACATACAGCTAGAAAGCTGTATTGCCTTTAGCACTCAAGCTCAAAAGACAACCTCAGAGTTCC
ACC

60 SEQ ID NO:39 (putative cap site)

ACATACAGCTAG AAAGCTGTAT TGCCTTTAGC ACTCAAGCTC AAAAGACAAC TCAGAGTTCA

SEQ ID NO:40 (fragment of ovalbumin promoter - chicken)

65 GAGGTCAGAAAT GGTTTCTTTA CTGTTGTCA ATTCTATTAT TTCAATACAG
 AACAAATAGCT TCTATAACTG AAATATATTT GCTATTGTAT ATTATGATTG

TCCCTCGAAC CATGAACACT CCTCCAGCTG AATTTACAAA TTCCTCTGTC
 ATCTGCCAGG CCATTAAGTT ATTCATGGAA GATCTTTGAG GAACACTGCA
 AGTTCATATC ATAAACACAT TTGAAATTGA GTATTGTTTT GCATTGTATG
 5 GAGCTATGTT TTGCTGTATC CTCAGAAAAA AAGTTTGTTA TAAAGCATTC
 ACACCCATAA AAAGATAGAT TTAAATATTC CAGCTATAGG AAAGAAAGTG
 CGTCTGCTCT TCACTCTAGT CTCAGTTGGC TCCTTCACAT GCATGCTTCT
 TTATTCTCC TATTTTGTCAG AAAAATAAT AGGTCACGTC TTGTTCTCAC
 TTATGTCTG CCTAGCATGG CTCAGATGCA CGTTGTAGAT ACAAGAAGGA
 TCAAAATGAAA CAGACTTCTG GTCTGTACT ACAACCATAG TAATAAGCAC
 10 ACTAACTAAT AATTGCTAAT TATGTTTTCC ATCTCTAAGG TTCCCACATT
 TTTCTGTTTT CTTAAAGATC CCATTATCTG GTTGTAACG AAGCTCAATG
 GAACATGAGC AATATTTCCC AGTCTTCTCT CCCATCCAAC AGTCTGTATG
 GATTAGCAGA ACAGGCAGAA AACACATTGT TACCCAGAAT TAAAACTAA
 TATTTGCTCT CCATTCAATC CAAAATGGAC CTATTGAAAC TAAATCTAA
 15 CCCAATCCCA TTAAATGATT TCTATGGCGT CAAAGGTCAA ACTTCTGAAG
 GGAACCTGTG GGTGGGTCAC AATTACGGCT ATATATTCCC CAGGGCTCAG
 C

SEQ ID NO:41 pTnMCS (CMV-CHOVg-ent-ProInsulin-synPA)
 20 1 ctgacgcgcc ctgtagcgcc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgccagcgcc ctagegcccgt ctccttctgc tttcttccct tcttttctcg
 121 ccagcttcgc cggcatcaga ttggtctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataaa ttacggggtc attagttcat agcccatata tggagttccg
 25 301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tgcctattac
 30 601 catggtgatg cggttttggc agtacatcaa tggcggtgga tagcggtttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg gttagcggtg
 781 atgggtggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgtaccagcc tccgcccgcg
 35 901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
 961 actctatagg cacacccctt tggtctctat gcctgctata ctgttttttg cttggggcct
 1021 atacaccccc gcttccctat gctatagggt atggtatagc ttacgctata ggtgtgggtt
 1081 attgaccatt attgaccact cccctatttg tgacgatact ttccattact aatccataac
 1141 ttggtctctt gccacaacta tctctatttg ctatattgca atactctgtc cttcagagac
 40 1201 tgacacggac tctgtatttt tacaggatgg ggtcccatct attatttaca aattcacata
 1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcgcc tcatggctgc tcggcagctc ctgtctcta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 45 1501 gccgtggcgg taggggtatg gtctgaaaat gagcgtggag attgggctcg cagcgtgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtatc
 1621 tgataagagt cagaggtaac tcccgttgcg gtgctgttaa cgggtggaggg cagtgtagtc
 1681 tgagcagtac tctgtgtgc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttctctt ccatgggtct tttctgcagt caccgtcgga ccatgtgca actcgatatt
 50 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggtct gccacgcatt acttgactgt aaaactctca ctcttaccga acttgccgt
 1921 aacctgccaa ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaaga gcgactcgt gtataccgtt ggcagtctag ctttatctgt
 2041 tccggcaata cgtgccccat tgtacttgtt gactggtctg atattcgtga gcaaaaacga
 55 2101 ttatgggtat tgcgagcttc agtcgcacta caccgtcggt ctgttactct ttatgagaaa
 2161 gcgttcccg tttcagagca atgttcaag aaagctcatg accaatttct agccgacctt
 2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgctgg ctttaaagtg
 2281 ccatggtata aatccgttga gaagctgggt tggtagtgg taagtgcagt aagaggaaaa
 2341 gtacaatatg cagacctagg agcggaaaaa tggaaacctc tcagcaactt acatgatag
 60 2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgccaaattc tattgtataa atctcgctct aaaggccgaa aaaatcagcg ctgcacacgg
 2521 ctcatgtgc accacccgct acctaaaac tactcagcgt cggcaaaagg gccatgggtt
 2581 ctgcaacta acttacctgt tgaaattcga acacccaaac aacttgttaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttcga gacttgaaaa gtctgccta cggactaggc
 65 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 2761 ctgcttcaac taacatgttg gcttgccggc gttcatgctc agaaacaagg ttgggacaag

2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggcgtcaacc
 2941 ctactagctc aaaattttat cacacatggt tacgcttttg ggaattatg aggggacgcg
 3001 tctagagcga tccgggatct cgggaaaagc gttggtgacc aaaggtgcct tttatcatca
 5 3061 ctttaaaat aaaaaacaat tactcagtcg ctgttataag cagcaattaa ttatgattga
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatggttgg tctgccttag aaagtattat
 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 3241 gatgcctatc attggttggg atgaacttga aaaaaattag ccttgaatac attactggta
 3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaagct ttcctgacgg
 10 3361 aatgttaatt ctcggtgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc
 3421 attaaagtaa ggtggataga catcttgta tatgatcccg gtaatgtgag ttatgctcact
 3481 cattaggcac cccaggcttt acactttatg ctccgggctc gtatgttgg tggaaattgtg
 3541 agcggataac aatttcacac aggaaacagc tatgaccatg attacgccaa gcgcgcaatt
 3601 aaccctcact aaagggaaca aaagctggag ctccaccgag gtggcggcgg cctctagaact
 15 3661 agtggatccc cgggcatca gattggctat tggccattgc atacgttga tccatcatc
 3721 aatatgtaca tttatattgg ctcatgtcca acattaccgc catgttgaca ttgattattg
 3781 actagttatt aatagtaatc aattacgggg tcattagtgc atagcccata ttgggagttc
 3841 cgcgttacat aacttacggg aaatggcccg cctggctgac cgcccaacga ccccgccca
 3901 ttgacgtcaa taatgacgta tgttcccata gtaacgccaa tagggacttt ccattgacgt
 20 3961 caatgggtgg agtatattacg gtaaacctgc cacttggcag tacatcaagt gtatcatatg
 4021 ccaagtacgc cccctattga cgtcaatgac ggtaaaatggc ccgctgggca ttatgccccg
 4081 tacatgacct tatgggactt tcctacttgg cagtacatct acgtattagt catcgctatt
 4141 accatgggtg tgcggttttg gcagtacatc aatgggctg gatagcgggt tgaactcacgg
 4201 ggatttccaa gtctccaccc cattgacgtc aatgggagtt tgttttggca ccaaaatcaa
 25 4261 cgggactttc caaaatgctg taacaactcc gcccatatga cgcaaatggg cgttaggcgt
 4321 gtacggtggg aggtctatat aagcagagct cgtttagtga accgtcagat cgctgggaga
 4381 cgccatccac gctgttttga cctccataga agacaccggg accgatccag cctccgcggc
 4441 cgggaacggt gcaattggaac gcggattccc cgtgccaaaga gtgacgtaag taccgctat
 4501 agactctata ggcaaccccc tttggctctt atgcatgcta tactgttttt ggttggggc
 30 4561 ctatacacc cgccttcctt atgctatagg tgatggtata gcttagccta taggtgtggg
 4621 ttattgacca ttattgacca ctcccctatt ggtgacgata ctttccatta ctaatccata
 4681 acatggctct ttgccacaac tatctctatt ggctatatgc caatactctg tccctcagag
 4741 actgacacgg actctgtatt ttacaggat ggggtcccat ttattattta caaattcaca
 4801 tatacaacaa cgccgtcccc cgtgccccga gtttttatta aacatagcgt gggatctcca
 35 4861 cgcaaatctc ggttagcgtg tccggacatg ggctcttctc cgttagcggc ggagcttcca
 4921 catccgagcc ctggctccat gcctccagcg gctcatggtc gctcggcagc tccttgcctc
 4981 taacagtggg ggccagactt aggcacagca caatgccac caccaccagt gtgcgcgaca
 5041 aggcgtggc ggtagggtat gtgtctgaaa atgagcgtgg agattgggt cgacggctg
 40 5101 acgcagatgg aagacttaag gcagcggcag aagaagatgc aggcagctga gttgtgtat
 5161 tctgataaga gtcagaggta actcccgttg cgtgtctgtt aacggtggag ggcagtgtag
 5221 tctgagcagt actcgttgcg gccgcgcgcg ccaccagaca taatagctga cagactaaca
 5281 cgtgttctct ttccatgggt cttttctgca gtcaccgtcg ggtatccatg gctccatcgg
 5341 cgcagcaagc atggaatttt gttttgatgt attcaaggag ctcaaaagtc accatgccaa
 5401 tgagaacatc ttctactgcc ccattgccat catgtcagct ctagccatgg tatacctggg
 45 5461 tgcaaaagac agcaccagga cacagataaa taaggttgtt cgcttgata aactccagg
 5521 attcggagac agtattgaag ctcatgttgg cacatctgta aacgttccat cttcacttag
 5581 agacatctcc aaccaatca ccaaaccaa tgatgtttat tctgtcagcc ttgccagtag
 5641 actttatgct gaagagagat acccaatcct gccagaatac ttgagtggtg tgaaggaaat
 50 5701 gtatagagga ggcttggaa ctatcaactt tcaaacagct gcagatcaag ccagagagct
 5761 catcaattcc tgggtagaaa gtcagacaaa tgggaattatc agaaatgtcc ttccagccaag
 5821 ctccgtggat tctcaactg caatgggtct ggttaatgcc attgtcttca aaggactgtg
 5881 ggagaaaaca ttttaaggat aagacacaca agcaatgcct ttcagagtga ctgagcaaga
 5941 aagcaaacct gtgcagatga tgtaccagat tgggtttatt agagtggcat caatggcttc
 55 6001 tgagaaaatg aagatcctgg agcttccatt tgccagtggg acaatgagca tgttgggtg
 6061 gttgcctgat gaagtctcag gccttgagca gcttgagagt ataatacaact ttgaaaaact
 6121 gactgaatgg accagttcta atgttatgga agagagggaag atcaaaagtgt acttacctcg
 6181 catgaagatg gaggaaaaaa acaacctcac atctgtctta atggctatgg gcattactga
 6241 cgtgtttagc tcttcagcca atctgtctgg catctcctca gcagagagcc tgaagatatc
 60 6301 tcaagctgtc catgcagcac atgcagaaat caatgaagca ggcagagagg tggtagggtc
 6361 agcagaggct ggagtggatg ctgcaagcgt ctctgaagaa tttagggctg accatccatt
 6421 cctcttctgt atcaagcaca tcgcaaccaa cgccgttctc ttcttggca gatgtgttcc
 6481 ccgcccagc cagatgacgc accagcagat gacgcaccag cagatgacgc accagcagat
 6541 gacgcaccag cagatgacgc accagcagat gacgcaccaa catgtatcct gaaaggctct
 6601 tgtggctgga tcggcctgct ggatgacgat gacaaaattg tgaaccaaca cctgtgcggc
 65 6661 tcacacctgg tggaaagctc ctacctagtg tgcggggaac gaggttctct ctacacacc
 6721 aagaccgccc gggaggcaga ggacctgcag gtggggcagg tggagctggg cgggggccc
 6781 ggtgcaggca gcctgcagcc cttggccctg gaggggtccc tgcagaagcg tggcatgtg
 6841 gaacaatgct gtaccagcat ctgctccctc taccagctgg agaactactg caactagggc

6901 gcctaaaggg cgaattatcg cggccgctct agaccaggcg cctggatcca gatcacttct
 6961 ggctaataaa agatcagagc tctagagatc tgtgtgttgg tttttgtgg atctgctgtg
 7021 ccttctagtt gccagccatc tgttgtttgc cctcccccgc tgccttctt gacctggaa
 7081 ggtgccactc ccactgtcct ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt
 7141 aggtgtcatt ctattctggg ggggtgggtg gggcagcaca gcaaggggga ggattgggaa
 7201 gacaatagca ggcattgctg ggatgctgtg ggtcttatgg gtacctctct ctctctctct
 7261 ctctctctct ctctctctct ctctcggtag ctctctcgag gggggggccc gtacccaatt
 7321 cgccctatag tgagtctgat tacgcgcgt cactggccgt cgttttacia ctcctgtgact
 7381 gggaaaaccc tggcgttacc caacttaatc gccttcgagc acatccccct ttgcgcagct
 7441 ggcgtaatag cgaagaggcc cgcaccgatc gcccttccca acagttgctg agcctgaatg
 7501 gcgaatggaa attgtaagcg ttaatatatt gttaaaattc gcgttaaat tttgttaaat
 7561 cagctcattt ttaaccaat aggccgaaat cggcaaaatc ccttataaat caaaagaaata
 7621 gaccgagata ggggtgagtg ttgttccagt ttggaacaag agtccactat taaagaacgt
 7681 ggactccaac gtcaagggc gaaaaacgt ctatcagggc gatggccac tactccggga
 7741 tcatacgaca agatgtgtat ccaccttaac ttaatgattt ttacaaaat cattagggga
 7801 ttcatcagtg ctcagggtca acgagaatta acattccgtc aggaagcgtt atgatgatga
 7861 tgtgtctaaa aacttactca atggctgggt atgcataatg caatacatgc gaaaaaccta
 7921 aaagagcttg ccgataaaaa aggcccaatt attgctattt accgcggctt tttattgagc
 7981 ttgaaagata aataaaatag ataggtttta ttgaaagcta aatcttcttt atctgtaaaaa
 8041 atgcctctct gggttatcaa gagggtcatt atatttcgag gaataacatc atttgggtgac
 8101 gaaataacta agcacttgct tcctgtttac tcccctgagc ttgaggggtt aacatgaagg
 8161 tcactcgatg caggataata atacagtaaa acgctaaacc aataatccaa atccagccat
 8221 cccaaattgg tagtgaatga ttataataaa cagcaaacag taatggggca ataacaccgg
 8281 ttgcattggt aaggctcacc aataatccct gtaaaagcacc ttgctgatga ctcttctgtt
 8341 ggatagacat cactccctgt aatgcaggta aagcgatccc accaccagcc caataaaatta
 8401 aaacagggaa aactaaccaa ccttcagata taaacgctaa aaaggcaaat gcactactat
 8461 ctgcaataaaa tccgagcagt actgcccgtt ttccgcccac ttagtggcta ttcttctctg
 8521 cacaaggctt tggaaactg agtgtaaaag accaagacc gtatgaaaa gccaaccatc
 8581 atgctattca tcactcagat ttctgttaata gcaccacacc gtgctggatt ggctatcaat
 8641 gcgttgaaat aataatcaac aaatggcatc gttataaag tgatgtatag cgtacagctt
 8701 ttgttccctt tagtgagggt taattgctgc cttggcgtaa tcatggctat agctgtttcc
 8761 tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg
 8821 taaagcctgg ggtgcctaata gtagtgagta actcacatta atgctgttgc gctcactgcc
 8881 cgctttccag tcgggaaacc tgtcgtgcca gctgcattaa tgaatcgcc aacgcgcggg
 8941 gagaggcgtt ttgcgtattg ggcgctcttc cgcttctctg ctcactgact cgtcgcctg
 9001 ggtcgttcgg ctgcggcgag cgggtatcag tcactcaaag gcggtaatat ggttatccac
 9061 agaatacagg gataacgcag gaaagaacat gtgagcaaaa gggccagcaa aggccaggaa
 9121 ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca
 9181 caaaaatcga cgctcaagtc agagggtggcg aaaccgcaga ggaactataa gataccaggc
 9241 gtttccccct ggaagctccc tctgctgcgc tcctgttccg accctgccgc ttaccggata
 9301 cctgtccgcc ttttccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta
 9361 tctcagttcg gtgtaggtcg ttctctccaa gctgggtgtg gtgcacgaac ccccccttca
 9421 gcccagaccg tgcgccttat ccggtaaacta tctgtttgag tccaaccccg taagacacga
 9481 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg
 9541 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaaggc cagtatttgg
 9601 tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggttagct cttgatccgg
 9661 caaacaaccc accgctggta gcggtgggtt ttttgtttgc aagcagcaga ttacgcgcag
 9721 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggcttgacg ctcagtggaa
 9781 cgaaaactca cgtaaaggga ttttgggtcat gagattatca aaaaggatct tcacctagat
 9841 ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttgggtc
 9901 tgacagttac caatgcttaa tcagtggagg acctatctca gcgatctgtc tatttcgctc
 9961 atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc
 10021 tggccccagt gctgcaatga tacccgcgaga cccacgctca ccggtccag atttatcagc
 10081 aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc
 10141 catccagttc attaatgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt
 10201 gcgcaacggt gttgccattg ctacaggcat cgtgggtgta cgctcgtcgt ttggtatggc
 10261 ttcatcagc tccgggtccc aacgatcaag gcgagttaca tgatccccca tgtgtgcaa
 10321 aaaagcgggt agctccttcg gtccctcgat cgtgtcaga agtaagtgg ccgagtggt
 10381 atcactcatg gttatggcag cactgcataa ttctcttact gtcattgcat ccgtaagatg
 10441 cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtga tgcggcgacc
 10501 gagggtgctt tgcggcgct caatacggga taataccgag ccacatagca gaactttaa
 10561 agtgctcacc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt
 10621 gagatccagt tcgatgtaac cactcgtgc acccaactga tcttcagcat ctttacttt
 10681 caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaaataag
 10741 ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta
 10801 tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaat
 10861 aggggttccg cgcacatttc cccgaaaagt gccac

SEQ ID NO:42 (pTnMOD (CMV-CHOVg-ent-ProInsulin-synPA))

1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtgggtacg cgcagcgtga
5 61 cgcctacact tgcacgcgcc ctacgcgccg ctcccttcgc tttcttccct tccctttctcg
121 ccacgttctcg cggcatcaga ttggtatttg gccatttgcac acgttgtatc catatcataa
181 tatgtacatt tatatttgct catgtccaac attaccgcca tgttgacatt gattattgac
241 tagttattaa tagtaataa ttacggggtc attagtcat agcccatata tggagtccg
301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt
10 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc actgacgtca
421 atgggtggag tatttacggg aaactgcca cttggcagta catcaagtgt atcatgtcc
481 aagtacggcc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
541 catgacctta tgggactttc ctacttgga gtacatctac gtattagtca tcgctattac
601 catggtgatg cggttttggc agtacatcaa tggcggtgga tagcggtttg actcacgggg
661 atttccaagt ctccacccca ttgacgtcaa tgggagtgtg ttttggcacc aaatcaacg
15 721 ggactttcca aaatgtcgta acaactccg cccattgacg caaatggggc gtaggcgtgt
781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
841 ccattccacg tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcggcgg
901 ggaacggtgc attggaacgc ggattccccc tgccaagagt gacgtaagta ccgcctatag
961 actctatagg cacacccctt tggctcttat gcattgctata ctgtttttg cttggggcct
20 1021 atacaccccc gcttctctat gctatagggt atggtatagc tttagcctata ggtgtgggtt
1081 attgaccatt attgaccact cccctatttg tgacgatact ttccattact aatccataac
1141 atggctcttt gccacaacta tctctatttg ctatatgcca atactctgtc cttcagagac
1201 tgacacggac tctgtatttt tacaggatgg ggtccatttt attatttaca aattcacata
25 1261 tacaacaacg ccgtcccccg tgcgcgcagt ttttattaaa catagcgtgg gatctccacg
1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggggc agcttccaca
1381 tccgagccct ggtcccatgc ctccagcggc tcatggtcgc tcggcagctc ctgtgctcta
1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
1501 gccgtggcgg taggggtatg gtctgaaaat gagcgtggag attgggctcg cacggtgac
1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtatc
30 1621 tgataagagt cagaggtaac tccggttcg gtgctgttaa cgggtggagg caggtgtatc
1681 tgagcagtag tctgtgtcgc cgcgcgcgcc accagacata atagctgaca gactaacaga
1741 ctgttctctt ccatgggtgt tttctgagt caccgtcgga ccatgtgtga acttgatatt
1801 ttacatgatt ctctttacca attctgcccc gaattacact taaaacgact caacagctta
35 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggcgt
1921 aacctgcaa ccaaacgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
1981 aatcgtcacc tccacaaaga gcgactcgt gtataccgtt ggcagtctag ctttatctgt
2041 tggggcaata cgtgcccatt tgaactgtt gactggtctg atattcgtga gcaaaaacga
2101 cttatggtat tgcgagcttc agtcgcacta caggtctgt ctgttactct ttatgagaaa
40 2161 gcgttcccg tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgttg ctttaagtg
2281 ccatggtata aatccgttga gaagctgggt tggtagtgg taagtgcagt aagaggaaaa
2341 gtacaatatg cagacctagg agcggaaaac tggaaaccta tcagcaactt acatgatag
2401 tcatctagtc actcaaaagc tttaggctat aagaggctga ctaaaagcaa tccaatctca
45 2461 tgccaaattc tattgtataa atctcgtctt aaaggcga aaatcagcg ctgcacacgg
2521 actcattgtc accacccgct acctaaaaat tactcagcgt cggcaaaagg gccatgggtt
2581 ctagcaacta acttacctgt tgaatttcca acacccaaac aacttgttaa tatctatcg
2641 aagcgaatgc agattgaaga aaccttccga gacttgaaga gtcctgccta cggactaggc
2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
50 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgtc agaaaacagg ttgggacaag
2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggcgtcaacc
2941 ctactagctc aaaatttatt cacacatggg tacgttttgg ggaaattatg ataagtatc
3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg
55 3061 gatctgctgt gccttctagt tgcagccat ctgttgtttg cccctcccc gtgccttctt
3121 tgaccctgga aggtgccact cccactgtcc tttcttaata aaataggaa attgcatcg
3181 attgtctgag taggtgtcat tctattcttg ggggtggggg ggggcagcac agcaaggggg
3241 aggattggga agacaatagc aggcattgtg gggatgcggg gggctctatg ggtacctctc
3301 tctctctctc tctctctctc tctctctctc tctctcgta cctctctctc tctctctctc
60 3361 tctctctctc tctctctctc tgggtaccag gtgctgaaga attgaccggg tgaccaagg
3421 tgctttttat catcacttta aaaaataaaa acaattactc agtgctgtgt ataagcagca
3481 attaatatg attgatgctt acatcacaa aaaaactgat ttaacaaatg gttggtctgc
3541 cttagaaagt atatttgaa attatcttga ttatattatt gataataata aaaccttat
3601 cctatccaa gaagtgatgc ctatcattgg ttggaatgaa cttgaaaaaa attagccttg
65 3661 aatacattac tggtaaggta aacgccattg tcagcaaatg gatccaagag aaccaactta
3721 aagctttcct gacggaatgt taattctcgt tgaccctgag cactgatgaa tcccctaagt
3781 attttggtaa aaatcattaa gtttaagggtg atacacatct tgtcatatga tcccggtaat
3841 gtgagtttagc tcactcatta ggcacccag gctttacact ttatgcttcc ggctcgtatg

3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac
 3961 gccaagcgcg caattaaccc tcaactaaagg gaacaaaagc tggagctcca ccgcggtggc
 4021 ggcggtctta gaactagtgg atcccccggg catcagattg gctattggcc attgcatacg
 4081 ttgtatccat atcataatat gtacattttat attggctcat gtcccaacatt accgcatagt
 4141 tgacattgat tattgactag ttattaatag taatcaatta cgggggtcatt agttcatagc
 4201 ccatatatgg agttccgctg tacataaactt acggtaaatg gcccgccctgg ctgaccgccc
 4261 aacgaccccc gccattgac gtcaataatg acgtatgttc ccatagtaac gccaataggg
 4321 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgccactt gccagtagat
 4381 caagtgtatc atatgccaa gacgccccct attgacgtca atgacggtaa atggcccgcc
 4441 tggcattatg cccagtacat gaccttatgg gactttctta ctggcagta catctacgta
 4501 ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag
 4561 cggtttgact cacggggatt tccaagtctc caccctattg acgtcaatgg gagtttggtt
 4621 tggcaccaaa atcaacggga ctttccaaaa tgcgttaaca actccggccc attgacgcaa
 4681 atggcggtga ggcgtgtacg gtgggaggtc tatataagca gagctcgttt agtgaaccgt
 4741 cagatcgctt ggagacgcca tccacgctgt tttgacctcc atagaagaca ccgggaccca
 4801 tccagcctcc gcggccggga acggtgcatt ggaacgcgga tcccccgctc caagagtac
 4861 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg
 4921 tttttggctt ggggcctata ccccccgct tccttatgct ataggtgatg gtatagctta
 4981 gcctataggt gtgggttatt gaccattatt gaccactccc ctattgtgta cgatactttc
 5041 cactactaat ccataacatg gctctttgct acaactatct ctattgggta tatggcaata
 5101 ctctgtcctt cagagactga caccgactct gtatttttac aggatggggg cccatttatt
 5161 atttacaat tcacatatac aacaacgccc tcccccgctc ccgagttttt tattaacat
 5221 agcgtgggac ctccacgca atctcggtta cgtgttccgg acatggggct tctccggta
 5281 gcggcgagc ttccacatcc gagccctggt cccatgcctc cagcggtcca tggctgctcg
 5341 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcaaatg cccaccacca
 5401 ccagtgtgct gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag ctggagatt
 5461 gggctcgcac ggtgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca
 5521 gctgagttgt tgtattctga taagagtcag aggttaactcc cgttgcggtg ctgttaacgg
 5581 tggaggcgag tgtagtctga gcagtactcg ttgctgccgc gcgcgcaccc agacataata
 5641 gctgacgac taacagactg ttcccttcca tgggtctttt ctgcagtac ccgtcggtatc
 5701 catgggctcc atcggcgag caagcatgga attttgtttt gatgtattca agggagctcaa
 5761 agtccaccat gccaatgaga acatcttcta ctgccccatt gccatcatgt cagctctagc
 5821 catgggtatac ctgggtgcaa aagacagcac caggacacag ataaataaagg ttggtcgctt
 5881 tgataaactt ccaggatcgc gagacagtat tgaagctcag tgtggcacat ctgtaaacgt
 5941 tcactcttca cttagagaca tcttcaacca aatcaccaaa ccaaatgatg tttattcggt
 6001 cagccttgcc agtagacttt atgctgaaga gagataccca atcctgccag aatacttga
 6061 gtgtgtgaag gaactgtata gaggaggctt ggaacctatc aactttcaaa cagctgcaga
 6121 tcaagccaga gacgtcatca attcctgggt agaaagtcag acaaatggaa ttatcagaaa
 6181 tgtccttcag ccaagctccg tggattctca aactgcaatg gttctggtta atgccattgt
 6241 cttcaaagga ctgtgggaga aaacatttaa ggtatgaagc acacaagcaa tgcctttcag
 6301 agtgactgag caagaaagca aacctgtgca gatgatgtac cagattggtt tatttagagt
 6361 ggcacatcat gctcttgaga aaatgaagat cctggagctt ccatttgcca gtgggacaat
 6421 gagcatgttg gtgctgtgac ctgatgaagt ctacggcctt gagcagcttg agagtataat
 6481 caactttgaa aaactgactg aatggaccag ttctaattgt atggaagaga ggaagatcaa
 6541 agtgacttta cctcgcatga agatggagga aaaatacaac ctacatctct tcttaatggc
 6601 tatgggcatt actgacgtgt ttagctcttc agccaatctg tctggcagc cctcagcaga
 6661 gagcctgaag atactctcaag ctgtccatgc agcacatgca gaaatcaatg aagcaggcag
 6721 agaggtggta gggtcagcag aggcgtggag ggtatgctga agcgtctctg aagaatttag
 6781 ggcagatgt gtttcccgcg gccagcagat gacgcaccag cagatgacgc accagcagat
 6841 tggcagatgt gtttcccgcg gccagcagat gacgcaccag cagatgacgc aacaacatgt
 6901 gacgcaccag cagatgacgc accagcagat gacgcaccag cagatgacgc aacaacatgt
 6961 atcctgaaag gctcttgggt ctggatcggc ctgctggatg acgatgacaa atttgtgaac
 7021 caacacctgt gcggctcaca cctgggtgaa gctctctacc tagtgtgcgg ggaacgaggg
 7081 ttcttctaca caccgaagac ccgcccggag gcagaggacc tgcaggtggg gcaggtggag
 7141 ctggcggggg gccctgtgtc aggcagcctg cagcccttgg ccctggaggg gtccctgcag
 7201 aagcgtggca ttgtggaaca atgctgtacc agcatctgct ccctctacca gctggagaac
 7261 tactgcaact agggcgcccta aaggcgcaat tatcgcgccc gctctagacc aggcgctgg
 7321 atccagatca cttctggcta ataaaagatc agagctctag agatctgtgt gttggtttt
 7381 tgtggatctg ctgtgccttc tagttgccag ccactctgtt tttgcccctc ccccgctgct
 7441 tcttgacccc tggaaagtg cactccact gtcccttctt aataaaatga ggaaattgca
 7501 tgcattgtc tgagttagtg tcattctatt ctgggggggt ggggtgggga gcacagcaag
 7561 ggggaggatt ggaagacaa tagcaggcat gctggggatg cgggtgggctc tatgggtacc
 7621 tctctctctc tctctctctc tctctctctc ggtacctctc ctcgaggggg
 7681 ggcgggtac ccaattgcc ctatagttag tctattacg cgcgtcact ggcgctcgtt
 7741 ttacaacgct gtgactggga aaacctggc gttacccaac ttaatcgctc tgcagcacat
 7801 ccccttctgc ccagctggcg taatagcgaa gaggcccgca ccgacgccc tcccaacag
 7861 ttgcgcagcc tgaatggcga atggaaattg taagcgttaa tattttgtta aaattcgct
 7921 taaatttttg ttaaatcagc tcatttttta accaataggc cgaatcggc aaaatccct

7981 ataaatcaaa agaataagacc gagatagggt tgagtgttgt tccagtttgg aacaagagtc
 8041 cactattaaa gaacgtggac tccaacgtca aagggcgaaa aaccgtctat cagggcgatg
 8101 gccactact ccgggatcat atgacaagat gtgtatccac cttacttaa tgatttttac
 8161 caaaatcatt aggggatcca tcagtgtcca gggccaacga gaattaacat tccgtcagga
 8221 aagcttatga tgatgatgtg cttaaaaact tactcaatgg ctggttatgc atatcgcaat
 8281 acatgcgaaa aacctaaaag agcttgccga taaaaaggc caattttattg ctattttaccg
 8341 cggcttttta ttgagcttga aagataaata aaatagatag gttttatttg aagctaaatc
 8401 ttcttttatcg taaaaaatgc cctcttgggt tatcaagagg gtcattatat ttcgcggaat
 8461 aacatcattt ggtgacgaaa taactaagca cttgtctcct gtttactccc ctgagcttga
 8521 ggggttaaca tgaaggatcat cgatagcagg ataataatac agtaaaacgc taaaccaata
 8581 atccaaatcc agccatccca aattggtagt gaatgattat aaataacagc aaacagtaat
 8641 gggccaataa caccggttgc attggttaagg ctcaccaata atccctgtaa agcaccttgc
 8701 tgatgactct ttgtttggat agacatcact ccctgtaatg caggtaaaag gatccaccca
 8761 ccagccaata aaattaaaac agggaaaact aaccaacctt cagatatataa cgctaaaaag
 8821 gcaaatgcac tactatctgc aataaatccg agcagtactg ccgttttttc gccattttag
 8881 tggctattct tcctgccaca aaggcttggg atactgagtg taaaagacca agaccgttaa
 8941 tgaaaagcca accatcatgc tattcatcat cagcatctct gtaatagcac cacaccgtgc
 9001 tggattggct atcaatgcgc tgaaaataata atcaacaaat ggcacgttta aataagtgat
 9061 gtataccgat cagcttttgc tccctttagt gagggttaat tgcgcgcttg cgttaatcat
 9121 ggtcatagct gtttctgtg tgaaattgtt atccgctcac aattccacac aacatacgag
 9181 ccggaagcat aaagtgtaaa gcctgggggt cctaagtagt gagctaaact acattaatgt
 9241 cgttgcgctc actgccgctc ttccagtcgg gaaacctgtc gtgcccagtg cattaatgaa
 9301 tccgccaacg cgcggggaga ggcggtttgc gtattggcgc ctcttcgcgt tcctcgctca
 9361 ctgactcgct gcgctcggtc gttcggctgc ggcgagcggc atcagctcac tcaaggcggc
 9421 taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc
 9481 agcaaaaggc caggaaacgtg aaaaaggccg cgttgctggc gtttttccat aggtccgcgc
 9541 cccctgacga gcatacacia aatcgacgct caagtcagag gtggcgaaac ccgacaggac
 9601 tataaagata ccaggcggtt ccccttgga gctccctcgt gcgctctctt gttccgaccc
 9661 tgccgcttac cggatacctg tccgcttttc tcccttcggg aagcgtggcg ctttctcata
 9721 gctcagctg taggtatctc agttcggtgt aggtcggtcg ctccaagctg ggctgtgtgc
 9781 acgaaccccc cgttcagccc gaccgctcgc cttatccgg taactatcgt ctgagtcaca
 9841 acccggttaag acacgactta tcgccactgg cagcagccac tggtaaacagg attagcagag
 9901 cgaggtatgt aggcgggtgt acagatttct tgaagtggtg gcctaactac ggctacacta
 9961 gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagtgt
 10021 gtagctcttg atccggcaaa caaacaccg ctggtagcgg tggttttttt gtttgcaagc
 10081 agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctcggggt
 10141 ctgacgctca gtggaacgaa aactcacgtt aagggaattt ggtcatgaga ttatcaaaaa
 10201 ggatcttcac ctgactcctt ttaaaataaa aatgaagttt taaatcaatc taaagtatat
 10261 atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga
 10321 tctgtctatt tcggtcatcc atagttgctt gactccccgt cgtgtagata actacgatac
 10381 gggaggggtt accatctggc ccagtgctg caatgatacc gcgagaccca cgctcacccg
 10441 ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgacga agtggctcgt
 10501 caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtattg
 10561 cgccagttaa tagtttgccg aacgttggtg ccattgctac aggcacgtgt gtgtcacgct
 10621 cgctggttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat
 10681 ccccatgtt gtgcaaaaaa gcgggttagct ccttcgggtc tccgactggt gtcagaagta
 10741 agttggcgc agtggtatca ctcatggtta tggcagcact gcataattct cttactgtca
 10801 tgccatccgt aagatgcttt tctgtgactg gtgagtaact aaccaagtca ttctgagaat
 10861 agtggtatgc gcgaccgagt tgctcttgcc cggcgctcaat acgggataat accgcgccac
 10921 atagcagaac tttaaaagt ctcactcatt gaaaacgttc ttcggggcga aaactctcaa
 10981 ggatcttacc gctgttgaga tccagttcga tgaacccac tctgtgaccc aactgatctt
 11041 cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacagggaag caaaatgcgg
 11101 caaaaaaggg aataaaggcg acacggaaat gttgaatact catactcttc ctttttcaat
 11161 attattgaag catatatcag ggttatgtc tcatgagcgg atacatattt gaatgtattt
 11221 agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcga c

SEQ ID NO:43 (pTnMOD(Chicken OVep+OVg'+ENT+proins+syn polyA))

60
 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgccagcggc ctgacgcccc ctcctttcgc tttcttccct tcctttctcg
 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 65
 241 tagttattaa tagtaataa ttacggggc attagttcat agcccatata tggagtcccg
 301 cgttacataa cttacggtaa atggcccgcc tggctgacgg cccaacgacc cccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca

421 atgggtggag tatttacggt aaactgccta ctggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttgga gtacatctac gtattagtca tcgctattac
 601 catgggtgat cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
 5 atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 661 ggaetttcca aatgtctgta acaactccgc cccattgacg caaatgggctg tagggcgtgt
 721 acgggtggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tcgcggcgccg
 901 ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgctatag
 10 961 actctatagg cacacccctt tggctcttat gcatgctata ctgttttttg cttggggcct
 1021 atacaccccc gcttccttat gctatagggt atggtatagc ttagcctata ggtgtggggt
 1081 attgaccatt attgaccact cccctatttg tgacgatact ttccattact aatccataac
 1141 atggctcttt gccacaacta tctctatttg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtccccatt attatttaca aattccacata
 15 1261 tacaacaacg ccgtcccccg tgcccgagcgt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcggc tcatggctcg tcggcagctc cttgctccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg tagggtagtg gtctgaaaat gagcgtggag attgggctgc accggctgac
 20 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
 1621 tgataagagt cagaggtaac tcccggttgc gtgctgttaa cgggtggaggg cagtgtagtc
 1681 tgagcagtag tctgtgtctg cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcagatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 25 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt
 1921 aacctgcca ccaaacgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaaga gcgactcgct gtataccgtt ggcagtctag ctttatctgt
 2041 tccggcaata cgatgcccat tgtacttgtt gactggctcg atattcgtga gcaaaaacga
 2101 cttatggtat tgcgagcttc agtcgacta cecggtctgt ctgttactgt ttagagaaa
 30 2161 gcgttccgcg tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
 2221 gcgagcattc taccgagtaa caccacacgc ctcatgtca gtgatgctg ctttaaaagt
 2281 ccatggtata aatccgttga gaagctgggt tggtagtgg taagtcgagt aagagggaaa
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaacct tcagcaactt acatgatag
 2401 tcacttagtc actcaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 35 2461 tgccaaatc tattgtata atctcgctct aaaggccgaa aaaatcagcg ctgcacacgg
 2521 actcattgtc accacccgct acctaaaatc tactcagcgt cggcaaggga gccatgggtt
 2581 ctacgaacta acttacctgt tgaatttcga acacccaaac aacttgttaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtccctgccta cggactaggg
 2701 ctacggcata gccgaacgag cagctcagag cgttttgata tcatgctgtt aatcgcctg
 40 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgtc agaaaacagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgaacc
 2941 ctactagctc aaaaatttat cacacatggg tacgctttgg ggaaattatg aggggattcg
 3001 tctagagcga tccgggactc cgggaaaaag gttggtgacc aaaggtgcct tttatcatca
 45 3061 ctttaaaaat aaaaaacaat tactcagtcg ctgttataag cagcaattaa ttatgattga
 3121 tgctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag tctgctattt
 3181 tgaacattat cttgattata ttattgataa taataaaaac cttatcccta tccaagaagt
 3241 gatgcctatc attggttggg atgaacttga aaaaaattag ccttgaatac attactggga
 3301 aggtaaaacg cattgtcagc aaattgatcc aagagaacca acttaagctt tctctgacgg
 50 3361 aatgttaatt ctggttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc
 3421 attaaagtta ggtggataga catcttgtca tatgatcccg gtaatgtgag ttagctcact
 3481 cattaggcac cccaggcttt acactttatg cttccggctc gtatgttgtg tggatttgtg
 3541 agcggataac aatttcacac aggaacacgc tatgacctag attacgcca ggcgcgaatt
 3601 aacctctact aaagggaaca aaagctggag ctccaccgcg gtggcgccg ctttagaact
 55 3661 agtggatccc ccgggctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag
 3721 cttgacctga tacctgattt tcttcaaact ggggaaacaa cacaatccca caaaacagct
 3781 cagagagaaa ccatcactga tggctacagc accaaggat gcaatggcaa tccattcgac
 3841 attcatctgt gacctgagca aaatgattta tctctccatg aatggtgtgt tctttccctc
 3901 atgaaaaggc aatttccaca ctcaaatat gcaacaaaga caaacagaga acaattatg
 60 3961 tgctccttcc taatgtcaaa attgtagtgg caaaggagg aacaaaatct caagttctga
 4021 gtagggttta gtgattggat aagaggcttt gacctgtgag ctccactgga cttcatatcc
 4081 ttttgataa aaagtgtctt tataactttc aggtctccga gtctttatc atgagactgt
 4141 tgggttaggg acagaccac aatgaaatgc ctggcatagg aaaggcgagc agagccttag
 4201 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg acaaaactat ttgtactgct
 65 4261 ttgcacagct gtgctgggga gggcaatcca ttgccacct tcccaggtaa ctttccaact
 4321 gcaagaagat tgtgtcttac tctctctaga aagcttctgc agactgacat gcatttcata
 4381 ggtagagata acatttactg ggaagcacat ctatcatcat aaaaagcagg caagattttc
 4441 agactttctt agtggctgaa atagaagcaa aagacgtgat taaaaacaaa atgaaacaaa

4501 aaaaatcagt .tgatacctgt ggtgtagaca tccagcaaaa aaatattatt tgcactacca
 4561 tcttgctcta agtctcaga cttggcaagg agaagttaga tttctacagt atatatgttt
 4621 tcacaaaagg aaggagagaa acaaaagaaa atgggactga ctaaacttca gctagtggta
 4681 taggaaagta attctgctta acagagattg cagtgatctc tatgtatgtc ctgaagaatt
 5 4741 atgttgact tttttccccc atttttaaat caaacagtgc tttacagagg tcagaatggt
 4801 ttctttactg tttgtcaatt ctattatttc aatacagaac aatagcttct ataactgaaa
 4861 tatatttgct attgtatatt atgattgtcc ctcaacat gaacactcct ccagctgaat
 4921 ttcacaattc ctctgtcctc tgcaggcca ttaagttatt catggaagat ctttgaggaa
 4981 cactgcaagt tcatatcata aacacatttg aaattgagta ttgttttgca ttgtattggag
 10 5041 ctatgttttg ctgtatcctc agaaaaaag tttgttataa agcattcaca cccataaaaa
 5101 gatagattta aatattccag ctatagggaa gaaagtgcgt ctgctcttca ctctagtctc
 5161 agttggctcc ttcacatgca tgcttcttta tttctcctat tttgtcaaga aaataatagg
 5221 tcacgtcttg ttctcactta tgcctgcctc agcatggctc agatgcagct tgtagataga
 5281 agaaggatca aatgaaacag acttctggtc tgttactaca accatagtaa taagcacact
 15 5341 aactaataat tgctaattat gttttccatc tctaagggtc ccacattttt ctgttttctt
 5401 aaagatccca ttatctgggt gtaactgaag ctcaatggaa catgagcaat atttccagct
 5461 cttctctccc atccaacagt cctgatggat tagcagaaca ggcagaaaac acattgttac
 5521 ccagaattaa aaactaatat ttgtctctca ttcaatccaa aatggacctt ttgaaactaa
 5581 aatctaacc c aatcccatla aatgatttct atggcgctca aggtcaagga tctgaaggga
 20 5641 acctgtgggt gggtcacaat tcaggctata tattccccag ggctcagcca gtggatcaac
 5701 atacagctag aaagctgtat tgcctttagc actcaagctc aaaagacaac tcagagtcca
 5761 ccatgggctc catcggtgca gcaagcatgg aattttgttt tgatgtatc aaggagctca
 5821 aagtcaccca tgccaatgag aacatcttct actgccccat tgccatctat tgcactctag
 5881 ccatgggtata cctgggtgca aaagacagca ccaggacaca gataaataag gttgttcgct
 25 5941 ttgataaaat tccaggattc ggagacagta ttgaagctca gtgtggcaca tctgtaaacg
 6001 ttcactcttc acttagagac atcctcaacc aaatcaccaa accaaatgat gtttattcgt
 6061 tcagccttgc cagttagact tatgtgaag agagataccc aatcctgcca gaatacttgc
 6121 agtggtgtgaa ggaactgtat agaggaggct tggaaacctat caactttcaa acagctgcag
 6181 atcaagccag agagctcatc aattcctggg tagaaaagtc gacaaatgga atatcagaa
 30 6241 atgtccttca gccaagctcc gtggattctc aaactgcaat ggttctggtt aatgccattg
 6301 tcttcaaaagg actgtgggag aaaacattta aggatgaaga cacacaagca atgccttcca
 6361 gagtgactga gcaagaaagc aaacctgtgc agatgatgta ccagattggt ttatttagag
 6421 tggcatcaat ggcttctgag aaaaatgaaga tctctggagct tccatttgcc agtgggacaa
 6481 tgagcatggt ggtgctgttg cctgatgaag tctcaggcct tgagcagctt gagagtataa
 35 6541 tcaactttga aaaactgact gaattggacca gttctaattg tatggaagag aggaagatca
 6601 aagtgactt accctgcagt aagatggagg aaaaatacaa cctcacatct gctttaatgg
 6661 ctatgggcat tactgacgtg tttagctctt cagccaatct gtctggcctc tctcagcag
 6721 agagcctgaa gatattctaa gctgtccatg cagcacatgc agaaatcaat gaagcaggga
 6781 gagagggtgt agggctcagc gaggtggag tggatgctgc aagcgtctct gaagaattta
 40 6841 gggctgacca tccattcttc ttctgtatca agcacatcgc aaccacagcc gtctcttctt
 6901 ttggcagatg tgtttctccg cggccagcag atgacgcacc agcagatgac gcaccagcag
 6961 atgacgcacc agcagatgac gcaccagcag atgacgcacc agcagatgac gcaacaacat
 7021 gtatcctgaa aggtctctgt ggctggatcg gctgtctgga tgacgatgac aaatttctga
 7081 accaacacct gtgcggctca cacctggtgg aagctctcta cctagtgtgc ggggaacgag
 45 7141 gcttcttcta cacacccaag acccgccggg aggcagagga cctgcagggt gggcagggtg
 7201 agctggcggg gggccctggt gcaggcagcc tgcagccctt ggccctcctgc gggctcctgc
 7261 agaagcgtgg cattgtggaa caatgctgta ccagcatctg ctccctctac cagctggaga
 7321 actactgcaa ctaggggccc taaagggcga attatcgagg ccgctctaga ccaggcgcct
 7381 ggatccagat cacttctggc taataaaaga tcagagctct agagatctgt gtgttggtt
 50 7441 tttgtggatc tgctgtgctt tctagtgtcc agccatctgt tgtttgcccc tccccgtgc
 7501 cttccttgac cctggaaggt gccactccca ctgtccttct ctaataaaat gaggaaattg
 7561 catcgcttg tctgagttag tgtcattcta ttctgggggg tgggggtggg cagcacagca
 7621 agggggagga ttgggaagac aatagcaggc atgctgggga tgcgggtggc tctatgggta
 7681 cctctctctc tctctctctc tctctctctc tctctctctc tctctctctc tctcgagggg
 55 7741 gggcccgta cccaattcgc cctatagtga gtcgtattac gcgcgctcac tggccgtcgt
 7801 tttacaacgt cgtgactggg aaaaccctgg cgttacccaa cttaatcgcc ttgcagcaca
 7861 tcccccttcc gccagctggc gtaatagcga agaggccgc accgatcgcc cttcccaaca
 7921 gttgcgcagc ctgaatggcg aatggaaatt gtaagcggtt atattttggt aaaattcgcg
 60 8041 tataaatcaa aagaatagac cgagataggg ttgagtgttg ttccagtgtg gaacaagagt
 8101 ccaactattaa agaagctgga ctccaacgtc aaaggggcga aaaccgtcta tcagggcgat
 8161 gggccactac tccgggatca tatgacaaga tgtgtatcca ctttaactta atgattttta
 8221 ccaaaatcat taggggattc atcagtgtctc aggggtcaacg agaattaaca ttccgtcagg
 8281 aaagcttatg atgatgatgt gcttaaaaaa ttactcaatg gctgggtatg catatcgcaa
 8341 tacatgcgaa aaacctaaaa gagcttgccg ataaaaaagg ccaatttatt gctatttacc
 65 8401 gcggtctttt attgagcttg aaagataaat aaaatagata ggttttattt gaagctaaat
 8461 cttctttatc gtaaaaaatg ccctcttggg ttatcaagag ggtcattata tttcggcgaa
 8521 taacatcatt tgggtgacgaa ataactaagc actgtctctc tgtttactcc cctgagcttg

3581 aggggttaac atgaagggtca tcgatagcag gataataata cagtaaaacg ctaaaccaat
 3641 aatccaaatc cagccatccc aaattggtag tgaatgatta taaataacag caaacagtaa
 8701 tgggccaata acaccggttg cattggttag gctcaccaat aatccctgta aagcaccttg
 8761 ctgatgactc tttgtttgga tagacatcac tcctctgtaat gcaggtaaaag cgatcccacc
 5 1821 accagccaat aaattaaaaa cagggaaaaa taaccaacct tcagatataa acgctaaaaa
 1881 ggcaaatgca ctactatctg caataaatcc gagcagtagt gccgtttttt cgccatttta
 1941 gtggctatct ttctgcccac aaaggcttgg aatactgagt gtaaaagacc aagacccgta
 9001 atgaaaagcc aaccatcatg ctattcatca tcacgatttc tgaatagca ccacaccgtg
 9061 ctggattggc tatcaatgag ctgaaataat aatcaacaaa tggcatcgtt aaataagtga
 10 1121 tgtataccga tcagcttttg ttccctttag tgagggttaa ttgcgcgctt ggcgtaatca
 9181 tggatcatag tgtttctgtg gtgaaattgt tatccgctca caattccaca caacatacga
 9241 gccggaagca taaagtgtaa agcctggggt gcctaagtga tgagctaaat cacattaatt
 9301 gcgttgccgt cactgcccgc ttccacgtcg ggaacctgtt cgtgccagct gcattaatga
 9361 atcggccaac gcgcggggag agcgggtttg cgtattgggc gctcttcctc ttccctcgctc
 15 9421 actgactcgc tgcgctcggc cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg
 9481 gtaatacggc tatccacaga atcaggggat aacgcaggaa agaactgtg agcaaaaggc
 9541 cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc
 9601 cccctcgacg agcatcacia aaatcgacgc tcaagttaga ggtggcgaaa cccgacagga
 9661 ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc
 20 9721 ctgccgctta ccggatacct gtccgctttt ctcccttcgg gaagcgtggc gctttctcat
 9781 agctcacgct gtaggtatct cagttcgggt taggtcgttc gctccaagct gggctgtgtg
 9841 cacgaacccc cgttcagcgc cgaccgctgc gccctatccg gtaactatcg tcttgagtc
 9901 aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga
 9961 gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact
 25 10021 agaaggacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt
 10081 ggtagctctt gatccggcaa acaaacacc gctggttagc gtggtttttt tgtttgcaag
 10141 cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg
 10201 tctgacgctc agtggaacga aaactcacgt taagggtatt tggatcatg attatcaaaa
 10261 aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata
 30 10321 tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg
 10381 atctgtctat ttctgtctac catagttgcc tgactccccg tcgtgtagat aactacgata
 10441 cgggaggggt taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccg
 10501 gctccagatt tatcagcaat aaaccagcca gccggaaggc ccgagcgcag aagtggctct
 10561 gcaactttat ccgcctccat ccagttctatt aattgttgcc gggaagctag agtaagtagt
 35 10621 tcgccagtta atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc
 10681 tcgtcgtttg gtatggcttc attcagctcc gggtcccaac gatcaaggcg agttacatga
 10741 tcccccatgt tgtgcaaaaa agcgggttagc tccttcggtc ctccgacgt tgtcagaagt
 10801 aagttggcgc cagtggtatc actcatggtt atggcagcac tgcataatc tcttactgtc
 10861 atgcatccg taagatgctt ttctgtgact ggtgagtagt caaccaagtc attctgagaa
 40 10921 tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca
 10981 catagcagaa ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca
 11041 aggatcttac cgtgttgag atccagttcg atgtaacca ctcgtgcacc caactgatct
 11101 tcagcatctt ttactttcac cagcgtttct gggtagagca aaacaggaag gcaaaatgcc
 11161 gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa
 45 11221 tattattgaa gcatttatca gggttattgt ctcagtagcg gatacatatt tgaatgtatt
 11281 tagaaaaata aacaaatagc ggttcgcgc acatttcccc gaaaagtgcc ac

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/003157 A3

(51) International Patent Classification⁷: **C07H 21/24**,
C12N 15/00

(21) International Application Number:
PCT/US2003/020389

(22) International Filing Date: 26 June 2003 (26.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/392,415 26 June 2002 (26.06.2002) US
60/441,377 21 January 2003 (21.01.2003) US
60/441,502 21 January 2003 (21.01.2003) US
60/441,405 21 January 2003 (21.01.2003) US
60/441,447 21 January 2003 (21.01.2003) US
60/441,392 21 January 2003 (21.01.2003) US
60/441,381 21 January 2003 (21.01.2003) US

(71) Applicants (for all designated States except US): **TRANSGENRX, INC.** [US/US]; Suite 300, 1755 Wittington Place Drive, Dallas, TX 75234 (US). **THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE** [US/US]; P.O. Box 25055, Baton Rouge, LA 70894-5055 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COOPER, Richard**, K. [US/US]; 111 Pecan Meadow Drive, Baton Rouge, LA 70810 (US). **CADD, Gary**, G. [US/US]; 501 Turner Road, Apartment 1111, Grapevine, TX 76051 (US). **FIORETTI, William**, C. [US/US]; 2225 Lakeridge Road Drive, Grapevine, TX 76051 (US). **DEBOER, Kenneth**, F. [US/US]; 10720 Gee Norman Road, Belgrade, MT 59714 (US).

(74) Agents: **PRATT, John**, S. et al.; Kilpatrick Stockton LLP, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report

(88) Date of publication of the International search report:
28 October 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE REGULATION IN TRANSGENIC ANIMALS USING A TRANSPOSON-BASED VECTOR

(57) Abstract: Administration of modified transposon-based vectors has been used to achieve stable incorporation of exogenous genes into animals. These transgenic animals produce transgenic progeny. Further, these transgenic animals produce large quantities of desired molecules encoded by the transgene. Transgenic egg-laying animals produce large quantities of desired molecules encoded by the transgene and deposit these molecules in the egg.

WO 2004/003157 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/20389

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/24; C12N 15/00

US CL : 536/23.2; 800/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.2; 800/24

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/14537 A1 (THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE) 01 March 2001 (01.03.2001), entire document.	1-51
A	SHERMAN, A. et al. Transposition of the drosophila element marnier into the chicken germ line. Nature Biotechnology. Noveber 1998, Vol. 16, pages 1050-1053.	1-51
Y	WO 99/09817 A1 (BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL) 04 March 1999 (04.03.1999), page 5, lines 9-10; page 5, lines 4-5; page 7, lines 15-19; page 21, lines 29-31; page 22, lines 10-24.	1,20,11,18- 22,25,28,40,41 and 44
Y	US 6,218,185 B1 (SHIRK et al.) 17 April 2001 (17.04.2001), col. 3, lines 14-30; col. 6, lines 33-35; col. 7, lines 61-67; COL. 14, lines 10-18; col. 17, lines 9-11; col. 18, LINES 1-16, col. 22, lines 7-61; claim 9.	1,20,11,18-22,28 and 44
Y	SCHNEIDER, S. An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. Gene. 1997, Vol. 197, pages 337-341, specifically, Abstract, lines 6-8, page 339, col. 1, lines 12-15, col. 2, paragraph 1, line 15; Figure 1.	1, 22, 25, 40, 41, 44

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

01 February 2004 (01.02.2004)

Date of mailing of the international search report

02 APR 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Valerie Bertoglio

Telephone No. (571) 272-0532

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KOZAK, M. At least six nucleotides preceding the AUG inhibitor codon enhance translation in mammalian cells. J. Mol. Biol. 1987, Vol. 196, pages 947-950, specifically page 947, col. 1, lines 25-33; page 949, col. 2, line 16.	1, 22, 25, 40, 41, 44
Y	WO 97/47739 A1 (BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY) 18 December 1997 (18.12.1997), page 3, lines 29-30, page 6, lines 13-24, page 9, lines 7-34.	10, 11, 18-21, 28, 46